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Abstract 
Background: Perinatal mental illness, especially depression, is a leading cause of 
maternal morbidity and mortality in high-income countries.  In the United Kingdom 
(UK), mental illness commonly presents to and is treated at primary care level; 
however there are no up-to-date estimates of the burden of different mental illnesses 
in women in and around pregnancy.  The potential impact of mental illness with or 
without psychotropic medication on the risk of non-live pregnancy outcomes is 
unclear.  In this context, the safety of psychotropic drugs, especially antidepressants, 
remains controversial. 
Aim and objectives: To estimate the clinical burden of depression, anxiety and 
serious mental illness (defined as bipolar disorder, schizophrenia and other related 
psychotic disorders) presenting to and/or being treated in UK primary care, and to 
investigate the effects on pregnancy outcomes while trying to differentiate the effects 
of psychotropic medication from mental illness itself. 
Methods:  Women aged 15-45 years from 1990 to 2009 were identified from The 
Health Improvement Network, a UK primary care database.  Coding of mental illness 
diagnoses and psychotropic drug prescriptions were examined by separately 
assessing the proportions of women with recordings of diagnoses, symptoms, and 
drug prescriptions over the study period.  Three separate studies were then carried 
out.  A cross-sectional study was firstly conducted to estimate the prevalence and 
diagnostic overlap of mental illnesses before, during and after pregnancy and the 
variation by maternal age, socioeconomic status and other maternal factors.  The 
second study examined the risks of non-live pregnancy outcomes (defined as 
perinatal death, miscarriage, and termination) in women with no history of depression 
and anxiety, a diagnosis of such illness prior to pregnancy, illness during pregnancy 
or illness during pregnancy with use of medication (stratified by medication type).  
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Multinomial logistic regression models were used to compare risks of non-live 
outcomes across these groups, adjusting for important socio-demographic and 
lifestyle characteristics.  The third study examined the risks of major and system-
specific congenital anomalies in children born to women with depression or anxiety 
that was untreated or treated with psychotropic medication.  Logistic regression with a 
generalised estimating equation was used to compare risks of major congenital 
anomalies in children exposed and unexposed to psychotropic medication during the 
first trimester of pregnancy, adjusting for important socio-demographic, lifestyle and 
chronic comorbidity in the mother. 
Results: There were 344,042 women who had one or more singleton pregnancies 
identified between age 15 and 45 from 1990 to 2009.  Recording of mental illness and 
prescriptions of psychotropic drugs increased considerably over the study period.  
There was high prevalence and overlap of different maternal mental illnesses, 
especially depression and anxiety, during and after pregnancy, and the prevalence 
was generally highest in younger, socioeconomically deprived women who had 
smoked before childbirth, were outside the normal range of BMI and had other 
chronic medical conditions, such as diabetes.  Socioeconomic deprivation was 
associated with increased risk of all mental illnesses, although the impact of 
deprivation was more marked in older women.  Those aged 35-45 in the most 
deprived group had 2.63 times the odds of antenatal depression (95% confidence 
interval [CI] 2.22-3.13) compared with the least deprived; in women aged 15-25 the 
increased odds associated with deprivation was more modest (odds ratio [OR]=1.35, 
95%CI 1.07-1.70).  Similar patterns were found for anxiety and serious mental illness. 
Women with antenatal exposure to antidepressant or anti-anxiety drugs showed the 
greatest increased risks for non-live pregnancy outcomes, relative to those with no 
history of depression or anxiety, although women with prior (but currently un-
medicated) illness also showed modest increased risks.  Compared with un-
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medicated antenatal morbidity, there was weak evidence of an excess risk in women 
taking tricyclic antidepressants (TCAs), and stronger evidence for other medications. 
The absolute risks of major and system-specific congenital anomalies were small in 
the general population (269 per 10,000 children for major congenital anomalies).  
Compared with un-medicated antenatal depression or anxiety (278 per 10,000 
children for major congenital anomalies), the use of antidepressants during early 
pregnancy was associated with excess risks, especially for selective serotonin 
reuptake inhibitors (SSRIs) (290 per 10,000 children for major congenital anomalies).  
Compared with children born to women with no depression or anxiety, there was an 
increased risk of heart anomalies in children with antenatal exposure to SSRIs 
(adjusted OR=1.25, 95% 95%CI 1.02-1.53), particularly in those exposed to 
paroxetine (adjusted OR=1.89, 95%CI 1.24-2.88).  Children exposed to sertraline and 
escitalopram also had similar increased risks, although fewer women were exposed 
to these drugs.  No increased risks of major congenital anomalies were found in 
children exposed to TCAs or benzodiazepines; however, the risks of right ventricular 
outflow tract anomalies were notably higher for all drug classes. 
Conclusion: Strong socioeconomic inequalities in perinatal mental illnesses occur 
and persist with increasing maternal age.  Women with depression or anxiety have 
higher risks of miscarriage, perinatal death and therapeutic terminations than women 
without these diagnoses and the risks are even higher if prescribed psychotropic 
medication during early pregnancy than if not.  There is also an increased risk of 
congenital heart anomalies in children exposed to paroxetine and other SSRIs during 
the first trimester compared with those who are unexposed, although the absolute risk 
is small.  There could be other associated factors also related to depression, anxiety 
or use of medications, which yet unlikely fully explain the observed excess risks.  
Whilst medicated depression or anxiety could be a marker of more severe illness than 
un-medicated ones, my findings indicate there may be some specific drug effects. 
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Targeting detection and effective interventions to women at risk of mental illness 
during pregnancy may reduce inequity and avoid substantial psychiatric morbidity, 
and subsequently reduce the need for further psychotropic treatment.  GPs and other 
health care professionals should take a cautious approach when managing mental 
illness in pregnant women.  The findings in this thesis provide vital information for this 
purpose, namely helping communicate the magnitude of risk of major congenital 
anomalies to women with the use of different psychotropic drugs in the context of the 
baseline risk in the general population. 
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Terminology of Time-periods Related to Pregnancy 
x Antenatal (also antepartum): the period when a woman is pregnant. 
x Postnatal (also postpartum): the period following delivery.  Analyses in this 
thesis use 9 months; however, there is no strict definition and studies may use 
only a few weeks, 6 months, 9 months or up to a year. 
x Neonatal period: the 28 days after delivery. 
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1 Introduction 
1.1 Background 
1.1.1 The current burden of mental illness 
The most recent global burden of disease study from the World Health Organisation 
updated in 2004 reports that mental disorders, such as depression, anxiety, alcohol 
use disorders, bipolar disorder and schizophrenia and other related psychoses, are 
among the 20 leading causes of disability worldwide.1  Particularly, unipolar 
depression contributes considerably to the disease burden and is the third leading 
cause of disability worldwide, first in middle- and high-income countries and eighth in 
low-income countries.1  Mental illness has recently been estimated to cost £105 billion 
annually to the economy in England, of which around £30 billion is work related.2,3  
Nearly 11% of the annual secondary care health budget in England is spent on 
mental health4 and the cost of treating mental health problems are expected to double 
before the year 2026.5  In the United States (USA), the estimated economic burden of 
mental disorders from health care expenditure, loss of earnings and disability benefits 
was over $300 billion in 2002, equivalent to more than $1,000/year for every person 
in the country.6 
Compared with men, women are particularly vulnerable to mental illness, especially 
common mental disorders (such as depression and anxiety).7  Unipolar depression is 
estimated to be twice as common in women as in men,8±10 and contributes the most 
years of healthy life lost for women aged 15-44 years in both high-income and low- 
and middle-income countries.1    
In addition, it is common for women to have mental health problems, especially 
depression, during the perinatal period.11  A recent systematic review of studies from 
across the world reported 6.5-12.9% of women had depression during pregnancy and 
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in the first year postpartum.12  Although both high and low income countries have 
recognised the pressing need to detect and address maternal psychosocial health 
problems within antenatal and postnatal care pathways,13±19 few have developed 
comprehensive strategies for universal screening and management.16,17,19  Current 
JXLGDQFHIURPWKH8QLWHG.LQJGRP¶V8.1DWLRQDO,QVWLWXWHIRU+HDOWKDQG&OLQLFDO
Excellence (NICE) has emphasised that perinatal mental illness is one of the most 
LPSRUWDQWLVVXHVLQZRPHQ¶VKHDOWK19 yet there are no up-to-date estimates of the 
current burden of these conditions available at a population level in the UK. 
1.1.2 Maternal age, socioeconomic status and other factors associated with 
perinatal mental illness 
Socio-demographic factors have a significant impact on mental illness, which is well 
recognised in the general population, yet there have been less studies specifically in 
relation to maternal mental illness.  A US study published in 2010, including more 
than 75,000 non-pregnant women aged 18-44, found that the prevalence of major 
depression was greatest in women over 35 years of age, unmarried, less educated, 
unable to work or unemployed, and with low income.20  In addition, the latest UK 
national mental illness strategy highlighted the importance of reducing health 
inequalities as a key objective to promote mental wellbeing in the population,2 yet 
there remains a need to effectively identify and treat those who are most vulnerable.  
Whilst the increased risks of mental illness in people with greater socioeconomic 
deprivation has been well documented in the general population,21 very few studies 
have assessed this in women during the perinatal period and it is unclear if this may 
vary by type of illness, notably depression, anxiety or more severe mental illness, 
such as psychosis.  Previous research has shown that women with greater 
socioeconomic deprivation were more likely to have perinatal mental illness than 
those with lower socioeconomic deprivation after adjusting for other socio-
1.1-26 | P a g e  
 
demographic factors.22±25  The results, however, are inconsistent with other studies 
that did not show such associations.22,23,26,27 
Studies of the age at which women are at greatest risk of different perinatal mental 
illnesses are also limited.22,26±28  Patterns of the effect of maternal age on perinatal 
mental illness have been inconsistent in different studies,22,26±28,25 showing both 
decreased28 and increased26,27 risks in older women.  Whilst there is evidence that 
material deprivation may have varied impacts on different age groups, this has not 
been assessed in pregnant women.29 
1.1.3 Impacts of perinatal mental illness and exposure to psychotropic 
medication 
Maternal perinatal mental illness has an unfavourable impact on both the short-term 
and long-term physical and mental health of offspring.  For common mental illnesses, 
such as depression and anxiety, considerable research has been conducted to 
examine the impact on woPHQ¶VSUHJQDQFLHVDQGDOVRRQQHRQDWDOKHDOWK.  It has 
been shown that women with antenatal depression and anxiety have increased risks 
of a range of adverse pregnancy complications including preeclampsia,30 preterm 
delivery,31 prolonged labour,32 and caesarean delivery.33  For severe mental illness, 
such as psychoses, prior studies have suggested that women with schizophrenia are 
more likely to have placental abruption and to have children with low birth weight and 
congenital heart anomalies.34  Whether these associations are causal or due to other 
factors associated with mental illness is unclear, and there may be multiple 
mechanisms involved.  Previous research has highlighted associations of mental 
illness with maternal smoking and other lifestyle behaviours35, but also with abnormal 
endocrine and immune regulation,36 which may directly impair growth and 
development of the foetus and have an adverse impact on offspring such as foetal 
growth retardation and low birth weight.37 
1.1-27 | P a g e  
 
There is increased concern over the use of psychotropic medications during 
pregnancy in terms of potentially increased risks of adverse pregnancy and neonatal 
outcomes.  A recent systematic review on the safety of antipsychotic drugs in human 
pregnancy including papers published in English from 1966 to 2008 suggests that 
although there is little evidence of an important association between the use of 
antipsychotics during pregnancy and an increased risk of adverse pregnancy 
outcomes including congenital anomalies, the current evidence is insufficient to make 
a definitive conclusion in terms of the gestational safety of these drugs.38  Despite this 
uncertainty, the use of antidepressants during pregnancy has increased dramatically 
in the last two decades.39  Only from 2012 the British National Formulary (BNF) 
recommended that selective serotonin reuptake inhibitors (SSRIs) should not be used 
during pregnancy due to the potential adverse pregnancy and neonatal outcomes.40 
Non-live pregnancy outcomes 
Previous literature has indicated that mothers with mental illness during pregnancy 
have increased risks of stillbirth and neonatal death in their offspring.41±44  A large 
population-based study in Denmark, for example, found that mothers with psychiatric 
disorders during pregnancy had a 42% increased risk of stillbirth (relative risk ratio 
[RRR]=1.42, 95% confidence interval [CI] 1.23-1.63) and a 65% increased risk of 
neonatal death (RRR=1.65, 95% CI 1.44-1.90) in their offspring compared with 
mothers without such illness during pregnancy.43  The results however are 
inconsistent.  A population-based study in Western Australia for instance did not find 
any statistically significant association of perinatal death in offspring of mothers with 
psychiatric disorders.34 
In addition, women with mental illness are commonly treated with psychotropic drugs, 
particularly antidepressants and anti-anxiety medications.  Previous research 
suggests that women prescribed some antidepressants during early pregnancy also 
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have increased risks of non-live pregnancy outcomes, including perinatal death,45,46 
miscarriage,45,47,48 and termination.45,49  However, the majority of these studies have 
been small-scale in highly selected study populations and few have considered the 
contribution of the underlying mental health conditions which necessitate treatment to 
the observed effects.50 
Congenital anomalies in offspring 
There is increased concern over the use of some SSRIs, particularly paroxetine, 
during early pregnancy in terms of the risk of major congenital anomalies in the 
offspring.  In 2005, The USA Food and Drug Administration changed the pregnancy 
safety category for paroxetine from category C to category D with a warning of 
potential increased risks of congenital heart anomalies in children exposed to 
paroxetine in early pregnancy.51  A recent UK national guideline on perinatal mental 
illness published in 2007 also highlighted the association between paroxetine taken 
during the first trimester with congenital heart anomalies (but not with fluoxetine).19  
However, there was very limited evidence at that time and the subsequent research 
findings are very controversial.52,53  Studies on specific SSRI drugs have found 
increased risks of congenital heart anomalies, particularly septal heart defects and 
ventricular outflow tract defects, in children of women prescribed paroxetine and 
fluoxetine during early pregnancy,53±55 yet these results are not consistent.56,57  The 
relative safety of different antidepressants has been further clouded by a focus on 
studying paroxetine and SSRIs overall and publishing these data, leaving many fewer 
publications on the safety of other individual SSRI drugs or non-SSRI drug classes. 
In addition, there is little information available on the safety of tricyclic antidepressants 
(TCAs) and benzodiazepines in pregnant women despite their continued use in this 
population and few studies have examined the HIIHFWVRIZRPHQ¶VXQGHUO\LQJPHQWDO
health condition as well as the contribution of non-mental health comorbidity.  
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Previous studies on the safety of TCAs exclusively in pregnant women in Sweden58 
and the USA59  have reported that children born to women prescribed TCAs during 
pregnancy had increased risks of heart defects,58 limb abnormalities, and spina 
bifida.59  However, no such findings have been published in other populations.  In 
addition, some earlier studies found greater risks of congenital anomalies, particularly 
oral clefts and cleft palate, in children exposed to benzodiazepines during pregnancy 
compared with those unexposed children.60±62  More recent studies however did not 
find such associations.63±68 
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1.2 Weakness of current studies in estimating pregnancy risks 
Due to ethical concerns, it is impossible to conduct drug trials in pregnant women.  In 
addition, certain rare pregnancy outcomes, such as stillbirth and specific congenital 
anomalies, require large study designs.  However, previous studies generally use 
data from voluntary drug safety registers, or small highly selected groups, with 
potential problems of retrospective exposures and external comparison groups.  
Recent studies from Denmark, Sweden and Finland have overcome some of these 
concerns by using their large routinely-collected and national-representative 
databases.  Although such large databases are also available in the UK, very few UK 
studies on pregnancy risks have been conducted using these data. 
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1.3 Rationale and objectives 
Perinatal mental illness causes a considerable health and socioeconomic burden in 
high-income countries, yet in the UK there are no up-to-date estimates of this burden, 
especially for anxiety and serious mental illness (such as psychotic disorder) 
available at a population level.  The most affected socio-demographic groups remain 
unclear. 
Although previous research has suggested increased risks of adverse pregnancy and 
neonatal outcomes in women with mental illness, such increased risks could be 
attributed not only to disease itself but also to the use of psychotropic medication, 
such as antidepressants or anti-anxiety drugs, as well as other maternal 
characteristics associated with mental illness.  In addition, no population-based cohort 
study has been carried out in the UK to investigate the effects of exposure to 
psychotropic medications, especially newer antidepressants, in women during early 
pregnancy on the risk of congenital anomalies in their offspring.  It is important to use 
prospectively collected data on both exposures and outcomes in very large study 
populations to answer such questions.  UK primary care data is one such available 
source and will provide contemporary information that is clinically relevant to the UK. 
The objectives of this thesis are, therefore: 
x To estimate the prevalence and overlap of different mental illnesses 
presenting to, diagnosed and treated in UK general practice in women of 
childbearing age and around the perinatal period; 
x To examine the impact of maternal age, socioeconomic status and other 
maternal factors on the risk of maternal perinatal mental illness; 
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x To estimate the association between mental illness in women during 
pregnancy and the risk of non-live pregnancy outcomes (i.e. stillbirth and 
neonatal death, miscarriage and therapeutic termination); 
x To examine whether the risks of adverse pregnancy outcomes differ between 
women with and without antenatal psychotropic drug treatment; 
x To measure the association between maternal exposure to treated or 
untreated mental illness during early pregnancy and the risk of congenital 
anomalies in offspring. 
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1.4 Outline of the thesis 
The subsequent chapters of this thesis discuss firstly the data used for the work, 
secondly defining and assessing maternal mental illness using primary care data, 
followed by three separate studies that address the main research objectives of this 
thesis.  The outline below briefly describes the content of each chapter. 
Chapter 2: Description of The Health Improvement Network (THIN) general practice 
database, the database of linked mother-child records extracted from THIN, and a 
brief description of the study ethics, the datasets extracted from the database for all 
analyses and statistical software used. 
Chapter 3: Description of approaches of identifying maternal mental illness in UK 
general practice and a series of analyses to assess the recording of mental illness in 
the general population of women of childbearing age presenting to UK primary care. 
Chapter 4*: In the first study, the prevalence and overlap of different maternal 
perinatal mental illnesses presenting to UK primary care are estimated and the 
variations by maternal age, socioeconomic status and other maternal factors are 
quantified. 
Chapter 5*: In the second study, risks of non-live pregnancy outcomes, namely 
perinatal death, miscarriage and termination, in pregnant women with depression and 
anxiety are compared with those women without depression or anxiety.  The impact 
of psychotropic treatment on these risks is also assessed. 
Chapter 6*: In the third study, risks of congenital anomalies in live-born children are 
estimated and these risks are compared between women with and without 
antidepressant or anti-anxiety drugs in the first trimester of pregnancy. 
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*As three separate studies, Sections 4-6 each contain their own introduction (with a 
detailed literature review tailored for the study), description of methods, results, 
discussion and conclusion. 
Chapter 7: Summary of the main findings in the thesis, suggested clinical implications 
and directions of future research. 
1.5-35 | P a g e  
 
1.5 Role of the candidate 
The initial idea for this PhD was from my principal supervisor Dr Laila Jal Tata.  The 
candidate continued to develop the project and each specific research question, with 
guidance from my supervisors Dr Laila J Tata, Dr Jack E Gibson and Dr Joe West.  
Data were obtained from Cegedim Strategic Data for Medical Research (CSD-MR), 
and were initially processed by Mr Chris JP Smith.  Dr Linda Fiaschi extracted and 
provided a database of women of childbearing age and linked mother-and-child 
general practice records used for this thesis.  The candidate conducted the literature 
review, extracted Read codes for mental illness and medication, and carried out all 
the data management to create individual datasets for each study and all statistical 
analyses.  The candidate was provided with lists of Read codes for other conditions 
(i.e. smoking, body mass index, diabetes, hypertension, asthma, epilepsy and 
congenital anomalies) for the purpose of some analyses.  The candidate generated 
all tables and figures and wrote the thesis.  The final draft was read and approved by 
all three supervisors before submission. 
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2 Description of the data used for the work 
This chapter describes The Health Improvement Network (THIN), a database of 
computerised primary health care records in the United Kingdom, which is used for all 
analyses in this thesis.  This chapter also includes a brief description of the study 
ethics, datasets extracted from the database and statistical software used. 
2.1 The Health Improvement Network Database (THIN) 
2.1.1 Background 
THIN is a large computerised database containing primary care anonymised patient 
medical records that are collected from UK general practice.  The database was set 
up in 2002 through the collaboration of a medical research organisation, known as 
EPIC (later CSD-MR), with In Practice Systems (InPS) who provide Vision software to 
around 2000 general practices in the UK.  InPS have written unobtrusive data 
collection software for Vision practices that have joined the THIN scheme and data 
are downloaded from general practices monthly.  Although the THIN scheme started 
in 2003, EPIC has been collaborated with InPS in data collection much earlier and 
most data were collected prospectively from 1988 onwards.  For this thesis, the 
database contained information from 429 general practices across England, Scotland, 
Wales and Northern Ireland, comprising a total of 7.7 million patients of which more 
than three million patients were actively registered with the practices (the remaining 
patients had prospectively collected historic data but have either left the practice or 
died).  Most of these contributing practices had recorded over 15 years of data on 
their system. 
2.1.2 Information contained in THIN 
Upon data collection, patient identifying information such as name, address, exact 
date of birth and NHS number is stripped and is not exported from the computer 
system of THIN general practices.  Although identifying information is never available 
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to THIN, each patient in THIN has a unique identification number for use by 
researchers.  Additional demographic data such as age and sex are retained.  
Patients that live at the same address (including residential homes and flats) or are 
members of the same family can be linked using a household identification number 
provided they are registered with the same general practice.  THIN pDWLHQWV¶postcode 
information is also derived to measure socioeconomic status using household-level 
Townsend Index of Deprivation based on 2001 census data.  THIN also contains 
patient lifestyle information, such as smoking and alcohol intake, provided these are 
recorded by their general practitioner (GP) in the course of clinical care. 
Medical conditions and symptoms reported by patients to their GP during a 
consultation are recorded using Read codes, which is a very comprehensive, 
hierarchal clinical classification system and can be cross-referenced to the 
International Classification of Disease.69  Information on referrals to secondary care is 
also recorded.  Secondary care information, such as hospital admissions, discharge 
medication and diagnosis, outpatient consultation diagnosis, investigation and 
treatment outcomes, received by the practice should be transcribed and entered 
retrospectively.  Although the completeness of such transcribed information is 
uncertain, major medical events and diagnoses are mostly likely entered the primary 
care records. 
Compared to medical events and diagnoses, GP prescribing is particularly well 
recorded since the computerised system used by the GP is also used to print a copy 
of the prescription form for the patient to present at the pharmacy.  Drug prescribing 
through the computerised system is recorded using the Multilex coding system,70 
linked to chapters of the BNF.  Drugs prescribed by hospital doctors or other 
specialists will not appear in THIN data unless the treatment is continued in general 
practice.  However, due to the constraints of specialist/hospital prescribing budgets, 
prescriptions issued outside of the general practice will usually only cover the first 
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seven days.  After this time the patient will be required to get further prescriptions 
from their GP. 
THIN data are organised by practice.  The information for each patient is contained in 
five separate files, which can be linked by the patient and practice identification 
numbers.  Table 2-1 shows the major information contained in THIN. 
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Table 2-1 The information contained in The Health Improvement Network 
Files Information contained 
Patient file Basic socio-demographic information, such as sex, 
registration date, date of birth/death, transfer-out date 
Medical file Medical symptoms, disease diagnoses, hospital admissions, 
medical procedures and investigations (coded using Read 
codes) 
Therapy file Drug prescriptions, including frequency, quantity, dose, 
formulation of medication (coded using Multilex codes) 
Additional Health Data file Additional health information, such as lifestyle and 
preventative health care (coded using Read codes) 
Postcode variable indicators Socioeconomic, ethnicity and environmental indices 
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2.1.3 Retrospective and prospective recording in THIN 
Several dates are used in THIN to indicate when data were being prospectively 
recorded to a certain standard of quality and completeness.  The date of 
computerisation is calculated by EPIC from therapy records and is the date when the 
practice first started issuing prescriptions from the computer every day for a certain 
number of consecutive months.  The date for Vision is the date when the practice 
started using the Vision practice management software to record consultations.  The 
acceptable mortality reporting date denotes the year from which the practice was 
deemed to be correctly reporting all-cause mortality rates based on predicted 
QXPEHUVRIGHDWKVGHULYHGIURPQDWLRQDOVWDWLVWLFVJLYHQWKHSUDFWLFH¶VDJHVH[
register.71 
2.1.4 Justification for using THIN 
One major advantage of THIN for epidemiological research is that it provides routinely, 
prospectively collected patient information for a large, nationally representative 
population.72  THIN is a very large primary care database, making it particularly 
attractive for research on uncommon conditions, such as schizophrenia and other 
related psychotic disorders (the prevalence of which is about 1-2 per 1000 women 
during the perinatal period, as shown in Section 1.1.1).  Although depression is 
relatively common in the general population, THIN provides a good opportunity to 
examine the impact on rare pregnancy outcomes, such as perinatal death and some 
specific congenital anomalies.  A recent UK study published in 2010 has suggested 
that primary care data can be used to identify a wide range of congenital anomalies, 
ZKLFKFDQEHGRQHMXVWWKURXJKWKHSDWLHQWV¶FRPSXWHULVHGPHGLFDOUHFords.73  
In addition, THIN has a high standard of validated records of medical conditions 
(including diagnoses and symptoms) and prescriptions.72,74  A recent study published 
in 2010 has validated the depression diagnosis in THIN patients.75  In this study, the 
authors sent questionnaires to GPs requesting confirmation information for a random 
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sample of 140 patients diagnosed with dHSUHVVLRQDQGIRXQGRIWKHSDWLHQWV¶
diagnoses were confirmed.  Another similar study using THIN data conducted by the 
same group of authors has validated anxiety diagnoses.76    
Whilst GPs can always enter retrospective health information, the majority of data in 
THIN are prospectively recorded by GPs as part of routine health care in the general 
SUDFWLFH%\FRPSDULQJWKHGDWHRISDWLHQW¶VUHJLVWUDWLRQZLWKD*3DQGWKHGDWHRID
medical event one can ascertain whether certain information may be retrospectively 
recorded.  Therefore, it is less likely to have recall errors or recall bias in the recording 
of individual diagnoses, symptoms and other medical events in comparison with 
questionnaire studies of medical histories.  However, as some of the data included in 
THIN are based on correspondence from secondary care it is possible that there is 
some misclassification in the recording of exact dates of events. 
The quality of GP prescription recording is particularly good since the computerised 
system used by the GP is also used to print a copy of the prescription form.  Whilst it 
is of course not possible to be certain that those prescribed will have definitely been 
exposed and exactly when, this limitation holds also for questionnaire studies that rely 
on patient memory and reporting of taking specific drugs. 
THIN downloads data from practices every month and follows up individual patients 
until they or their practices exist to contribute to THIN.  The data I used were collected 
from June 1987 to July 2009, which provides a good opportunity to investigate the 
potential changes of mental illness diagnoses and treatment in UK primary care over 
time as well as to understand the contemporary experience of women with mental 
illness in and around pregnancy.  However since both THIN practices and patients 
can enter and/or exit THIN at different times, some patients may have relatively short 
follow-up time periods compared to others in THIN, requiring analyses that account 
for open cohort data. 
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THIN also contains basic socio-demographic and patient lifestyle information reported 
to the GP, such as smoking, body mass index (BMI) and socio-economic status.  
However, there is a potential problem regarding missing data.  As the information 
collected in THIN is not for research purposes, but based on what was deemed 
important and relevant for the on-going health care of the individual patient, it is likely 
that there are biases in which data are missing.  For example, a GP may be more 
OLNHO\WRUHFRUGDZRPDQ¶VVPRNLQJVWDWXVGXULQJSUHJQDQF\LIWKHZRPDQLVDUHJXODU
smoker and the GP think this may adversely affect the pregnancy outcome and the 
health outcome of the offspring.   
2.1.5 Quality and Outcomes Framework 
In 2004, the Quality and Outcomes Framework (QOF) was introduced as part of the 
General Medical Services Contract.77  The QOF is a voluntary incentive scheme for 
all general practices in the UK, which rewards GPs for how well they care for their 
patients.  The QOF contains four main components (known as domains), including 
clinical, organisational, patient experience and additional service domains.  A set of 
achievement measures, known as indicators, have been selected and developed in 
each domain to measure the health care quality for patients in each GP surgery.  The 
QOF gives an indication of the overall achievement of a practice through a points 
system, which contains groups of indicators, against which practices score points 
according to their level of achievement.  The higher the score, the greater the 
financial reward for the practice. 
The clinical indicators include mainly chronic health conditions, such as coronary 
heart disease, hypertension, diabetes, epilepsy, and asthma.  Some indicators for 
mental illness have also been developed.  There are no specific indicators for pre-
pregnancy or pregnancy care other than the offer of antenatal care and screening 
according to local guidelines, which is included in the additional services domain.  In 
2006/2007, separate indicators for smoking management were added to the QOF, 
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which requires GPs WRUHFRUGDQGPRQLWRUSDWLHQWV¶VPRNLQJVWDWXVLIWKH\KDYH
certain chronic conditions listed in the QOF and more recently for all registered 
patients.  As women of childbearing age represent a relatively healthy portion of the 
general population, their recording will be likely less affected than other groups, such 
as the elderly. 
Nevertheless, the development of the QOF presumably has had a substantial impact 
on the completeness of recording of these medical diseases and events.  For 
example, an indicator for depression is the percentage of patients who have had an 
assessment of severity at the time diagnosis using an assessment tool validated for 
use in primary care in those patients with a new diagnosis of depression.77  Previous 
research suggested that financial incentives in pay for performance schemes might 
not improve the quality of patient care,78 but may result in some unintended 
outcomes.79  No studies however have assessed potential impacts of the 
implementation of QOF on the care that patients with mental illness receive or 
ZKHWKHUWKLVDIIHFWVSDWLHQWV¶UHFRUGHGGLDJQRVHV. 
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2.2 Ethical approval 
Ethical approval for this research was obtained from the UK Medical Research Ethics 
Committee (administered and approved by the National Health Service South East 
Research Ethics Committee) REC reference 04/MRE01/9. 
THIN data are wholly and only collected and recorded for the purpose of routine 
management and optimal health care for patients in the UK National Health Service 
(NHS) general practice setting, not directly for research purposes.  NHS general 
practices contributing data to THIN provide consent for the use of these data by 
researchers.  Whilst ethical approval is required for each study using THIN data, 
direct consent from individual patients is not required under the UK Data Protection 
Act because all data are anonymised, such that individual patients as well as the 
names and specific locations of general practices cannot be identified by researchers.
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2.3 Datasets used for the work and statistical software 
From THIN, several sub-set populations were extracted for the analyses in this thesis 
(Figure 2-1), starting with all women permanently registered with a THIN general 
practice using a computerised system at some point during their potentially fertile 
period (age 15-45 years) between 1990 and 2009 (Population 1).  On average, there 
were 5.5-\HDUV¶SURVSHFWLYHUHFRUGHGGDWDIRUHDFKZRPDQLQ3RSXODWLRQ
(median=5.5, interquartile range [IQR] 1.9-11.6).  From Population 1, all women with 
at least one singleton pregnancy during the study period were included as Population 
2, thus women were excluded if they only had multiple pregnancies during the study 
period or only had pregnancies started before they registered with a GP.  Women 
were then separated according to whether they had pregnancies ending in a live or 
non-live birth (Populations 3 and 4) and women may be included in both populations if 
they had both live and non-live births during the study period.  From women with a 
live birth, those women with one or more children linked in THIN were then extracted 
(Population 5). 
The linkage between women and their children was done by using delivery details 
and unique household identification number LQERWKZRPHQ¶VDQGFKLOGUHQ¶VPHGLFDO
records.  Dates of conception were estimated based on a range of recordings relating 
to pregnancy, including last menstrual period dates, expected delivery dates, maturity 
estimates (e.g. codes for post-term or preterm deliveries), timing of routine monitoring 
HYHQWVDQGUHFRUGHGZHHNVRIJHVWDWLRQDWELUWKLQFKLOGUHQ¶VUHFRUGV, and where no 
information was available, live births were assumed to take place at 40 weeks and 
miscarriage and termination at 10 weeks. 
For the studies in Chapters 4-6, based on the populations in Figure 2-1, slight 
changes were also made to accommodate some specific criteria for different studies 
(please see the methods part for each individual study).  All data management and 
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statistical analyses were carried out using Stata SE 11.0 (Stata Corp., TX, USA) for 
Windows 2007 Enterprise Edition (Microsoft Corporation, Seattle, USA). 
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*Women may be included in both populations. 
Figure 2-1 Sub-datasets extracted from THIN for all analyses in this thesis 
 
Population 1: Women registered permanently with computerised general practice at some point 
during their potentially fertile period (age=15-45 years) between year 1990 and 2009 
Total number of women=1,962,051 
Population 2: Women with one or more singleton pregnancies during the period 
Total number of women=344,042 
Population 3*: Women with pregnancies ending in a non-
live birth (i.e. stillbirth, miscarriage and termination) 
Total number of women=118,711 
Population 4*: Women with pregnancies ending in a live birth 
 Total number of women=279,246 
Population 5: Women with one or more linked children in the database 
Total number of women=253,840 
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3 Defining and assessing mental illness in primary care data 
This chapter describes the process of identifying different mental illnesses in women 
of childbearing age in UK general practice by extracting recording of medical 
diagnoses, symptoms and prescriptions of psychotropic drugs from the primary care 
database.  This includes a series of analyses to assess the recording of maternal 
mental illness in the general population presenting to primary care using Population 1 
in Figure 2-1. 
3.1 Background 
3.1.1 Identification and diagnosis of mental illness 
Although psychiatric disorders are increasingly recognised as one of the most 
common human disorders which cause great morbidity worldwide, the information 
about aetiology and treatment in psychiatric disorders is vague, compared with other 
specialties of medicine.80  Psychiatric disorders are predominantly disorders of brain 
functions.  Currently, there are no gold standard diagnostic tests for psychiatric 
disorders.  Physical examination or other investigations (e.g. blood tests) are more 
likely to be investigations of exclusion and some functional mental illnesses are 
presumably defined by a failure to locate a physical cause.  Psychiatrists and other 
clinicians therefore commonly base diagnosis and treatment on symptom clusters 
alone.80  Since people with mental illnesses may not be willing to disclose their 
feelings to doctors or other health professionals, under-diagnosis of mental illness 
could be fairly common in the general population,81 yet it is also possible that there is 
over-diagnosis in the medical setting for some people. 
Psychiatric research generally classifies psychiatric disorders according to defined 
criteria.  There are two main medically accepted systems of psychiatric classification: 
WKH:RUOG+HDOWK2UJDQLVDWLRQ¶V,QWHUQDWLRQDO&ODVVLILFDWLRQRI'LVHDVH,&'82 and 
3.1-49 | P a g e  
 
WKH$PHULFDQ3V\FKLDWULF$VVRFLDWLRQ¶V'LDJnostic and Statistical Manual of Mental 
Disorders (DSM).83  Although the two systems of classification are fairly similar and 
generally correspond with each other well, there is considerable uncertainty and 
controversy around diagnosis and classification of different types of mental illnesses, 
much of which stems from a lack of accurate measurements to validate the 
diagnoses,84 JLYHQFRQVLGHUDEOHYDULDWLRQEHWZHHQSHRSOH¶VV\PSWRPVDQG
presentation as well as possible comorbidity of different mental illnesses within 
individuals. 
3.1.2 Issues and concerns using general practice records 
In daily practice the concept of mental illness is increasingly questioned.  Mental 
illness especially depression and anxiety may be described as an everyday problem 
rather than as an objective diagnostic category by the GP and standardised 
diagnostic interviews are not, and cannot at present, be used in primary care.85  
Although a systematic review found low accuracy of depression recognition by non-
psychiatrist physicians,86 prior research has suggested that GPs are able to recognise 
more severe depression,87,88 and try to avoid labelling people with mild symptoms as 
being mentally ill.89  A recent study in general practice data found that whilst recording 
of depression diagnoses had decreased over the period 1996-2006, symptom 
recording of depression increased substantially and the combined total varied 
minimally over time.89 
In addition, in UK general practice it is common for patients to be prescribed 
psychotropic drugs without direct recording of the diagnostic indication for the 
prescription, which likely reflects both the diagnostic pathway (e.g. prescriptions of 
psychotropic drugs as part of diagnostic procedure) and routine clinical practice (e.g. 
D*3ZLWKNQRZOHGJHRIKLVRUKHUSDWLHQW¶VFOLQLFDOKLVWRU\ZLOOQRWQHHGWRUHFRUGD
new diagnosis of depression with each prescription for effective clinical care).  
Previous studies of mental illness using primary care data typically define mental 
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disorders using recordings of both diagnoses and psychotropic drug 
prescriptions.76,89±94 
In addition, previous research in the General Practice Research Database (GPRD), a 
large general practice database similar to THIN, has reported exceptionally high 
incidence rates of various diseases in the period shortly after registration.95  This likely 
means that the diagnoses within the first few months after registration are more often 
prevalent or past diagnoses UHFRUGHGDVSDUWRIDSDWLHQW¶VLQLWLDOLPSRUWant medical 
history when they join a new practice.  However, this research only examined specific 
morbidities (e.g. heart disease and cancer) and did not include any mental illness, nor 
did it examine the pattern of drug prescriptions.  Since about half of the general 
practices in GPRD also contribute to THIN, a similar finding would be expected in 
studies using data from THIN, in which case the post-registration period needs to be 
separately examined. 
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3.2 Defining mental illness in primary care data 
For this PhD I focused on clinically recognised mental illness presenting to and/or 
treated in UK general practice.  Depression, anxiety, bipolar disorder and 
schizophrenia and other related psychotic disorders which are not due to known 
organic illness or substance misuse (based on the two classification systems) were 
investigated.  I categorised these mental health conditions as common mental illness 
(depression and anxiety) and rarer but more severe disorders, as serious mental 
illness (bipolar disorder, schizophrenia and other related psychotic disorders). 
I extracted Read codes for both diagnoses and symptoms of each mental illness.  I 
also extracted prescriptions for some psychotropic drugs, which included 
antidepressants, antipsychotics, anti-anxiety drugs, and anti-manic drugs including 
lithium and mood stabilisers (valproate acid and carbamazepine).  A series of 
analyses were carried out to examine the recording of these mental illnesses and 
related prescribing in women of childbearing age in UK general practice. 
3.2.1 Extracting Read codes for diagnoses and symptoms 
Most diagnostic Read codes for psychiatric disorders are under chapter KHDGLQJµ(-
Mental Disorders¶7KHFRPPDQGµVHDUFKUF¶96 in Stata SE 11 was also used to 
extract both diagnostic and symptom codes from the Read code dictionary.  Table 3-1 
summarises the search terms used for each mental illness.  The category retention 
option of the command was also used to extract codes in the same Read code 
categories as the matched codes. 
UVLQJWKHFRPPDQGµVHDUFKUF¶DQGWKHVHDUFKWHUPs in Table 3-1, more than 10,000 
codes were initially extracted.  By comparing with previous research of which Read 
codes were used to define different mental illnesses in general practice,89,97 exclusive 
code-lists were created for depression, anxiety, bipolar disorder and schizophrenia 
and other related psychotic disorders (Appendix I), separately. 
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Table 3-1 Search terms for different mental illnesses 
Mental illness Search terms 
Depression *depress*, *dythami*, *mood*, *affect*, *tired*, *sad*, 
*blunt* or *stupor* 
Anxiety *anxi*, *phobi*, *panic*, *fear*, *stress*, *traumatic* or 
*obsessive* 
Bipolar disorder *bipolar*, *manic depress*, *manic-depress*, 
*cyclothymi*, *mood* or *affect* 
Schizophrenia and other psychoses *schizo*, *psycho*, *delusion*, *hallucina*, 
*diaorgani*, *amusia* or *oneirophreni* 
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3.2.2 Extracting Multilex codes for drug prescriptions 
BNF 57 (2009)98 and key UK psychiatry handbooks80,99 were used to help identify 
psychotropic medicines that were normally used for treating depression, anxiety, 
bipolar disorder, and schizophrenia and other related psychotropic disorders in the 
UK.  Since the same drug can be used to treat different mental illnesses (e.g. 
citalopram for both depressive disorders and anxiety) and the same mental illness 
can be treated by drugs from different drug classes (e.g. bipolar disorders treated by 
both anti-mantic and antipsychotic drugs), instead of making drug code-lists for each 
mental illness, four drug code-lists based on the BNF drug classification were 
extracted.  These are anti-anxiety drugs (including hypnotics in BNF chapter 4.1.1 
and anxiolytics in BNF chapter 4.1.2), antipsychotic drugs in BNF chapter 4.2.1 and 
chapter 4.2.2, anti-manic drugs (lithium and mood stabilisers) in BNF chapter 4.2.3 
and chapter 4.8.1, and antidepressants in BNF chapter 4.3.  All Multilex codes, linked 
to these chapters of the BNF, were extracted from the drug code dictionary of THIN.  
Please see Appendix II for the lists of drugs from the BNF that were used in this 
thesis. 
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3.3 Assessing recordings of mental illness 
3.3.1 Frequency of Read codes used for each mental illness 
For Population 1 in Figure 2-1, all recording for depression, anxiety, bipolar disorder, 
schizophrenia and other related psychotic disorders were extracted using Read codes 
identified in Section 3.2.1.  Of the 1,962,051 women in Population 1, more than 26% 
had some kind of recording for these mental conditions, of whom 63.5% had at least 
two recordings in their medical records.  Overall, over two-million mental illness 
related recordings were extracted and about three out of four were diagnostic records.  
Table 3-2 shows the frequency of mental illness overall for the recording of diagnoses 
and symptoms separately and the top 10 most common codes which accounted for 
89.3% of the recorded diagnoses and 96.1% of the recorded symptoms.  The 
following tables show the frequency results for depression (Table 3-3), anxiety (Table 
3-4), bipolar disorder (Table 3-5) and schizophrenia and other related psychotropic 
disorders (Table 3-6) separately. 
Overall, for diagnostic codes, nearly one third of the recordings were coded with 
µ'HSUHVVLYHGLVRUGHUQRWHOVHZKHUHFODVVLILHG1(&¶DQG% was the code 
µ$Q[LHW\VWDWH¶Table 3-2).  The most frequently used symptomatic code was `Low 
PRRG¶IROORZHGE\WKHFRGHC'HSUHVVHG¶Table 3-2).  For depression, more than half 
of the recordings for diagnoses used non-VSHFLILFFRGHVVXFKDVµ'HSUHVVLYH
GLVRUGHU1(&¶DQGC'HSUHVVLRQQRWRWKHUZLVHVSHFLILHG126¶Table 3-3). For 
aQ[LHW\RYHUKDOIRIWKHGLDJQRVWLFUHFRUGLQJVXVHGWKHWZRFRGHVC$Q[LHW\VWDWH¶DQG
C$Q[LHW\ZLWKGHSUHVVLRQ¶DQGnearly 60% of the recordings for symptoms used the 
codes `Anxiousness ± V\PSWRP¶DQGC$Q[LRXVQHVV¶Table 3-4).  There were far 
fewer women with recordings of bipolar disorder (Table 3-5) or schizophrenia and 
other related psychotic disorders (Table 3-6) and the vast majority were recorded 
using diagnostic codes rather than recordings of symptoms. 
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Table 3-2 Top 10 most frequently used Read codes for recording of diagnoses 
and symptoms separately in women of childbearing age (N=1,962,051) 
 
All diagnostic codes (1,451,878) All symptom codes (664,617) 
 
Read code description n %* Read code description n %* 
1 Depressive disorder 
NEC 
443,239 30.5 Low mood 134,332 20.2 
2 Anxiety states 183,041 19.4 Depressed 97,502 14.7 
3 [X]Depression NOS 154,977 12.6 C/O - feeling depressed 78,345 11.8 
4 Anxiety with depression 141,075 10.7 Anxiousness - symptom 73,615 11.1 
5 Postnatal depression  57,653 4.0 Anxiousness 72,457 10.9 
6 [X]Depressive episode 51,520 3.5 Panic attack 57,142 8.6 
7 Neurotic depression 
reactive type 
48,774 3.4 Depressed mood 37,587 5.7 
8 Panic disorder 30,752 2.1 Stress related problem 31,989 4.8 
9 Endogenous depression 
- recurrent 
24,136 1.7 Symptoms of 
depression 
31,402 4.7 
10 Endogenous depression 
first episode 
20,779 1.4 O/E - depressed 23,783 3.6 
* 11% other codes of diagnoses and 4% other symptom codes  
NEC=not elsewhere classified 
NOS=not otherwise specified 
C/O=complain of 
O/E=on examination of  
[X]: These Read codes have been added to ensure mapping to all ICD codes 
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Table 3-3 Top 10 most frequently used Read codes for recording of depression 
(N=417,048) 
 
Diagnostic codes (1,123,529) Symptom codes (409,083) 
 
Read code description n % Read code description n % 
1 Depressive disorder NEC 443,239 39.5 Low mood 134,332 32.8 
2 [X]Depression NOS 154,977 13.8 Depressed 97,502 23.8 
3 Anxiety with depression 141,075 12.6 C/O - feeling depressed 78,345 19.2 
4 Postnatal depression 57,653 5.1 Depressed mood 37,587 9.2 
5 [X]Depressive episode 51,520 4.6 Symptoms of 
depression 
31,402 7.7 
6 Neurotic depression 
reactive type 
48,774 4.3 O/E - depressed 23,783 5.8 
7 Endogenous depression - 
recurrent 
24,136 2.1 Depressive symptoms 6,132 1.5 
8 Endogenous depression 
first episode 
20,779 1.8 ---   
9 [X]Moderate depressive 
episode 
19,750 1.8 ---   
10 [X]Depressive episode, 
unspecified 
18,512 1.6 ---   
NEC=not elsewhere classified 
NOS=not otherwise specified 
C/O=complain of 
O/E=on examination of 
[X]: These Read codes have been added to ensure mapping to all ICD codes 
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Table 3-4 Top 10 most frequently used Read codes for recording of anxiety 
(N=267,483) 
 
Diagnostic codes (545,926) Symptom codes (251,472)  
 
Read code description n % Read code description n % 
1 Anxiety states 183,041 33.5 Anxiousness - symptom 73,615 29.3 
2 Anxiety with depression 141,075 25.8 Anxiousness 72,457 28.8 
3 Panic disorder 30,752 10.5 Panic attack 57,142 22.7 
4 Anxiety state NOS 14,430 5.6 Stress related problem 31,989 12.7 
5 [X]Obsessive - 
compulsive disorder 
7,869 2.6 C/O - panic attack 9,553 3.8 
6 Generalised anxiety 
disorder 
6,665 1.4 Feeling stressed 5,183 2.1 
7 [X]Mixed anxiety and 
depressive disorder 
6,590 1.2 O/E - anxious 979 0.4 
8 [X]Post - traumatic stress 
disorder 
5,874 1.2 Obsessional thoughts 554 0.2 
9 Chronic anxiety 4,703 1.1 ---   
10 Obsessive-compulsive 
disorders 
3,867 0.9 ---   
NOS=not otherwise specified 
C/O=complain of 
O/E=on examination of 
[X]: These Read codes have been added to ensure mapping to all ICD codes 
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Table 3-5 Top 10 most frequently used Read codes for recording of bipolar 
disorder (N=5,168) 
 
Diagnostic codes (15,115)   Symptom codes (214) 
 
Read code description n % Read code description n % 
1 [X]Bipolar affective disorder 5,846 38.7 Elevated mood 158 73.8 
2 [X]Hypomania 2,236 14.8 O/E - elated 56 26.2 
3 [X]Manic-depressive illness 1,344 8.9 ---   
4 Bipolar psychoses 1,045 6.9 ---   
5 Unspecified bipolar affective 
disorder 
821 5.4 ---   
6 Single manic episode, mild 609 4.0 ---   
7 [X]Mania NOS 338 2.2 ---   
8 [X]Manic episode 262 1.7 ---   
9 Manic disorder, single episode 237 1.6 ---   
10 [X]Cyclothymia 210 1.4 ---   
O/E=on examination of 
[X]: These Read codes have been added to ensure mapping to all ICD codes 
 
3.3-59 | P a g e  
 
Table 3-6 Top 10 most frequently used Read codes for recording of 
schizophrenia and other related psychotic disorders (N=12,335) 
 
Diagnostic codes (29,257)  Symptom codes (3,848) 
 
Read code description n % Read code description n % 
1 Schizophrenic disorders 5,991 20.5 Hallucinations 2,900 75.4 
2 [X]Psychosis NOS 2,629 9.0 Delusions 788 20.5 
3 Paranoid schizophrenia 1,781 6.1 Delusion 160 4.2 
4 Psychotic episode NOS 1,602 5.5 ---   
5 Nonorganic psychosis NOS 1,556 5.3 ---   
6 [X]Schizoaffective disorders 1,101 3.8 ---   
7 Bipolar psychoses 1,045 3.6 ---   
8 [D]Hallucinations, auditory 1,011 3.5 ---   
9 Paranoid states 1,000 3.4 ---   
10 [X]Paranoid psychosis 966 3.3 ---   
NOS=not otherwise specified 
[D]: Working diagnosis 
[X]: These Read codes have been added to ensure mapping to all ICD codes 
 
3.3-60 | P a g e  
 
3.3.2 Recording of each mental illness over time 
To investigate whether the recording of mental illness changed during the study 
period and how, yearly prevalence figures of clinically recognised depression, anxiety, 
bipolar disorder and schizophrenia and other related psychotropic disorders from 
1990 to 2008 were calculated as the number of women with recordings of each type 
of mental illnesses during each year among all women who remained registered on 
the first day of July of that year.  Recording for diagnoses and symptoms were 
examined separately for each mental illness.  Data from 2009 were excluded since 
data were only collected up to July and were thus incomplete for that year. 
Figure 3-1 shows proportions of women with one or more recordings of clinically 
recognised depression by diagnoses and symptoms separately during each year from 
1990 to 2008.  From 1990 to 2003, the prevalence of recording of both diagnoses and 
symptoms generally increased but overall was approximately 2-4.5% annually.  
Recording of depressive diagnoses however decreased after 2004 but recording of 
symptoms continued to increase (Figure 3-1). Similar patterns were also found in 
women with recording of anxiety (Figure 3-2) with overall 1-2.5% annually, bipolar 
disorder (Figure 3-3) with overall 0.03-0.06% annually and schizophrenia and other 
related psychotic disorders (Figure 3-4) with overall 0.07-0.10% annually, although 
the trend was less marked for these conditions. 
My results show that before 2004, recording of diagnostic codes for depression, 
anxiety and serious mental illness in THIN general practices increased steadily.  Prior 
research on diagnoses in THIN data100 have also shown increases over time and this 
may partially be due to more complete recording especially after the mid-1990s, by 
which time most of the THIN general practices had started using Vision system.  
Compared with recording of diagnoses, recording of mental illness symptoms was 
rare in early 1990s, though it increased slightly afterwards, especially for depressive 
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symptoms.  However, the recording of diagnostic codes for all mental illnesses was 
decreasing after the year 2004 but the recording of symptoms continued to increase.  
The reasons for these changes are unclear.  One potential explanation is that the 
introdXFWLRQRI42)SD\PHQWVDIWHUKDGDQHIIHFWRQWKHVSHFLILFLW\RI*3¶V
diagnostic coding, such that they were less willing to assign more definitive diagnoses 
in uncertain or borderline cases of mental illness in their patients.  Several studies 
have found unintended effects of performance-based contracting on clinical practice 
in primary care.79,101,102  The QOF incentive may produce changes in documentation 
rather than changes in the actual diagnosis or health care treatment delivered to 
patients.  Our findings may be an example of this behaviour; however, the inclusion of 
both diagnosis and symptom records show that there is some but not considerable 
variation over time.  The overall increase in recording may also be due to a general 
increase in awareness of mental illness by doctors and the general population over 
the past two decades.
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Figure 3-1 Proportions of women with one or more recordings of clinically 
recognised depression by diagnoses and symptoms separately each year from 
1990 to 2008 
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Figure 3-2 Proportions of women with one or more recordings of clinically 
recognised anxiety by diagnoses and symptoms separately each year from 
1990 to 2008 
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Figure 3-3 Proportions of women with one or more recordings of clinically 
recognised bipolar disorder by diagnoses and symptoms separately each year 
from 1990 to 2008 
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Figure 3-4 Proportions of women with one or more recordings of clinically 
recognised schizophrenia and other related psychotic disorders by diagnoses 
and symptoms separately each year from 1990 to 2008 
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3.3.3 Length of psychotropic drug prescriptions  
The duration of prescriptions was calculated by using three variables in the Therapy 
WDEOHRI7+,17KHVHDUHYDULDEOHµU[GD\V¶ZKLFKLVWKHGXUDWLRQRIWKHSUHVFULSWLRQLQ
GD\VYDULDEOHµU[TW\¶ZKLFKLVTXDQWLWy prescribed in the prescription and variable 
µGRVJYDO¶ZKLFKLVWKHGDLO\GRVDJHRIWKHSUHVFULSWLRQ.  If the duration of a prescription 
YDULDEOHCU[GD\V¶ZDVPLVVLQJWKHOHQJWKRIWKHSUHVFULSWLRQVZDVFDOFXODWHGE\
using quantity prescribed in that pUHVFULSWLRQYDULDEOHµU[TW\¶GLYLGHGE\WKHGDLO\
GRVDJHYDULDEOHµGRVJYDO¶ZKHQVXFKLQIRUPDWLRQZDVDYDLODEOH  It was assumed 
that the maximum of duration of a single prescription was no more than 6 months (24 
weeks, 168 days).  Extreme values (more than 168 days) therefore were excluded 
and treated as missing data in the estimation.  In addition, since women may have 
more than one psychotropic drug prescription recorded in the same day, it was 
assumed that these prescriptions would be taken around the same time and only the 
prescription with the longest duration was included in the estimation.  The results from 
the descriptive analyses show that overall approximately one third of the prescriptions 
had missing value on duration of prescriptions and the median time of prescriptions 
was 28 days (IQR 28-30). 
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3.3.4 Prescriptions of psychotropic medication over time 
To investigate whether the recording of prescriptions of psychotropic drugs changed 
over the study period and how it changed, I calculated the yearly prevalence of 
prescriptions of antidepressants, anti-anxiety drugs, anti-manic drugs, and 
antipsychotic drugs from 1990 to 2008 as a proportion of women with recordings of 
each type of psychotropic drugs during each year in women who remained registered 
on the first day of July of that year.  Information from 2009 was excluded since the 
data were incomplete for that year. 
Figure 3-5 shows the prevalence of drug prescriptions during each year over time. 
There was an increase in prevalence of all psychotropic drugs, but this was most 
evident for prescriptions of antidepressants.  Prescriptions of antidepressants 
increased dramatically in the last two decades from about 3% in 1990 to 12% in 2008, 
and became the most frequently prescribed class of psychotropic drugs in women of 
childbearing age (Figure 3-5).  The increasing trend for prescriptions of 
antidepressants and anti-anxiety drugs was clearly larger than the increases 
observed in the medical recording of mental illness.  Previous UK studies using 
primary care data also report a substantial increase in the prevalence of 
antidepressant prescribing from the early 1990s,103±105 especially in women.103 
No clear explanations however have been given for such remarkable increases.106±109  
Moore et al. conducted a study attempting to explain the rise in antidepressant 
prescribing by using GPRD,108  and suggested that the dramatic change in 
antidepressant prescribing was largely due to the increased proportion of patients 
remaining on long term antidepressant treatment (at least five years), who were also 
prescribed the most antidepressants in the primary care.  However, another study 
IRFXVHGRQWKH*3¶VSHUVSHFWLYHVDUJXHGWKDWWKHLQFUHDVHGSUHVFULELQJRI
antidepressants could be simply because more attention to mental illness has been 
3.3-68 | P a g e  
 
paid by both doctors and patients which could be due to increased awareness of its 
high social and economic burden and decreased discrimination related to it.109 
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Figure 3-5 Proportions of women with one or more prescriptions of different psychotropic drugs during each year from 1990 to 2008 
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3.3.5 The pattern of antidepressant prescribing and switching 
Since antidepressants were becoming the most frequently prescribed psychotropic 
medication, I additionally investigated the prevalence by different types of 
antidepressants separately, namely selective serotonin re-uptake inhibitors (SSRIs), 
tricyclic antidepressants (TCAs) and other antidepressants which are not included as 
SSRIs or TCAs (i.e. venlafaxine, reboxetine, mirtazapine, tryptophan, duloxetine, 
flupentixol, and monoamine-oxidase inhibitors). 
Figure 3-6 shows the changes in proportions of different classes of antidepressants 
prescribed to women as their first ever antidepressant during each year from 1990 to 
2009 (the denominator was the number of women with a first ever antidepressant 
prescription during each year).  The proportion of TCAs as first prescriptions 
decreased steadily from nearly 90% in 1990 to just about 20% in 2009 in contrast with 
a substantial increase in prescriptions of SSRIs (less than 10% in 1990 but more than 
70% in 2009).  There were no remarkable changes for other antidepressants (7% and 
5% in 1990 and 2009, respectively). 
Figure 3-7 shows the changes in proportions of women prescribed the same class of 
antidepressants for their first three antidepressant prescriptions for women initially 
prescribed TCAs, SSRIs or other antidepressants separately during each year from 
1990 to 2009 (the denominators were the numbers of women with the first ever TCA, 
SSRI or other antidepressant who had at least three prescriptions).  In 1990, women 
were most likely to stay in the same drug class for the next two prescriptions if they 
were prescribed a TCA as the first-line antidepressant, compared with those 
prescribed a SSRI or other antidepressant.  This however changed over the next 
decade, during which time the proportions of women prescribed the same drug class 
for their first three prescriptions steadily increased for those initially prescribed an 
SSRI (67% in 1990 and 88% in 2000) but decreased for those prescribed a TCA (85% 
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and 64%, respectively).  After 2000, the figure for TCAs also increased along with 
those for SSRIs (84% for TCAs and 96% for SSRIs in 2009).  For women initially 
prescribed other antidepressants, the proportion of women prescribed the same drug 
class for their first three prescriptions was lowest in 1990 (45%) among all three type 
of antidepressants and continued to decrease to 35% in 1993; however, this figure 
increased dramatically afterwards to 86% in 2009 (Figure 3-7). 
My results from examining antidepressant prescribing show that antidepressant 
prescribing and switching of drug classes has changed remarkably since 1990s.  In 
THIN general practices, women are increasingly prescribed SSRIs as the first choice 
antidepressant in contrast to a considerable decreased use of TCAs.  Subsequent 
drug switching within the same drug class rather than to a different class 
progressively happens in women initially prescribed an SSRI and other 
antidepressants but not in those with a TCA which is in accordance with the current 
guidelines.110,111 
During the study period, several guidelines have been published to regulate 
antidepressant prescribing and switching in the UK primary care.110,112±114  In general, 
the guidelines emphasised that GPs should choose relatively safe and tolerable 
antidepressants (mainly newly developed antidepressants, such as SSRIs) as the 
first-line antidepressants.  More recent guidelines also suggested that switching of 
antidepressants should be first within the same drug class, especially when SSRIs 
were initially prescribed.98 
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Figure 3-6 Proportions of different antidepressants prescribed as the first-line drug treatment during each year from 1990 to 2009 
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Figure 3-7 Proportions of women prescribed the same class of antidepressants for the first three prescriptions from 1990 to 2009 
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3.3.6 First recording of mental illness and psychotropic drug prescriptions in the 
early period following registration: incident or prevalent illness? 
To assess the extent of mental illness recording as a medical history, I calculated the 
rate of first recorded mental illness (including recording of diagnoses and/or 
symptoms) for women newly registering with a computerised general practice 
(registered after general practice computerisation date), every three months for the 
first four years following registration, for each type of mental illness.  The results are 
shown separately for depression (Figure 3-8), anxiety (Figure 3-9), bipolar disorder 
(Figure 3-10) and schizophrenia and other related psychotic disorders (Figure 3-11) 
since registration.  For all mental illnesses, the incidence was much higher in the first 
three months following registration and then plateaued in the remaining period. 
I also repeated the same analyses for first recorded prescriptions of each type of 
psychotropic drugs since women registered with a general practice using a 
computerised system.  The results are shown for antidepressants (Figure 3-12), anti-
anxiety drugs (Figure 3-13), anti-manic drugs (Figure 3-14), and antipsychotics 
(Figure 3-15) separately.  For all psychotropic drug prescriptions, the incidence of 
ZDVKLJKHVWLQWKHILUVWWKUHHPRQWKVIROORZLQJZRPHQ¶VUHJLVWUDWLRQDQGWKHQ 
plateaued in the remaining period. 
My results show that there was increased recording of mental illness in the first three 
PRQWKVIROORZLQJZRPHQ¶UHJLVWUDWLRQZLWKDFRPSXWerised general practice.  Lewis et 
al., who used data from GPRD, examined several acute and chronic conditions, but 
did not include mental illness, and found increased recording during the early period 
of registration.95  This may suggest that the cases identified in the period immediately 
following registration could be those patients with existing mental illness actively 
seeking medication or those with a history of mental illness.  The increased recording 
of psychotropic drug prescriptions in the first three months after registration 
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suggested these patients were likely to have active illness and need medical 
treatment.  My analysis suggested that at least the first three months should be 
excluded when attempting to identify cases of patients with a new incident episode of 
mental illness.  It is also possible, however, that some patients were suffering from a 
new episode of illness, which prompted them to register with a GP so than they could 
receive medical care. 
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Figure 3-8 Rate of first recorded depression in women registered with a 
computerised general practice 
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Figure 3-9 Rate of first recorded anxiety in women registered with a 
computerised general practice 
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Figure 3-10 Rate of first recorded bipolar disorder in women registered with a 
computerised general practice 
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Figure 3-11 Rate of first recorded schizophrenia and other related psychotic 
disorders in women registered with a computerised general practice 
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Figure 3-12 Rate of first recorded antidepressants prescriptions in women 
registered with a computerised general practice 
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Figure 3-13 Rate of first recorded anti-anxiety drug prescriptions in women 
registered with a computerised general practice 
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Figure 3-14 Rate of first recorded anti-manic drug prescriptions in women 
registered with a computerised general practice 
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Figure 3-15 Rate of first recorded antipsychotic prescriptions in women 
registered with a computerised general practice 
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3.4 Discussion and conclusion 
My results on assessing recordings of mental illness in THIN are generally consistent 
with general practice guidelines and results from previous studies using other primary 
care data and reflect current GP clinical practice.  The THIN data I have used are 
therefore appropriate for assessing the clinical burden and the health care needs of 
the women with mental illness in UK primary care. 
To define women with mental illness, alongside recording of diagnoses, recordings of 
psychotropic drug prescriptions and mental illness symptoms should also be 
considered to reflect the on-going health care management for patients with mental 
health problems in UK primary care and the changes in its clinical practices adopted 
by GPs.  I have therefore attempted to identify patients with mental illness presenting 
to and/or treated in UK general practice by using combinations of recordings of 
mental illness diagnoses, symptoms and drug prescriptions as described later (please 
see Section 4.3.2 for the details).  However, I will have missed women with mental 
illness who did not report their symptoms to their GPs or health care workers.  Since 
all pregnant women must be registered with GPs in order to benefit from antenatal 
checks, free medications, hospital antenatal and postnatal care, and health services 
provided by midwives or health visitors, it is unlikely that a high proportion of women 
with significant mental illness, especially those with psychotropic drug prescriptions, 
would be misclassified.  The results however are PRUHOLNHO\WRUHIOHFWSDWLHQWV¶KHDOWK
seeking behaviours rather than the true disease activity.  My approaches to identify 
women with mental illness therefore is likely to be pragmatic rather than exhaustive 
and the population identified by such approaches represents those presenting to 
and/or clinically treated in UK primary care which will be relevant for public health 
planning and policy making. 
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4 Clinical burden of maternal perinatal mental illness in United 
Kingdom primary care and its associated factors 
This chapter describes a cross-sectional study conducted to estimate the current 
clinical burden of maternal depression, anxiety and serious mental illness (bipolar 
disorder, schizophrenia and other related psychotropic disorders) presenting to UK 
primary care in women in and around pregnancy, and the associations with age, 
socioeconomic status, and other maternal factors. 
4.1 Introduction 
4.1.1 Occurrence of depression and associated factors 
Prevalence and incidence of maternal depression 
There have been a great number of studies estimating the prevalence and incidence 
of maternal depression during and after pregnancy in the literature.  Previous work 
however commonly focuses on subgroups and few general population based 
estimates are available.  A meta-analysis of maternal depression in high-income 
countries found the prevalence of major depressive disorder in women during 
pregnancy and in the first year postpartum was approximately 6.5% to 12.9%, yet 
individual study estimates have varied very widely.12  Table 4-1 summaries all 
systematic reviews (and/or meta-analyses) published on estimating prevalence 
and/or incidence of depression in women in and around pregnancy in English 
language journals. 
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Table 4-1 Systematic reviews and/or meta-analyses on estimating prevalence and/or incidence of maternal depression in and around 
pregnancy 
Author(s), 
publication year 
Study type and 
period 
Interested 
outcome 
Inclusion criteria Number of 
studies 
initially 
identified 
Number of 
studies 
finally 
included 
Total population Prevalence (95% CI) 
Study population Diagnosis method 
Gavin et al., 
200512 
Systematic 
review from 
January 1980 to 
March 2004 
Prenatal and/or 
postnatal 
depression 
Women recruited during 
pregnancy or the first year 
postpartum 
Clinical assessment or 
structured clinical 
interview (i.e. RDC, DSM 
and ICD) 
109 28 54 to 4,964 women 
per study (median 
sample size=202) 
During pregnancy and in 
the first postpartum year: 
6.5% to 12.9% 
Bennett et al., 
2004115 
Meta-analysis 
from 1966 
Prenatal 
depression by 
different trimester 
Pregnant women aged over 
17 years recruited from 
general obstetric and 
prenatal units or from 
population surveys 
Self-report questionnaire 
(i.e. BDI and EPDS) or 
structured clinical 
interview (i.e. SADS, SCID 
and RDC) 
714 21 19,284 First trimester: 
7.4% (2.2-12.6) 
Second trimester: 
12.8% (10.7-14.8) 
Third trimester: 
12.0% (7.4-16.7) 
2¶+DUDHWDO
199625 
Meta-analysis Postnatal 
depression by 
different diagnosis 
method 
Pregnant women recruited 
through random or quasi-
random techniques and 
assessed after at least two 
weeks postpartum 
Self-report questionnaire 
or structured clinical 
interview 
Not reported 59 12,810 Overall:12.8% (12.3-13.4) 
BDI:11.6% (9.7-13.5) 
CES-D:18.0% (16.1-19.9) 
EPDS:12% (10.9-13.1) 
RDC:10.5% (9.7-11.3) 
DSM:7.2% (3.7-10.7) 
BDI=Beck Depression Inventory 
CES-D=Centre for Epidemiological Studies-Depression 
CI=confidence interval 
DSM=Diagnostic and Statistical Manual III, III-R 
DSM-IV=Diagnostic and Statistical Manual of Mental Disorders, IV 
EPDS=Edinburgh Postnatal Depression Score 
RDC=Research Diagnostic Criteria 
SADS=Schedule for Affective Disorders and Schizophrenia 
SCID=Structured Clinical Interview for DSM Disorders 
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While previous studies have generally found that depression is highly prevalent in 
women during the perinatal period, the estimates have varied considerably based on 
different study population and assessment methods.  Most previous research has 
assessed depression by, often study-specific, screening with self-administered 
questionnaires, such as the Edinburgh Postnatal Depression Scale (EPDS, Appendix 
III).  The EPDS questionnaire was designed to assess how a pregnant woman or a 
new mother felt in the past seven days.116  It contains 10 single-choice questions and 
the maximum score is 30.  Although a score above 12 or 13 is widely used to indicate 
that mothers are likely to be suffering from depressive symptoms of varying severity, 
a score above certain threshold cannot in itself confirm a diagnosis of depression and 
such thresholds may over- or under-estimate depression during pregnancy or 
postpartum.117±119  Therefore, the EPDS score should not override clinical judgement.  
For example, a previous cohort study in south-west England assessed 12,000 women 
using the EPDS and found that at 32 weeks of pregnancy 13.5% of women scored 
equal or over 12 on EPDS for probable depression and 9.1% at eight weeks 
postpartum.120  The study found a similar risk pattern after the researchers used a 
higher EPDS threshold (a score equal or over 13) in pregnancy.  This study found 
that overall depression scores (measured by the EPDS) were also higher at 32 weeks 
of pregnancy than eight weeks postpartum (mean difference=0.88, 95% confidence 
interval [CI] 0.79-0.97) and concluded that symptoms of depression are not more 
common or severe after childbirth than during pregnancy.  In addition, an Australian 
study retrospectively assessed women for symptoms of depression using the 
Delusions-Symptoms-States Inventory (similar to EPDS) during the perinatal period 
and found that the risk of depression at 6-month postpartum was lower compared 
with shortly after childbirth.121 
In contrast to studies using various questionnaires to measure depression, by using a 
structured clinical interview a UK study examining nearly 5,000 women found 15% of 
4.1-88 | P a g e  
 
women had depression in the early postpartum period.122  Another fairly recent UK 
study using routine primary health care data from general practice records found the 
incidence of new maternal depression, defined as first depression diagnosis or 
antidepressant prescription after at least 12 months with neither, was 14/100 person-
years at the time of the birth and then decreased to 10/100 person years at 6 months 
after birth.91 
Very few studies have compared the burden of maternal depression in women during 
the perinatal period with those in non-childbearing periods.  Previous studies in high-
income countries comparing women before or after pregnancy with similar age 
groups of women during non-childbearing periods found slightly higher, but not 
statistically significant, prevalence of non-psychotic psychiatric illness (mainly 
depression) in women during the perinatal period.123±125  These studies however had 
very small sample sizes and all dated back to the early 1990s.  In addition, after 
restricting to new onset of depression, one of the studies conducted in UK found a 3-
fold increased incidence of postpartum depression in women within five weeks of 
delivery compared to women during non-childbearing periods.124 
Factors associated with maternal depression in and around pregnancy 
Previous research suggests that the prevalence and/or incidence of maternal 
depression may vary substantially by different maternal socio-demographic and 
lifestyle factors.  For instance, a recent American study of more than 75,000 non-
pregnant women aged 18-44 years found that the prevalence of major depression 
was greatest in women who were over 35 years of age, unmarried, less educated, 
unable to work or unemployed or with low income.20 
For maternal depression in and around pregnancy, most studies have focused on 
women during the postpartum period.  O'Hara and Swain conducted a meta-analysis 
to identify risk factors associated with postpartum depression, which included 59 
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studies from high-income countries.25  This study found that the prevalence of 
postpartum depression was 13% and was highest in women with a history of 
psychological disorder during pregnancy, poor marital relationship and low social 
support, and stressful life events.  Particularly, this study showed that women with 
higher income had a lower score of depression (measured by various self-
administrated questionnaires, such as the EPDS) than women with low income (mean 
difference=-0.14, 95% CI -0.21 to -0.08).  In addition, it only found a marginally 
increased, but not statistically significant, score for depression with increased age 
(mean difference=0.04, 95% CI 0.00 to 0.09).25 
Rich-Edwards and colleagues in America investigated whether socio-demographic 
factors were associated with antenatal or postnatal depression measured using 
EPDS (EPDS>12 defined as having probable depression).22  They examined 1,662 
women during and after pregnancy prospectively and found that the strongest risk 
factor for maternal depression in mid-pregnancy was a history of depression (odds 
ratio [OR] =4.07, 95% CI 3.76 to 4.40), and the strongest risk for depression at six 
weeks postpartum was depressive symptoms during pregnancy (OR=6.78, 95% CI 
4.07 to 11.31) or a history of depression before pregnancy (OR=3.82, 95% CI 2.31 to 
6.31). 
In addition, the American study found an increased odds of postpartum depression in 
women with financial hardship (OR=3.6, 95% CI 1.9-6.7) after adjusting for maternal 
age, race/ethnicity, immigration status, parity and annual household income.22  
Although women aged less than 23 years had two to three times the odds of having 
maternal depression during or after pregnancy as those aged 30-34 (OR=2.71, 95% 
CI 1.4-5.2 in mid-pregnancy and OR=2.37, 95% CI 1.05-5.38 at six months 
postpartum after adjusting for race/ethnicity), after adjusting for household income, 
the association of maternal age with depression was decreased and was not 
statistically significant (e.g. OR=1.87, 95% CI 0.93-3.74 for antenatal depression), 
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suggesting that the effect of maternal age was largely driven by different financial 
circumstances.22 
Likewise, Warner et al. carried out a study in the south Manchester area of England 
to identify the risk factors of postnatal depression.24  They examined 2,375 women at 
six weeks postpartum and found unplanned pregnancy (OR=1.44, 95% CI 1.10-1.89), 
not breast feeding (OR=1.52, 95% CI 1.12-2.06), maternal unemployment (OR=1.56, 
95% CI 1.14-2.12) and head of household unemployed (OR=1.50, 95% CI 1.10-2.04) 
were associated with an increased risk of postpartum depression after they mutually 
adjusted for each other.  This study also found a slightly decreased risk of postpartum 
depression in women with increased age (unadjusted OR=0.94, 95% CI 0.92-0.96).  
This association however disappeared after adjusting for other socio-demographic 
factors. 
A more recent American study recruited nearly 2,000 women during pregnancy and 
depression was assessed using criteria from the DSM-IV based on the Patient Health 
Questionnaire.126  About 10% of women had antenatal depression and half had major 
depression.  After mutual adjustment, psychosocial stress, domestic violence, chronic 
medical conditions and ethnicity were associated with an increased odds of both 
antenatal and postpartum depression, whereas older age was associated with a 
decreased odds.  No association however was found between depression and years 
of education. 
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4.1.2 Occurrence of anxiety and associated factors 
Compared with depression, far fewer studies have been conducted to estimate the 
prevalence and/or incidence of maternal anxiety during the perinatal period.  To my 
best knowledge, there has been only one systematic review on maternal anxiety.  
Based on three small studies, this systematic-review however reported that the 
prevalence of generalised anxiety disorder ranged from 4.4-8.2% postpartum.127  It 
concluded that there were too few studies to obtain adequate estimates around 
pregnancy. 
In addition, studies that have estimated the burden of maternal anxiety so far have 
been on a much smaller scale.  For example, a previous US study interviewed 68 
women and found 4.4% of them had generalized anxiety disorder during the early 
postnatal period.128  Another more recent French study assessing 497 women using a 
structured diagnostic interview found that nearly 25% of women suffered from anxiety 
during the third trimester of pregnancy.129 
Very few studies have been conducted to examine factors associated with the 
occurrence of maternal anxiety.  Wenzel et al. interviewed 174 women at 
approximately eight weeks after childbirth and found that personal psychiatric history, 
family psychiatric history, and socioeconomic status were significantly associated with 
increased risks of anxiety symptoms measured using the Beck Anxiety Inventory.130  
In addition, research has shown that a history of previous mental illness, and 
particularly a history of major depression or generalised anxiety disorder, is 
associated with increased risks of post-traumatic stress disorder following 
childbirth.131±133 
4.1.3 Occurrence of serious mental illness and associated factors 
Whilst relatively few studies have estimated prevalence and/or incidence of less 
common but more severe psychiatric illness (i.e. bipolar affective disorder and 
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schizophrenia and other related psychotic disorders), their estimates are fairly 
consistent at about 1 per 1,000 women during the perinatal period.26,134±136  Two 
previous large population studies in Denmark found the prevalence of first-time 
severe mental disorders was 0.45-1.03 per 1000 births within the first three months 
after delivery.134,135  Nager et al. examining half a million Swedish first-time mothers 
found that during the postpartum period, 0.07% of them had their first hospitalisation 
due to psychotic disorders.26 
Kendell et al. carried out a large population-based study in Edinburgh, Scotland in 
1987 and found a higher proportion of psychiatric admission in women, mainly 
diagnosed with severe depression and psychotic disorder, after childbirth than during 
pregnancy.136  This higher risk postpartum was particularly evident in first-time 
mothers with a history of mental illness.  In Denmark, Munk-Olsen and colleagues 
examined more than one million first-time parents between 1973 and 2005 and found 
that compared with 6-11 months after childbirth, there was an increased risk of 
hospital admission or outpatient contact for any mental disorder in women during the 
first month postpartum (relative risk ratio [RRR] =3.49, 95% CI 3.01-4.04), but a 
decreased risk during pregnancy (RRR=0.72, 95% CI 0.63-0.81).134  However, a more 
recent study in the same population conducted by the same researchers reported that 
compared with women without children, hospital readmission rate was in fact lower in 
new mothers within the two months after childbirth.137 
In addition, a very large population-based study in Sweden examined the association 
between first hospital admissions due to postpartum psychosis within the first year 
after childbirth and socio-demographic factors in first-time mothers from 1986 to 1997.  
This study found there was an increased risk of having first hospital admission in 
mothers with increased age (e.g. adjusted hazard ratio=6.6, 95% CI 3.1-13.8 in 
women aged 40-44 years compared with women aged 20-24 years after adjusting for 
maternal education level, marital status and year of delivery).26  This Swedish study 
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used education level as a measure of socioeconomic status and found there was no 
association between education level and first hospital admission due to postpartum 
psychosis in first-time mothers.  In contrast, a later study using the same population 
cohort found that women with less years of education were more likely to have 
postpartum psychosis.27 
4.1.4 Overlap or concurrent diagnoses of different mental illnesses 
Although co-morbidity of different mental illnesses, especially between depression 
and anxiety, is fairly common, few studies have estimated the degree of overlap in 
women during the perinatal period.138±143  An Australian study assessing both 
depression (including major or minor depression) and anxiety (including panic, phobia 
and generalised anxiety disorders) found 3.2% of women had both depression and 
anxiety at 6-8 weeks postpartum.139  Lee et al. studied 357 women in an antenatal 
clinic in Hong Kong and found 39-47% of women with common mental disorders had 
both anxiety and depressive symptoms when individually assessed at 6-8 weeks 
postpartum.139  Two previous cross-sectional studies using self-reported patient 
questionnaires in high-income countries found that nearly one third of patients with 
anxiety and/or depression had both conditions.141,143 
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4.2 Rationale and objectives 
Although maternal mental illness during and after pregnancy commonly presents to 
and is primarily treated in general practice, there were no up-to-date estimates of 
these conditions, especially for anxiety and serious mental illness, and hardly any 
estimates of concurrent diagnoses of different mental illnesses in women in and 
around pregnancy at primary care level.  In addition, the most affected groups of 
pregnant women in focus of age and socio-demographics remain unclear. 
The objectives of this large population-based study therefore were to provide current 
estimates of maternal perinatal depression, anxiety and serious mental illness 
identified in UK general practice and its variations by different maternal factors, 
including age, socioeconomic status, lifestyle characteristics, history of previous 
pregnancy and maternal chronic comorbidities. 
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4.3 Methods 
4.3.1 Study population 
From Population 4 in Figure 2-1, I identified women of childbearing age with at least 
one recorded pregnancy ending in live birth between April 1994 and July 2009, and 
with at least 15 months of prospectively recorded data preceding conception and nine 
months following childbirth.  To remove any clustering effects, I randomly selected 
one pregnancy for each woman. 
4.3.2 Measuring perinatal mental illness 
As shown in the previous chapter, recording of diagnoses of mental illness was 
decreasing substantially after 2003 whereas the recording of symptoms was 
increasing, which likely reflected shifting of how GPs label their patients rather than 
decrease of actual disease prevalence.  Both diagnostic and symptom records were 
therefore used to identify women with mental illness.  In addition, in UK general 
practice it is common for patients to be prescribed psychotropic drugs without direct 
recording of the diagnostic indication for the prescription, which likely reflects both the 
diagnostic pathway (e.g. prescriptions of psychotropic drugs as part of diagnostic 
procedure) and routine clinical practice (e.g. a doctor with knowledge of his or her 
SDWLHQW¶VFOLQLFDOKLVWRU\ZLOOQRWQHHGWRUHFRUGDQHZGLDJQRVLVRIGHSUHVVLRQZLWK
each prescription for effective clinical care).  Furthermore, individuals may receive 
more than one type of diagnosis, concurrently or at different times during their life. 
A comprehensive approach therefore was adopted to define and distinguish between 
different t\SHVRIPHQWDOLOOQHVVLQZRPHQ¶VUHFRUGVE\XVLQJDFRPELQDWLRQRIPHGLFDO
diagnoses and psychotropic drug prescriptions.  Maternal mental illness was defined 
during the 9 months before pregnancy, during pregnancy (antenatal period) and 
during the 9 months after pregnancy (postnatal period).  Periods of 9-months were 
used as they were similar in length to the average pregnancy, minimising potential 
4.3-96 | P a g e  
 
effects of different period lengths on prevalence estimates.  Definitions of how 
clinically recognised depression, anxiety and serious mental illness (bipolar disorder, 
schizophrenia, other psychotic disorders) were measured in and around pregnancy 
are shown below: 
x Depression 
 I identified women as having clinically recognised depression in each period 
 if they had records of depression and/or antidepressant prescriptions 
 during that time.  Because antidepressants are also commonly prescribed 
 for other mental illnesses (e.g. anxiety), women who had been prescribed 
 antidepressants but had no diagnosis of depression in their entire medical 
 records were excluded. 
x Anxiety 
 I firstly identified women as having clinically recognised anxiety if they had 
 records of anxiety and/or anxiolytic prescriptions during each period, 
 excluding women who were prescribed anxiolytics with no diagnosis of 
 anxiety throughout their medical record.  Secondly, since anxiety is 
 commonly treated using antidepressants, we identified women with 
 antidepressant prescriptions during the period and a diagnosis of anxiety at 
 any time but without records of depression. 
x Serious mental illness 
 Although serious mental illnesses are considered clinically to have life-long 
 LPSDFWDQG1,&(JXLGHOLQHVLQGLFDWHWKHLPSRUWDQFHRINQRZLQJDZRPDQ¶V
 history of psychotic illness, I focused on evidence of currently recognised 
 illness.  Women were considered to have clinically recognised bipolar 
 disorder during each period if they had medical records of the illness 
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 and/or prescriptions of lithium or mood stabilisers during that time.  Since 
 mood stabilisers are also used for other conditions (e.g. epilepsy), women 
 prescribed mood stabilisers but with no diagnoses of bipolar disorder in their 
 medical records were excluded.  We identified women with schizophrenia and 
 other psychotic disorders in the same way and, as these are rare conditions, 
 JURXSHGWKHPWRJHWKHUDVµVHULRXVPHQWDOLOOQHVV¶ 
4.3.3 Extracting maternal age, socioeconomic status and other factors 
)URPZRPHQ¶VPHGLFDOUHFRUGV,H[WUDFWHGGDWDRQWKHIROORZLQJFKDUDFWHULVWLFVRI
women: maternal age at the end of pregnancy (categorised as 15-24, 25-34, and 35-
45 years), year of childbirth (categorised as 1994-1999, 2000-2004, and 2005-2009),  
household socioeconomic status, maternal body mass index (BMI, kg/m2) before 
pregnancy and most recent smoking status before delivery.  I also extracted data on 
ZRPHQ¶VSUHJQDQF\KLVWRU\LHQXPEHURISUHYLRXVNQRZQOLYHELUWKVDVDSUR[\RI
parity) and other known important maternal comorbidities which might complicate the 
pregnancy, including maternal pre-existing diabetes and hypertension and maternal 
asthma and epilepsy.  Definitions of how these factors were measured are shown 
below: 
x Socioeconomic status 
 Socioeconomic status was measured using postcode-level Townsend 
 Index of Deprivation.144  To maintain anonyPLW\LQ7+,1SDWLHQWV¶KRPH
 postcodes are assigned a quintile of Townsend Index before data leave the 
 general practice.  As quintiles are based on census data distribution, they  are 
 UHSUHVHQWDWLYHRIZRPHQ¶VUHODWLYHVRFLRHFRQRPLFSRVLWLRQDWUK national 
 level. 
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x Pre-gestational diabetes (pre-existing diabetes before pregnancy) 
 Records of diagnosed diabetes were extracted from both Medical and 
 Additional Health Data files and records for anti-diabetic drug prescriptions 
 were extracted from Therapy file, according to BNF (Chapter 6.1.1, 6.1.2,  and 
 6.1.3).  Women were defined as having pre-existing diabetes if they ever had  
 a clinical record of diabetes (except gestational diabetes) before the expected 
 date of conception or ever had a prescription of either insulin or oral 
 hypoglycaemic agents during or before pregnancy but without diagnoses of 
 diabetes. 
x Pre-gestational hypertension (pre-existing hypertension before pregnancy) 
 Records of diagnosed hypertension and prescriptions of anti-hypertensive 
 drugs were extracted.  Women were identified as having pre-existing 
 hypertension if they had records of either diagnoses or drug prescriptions 
 before pregnancy.  Women with records of drug prescriptions during 
 pregnancy but no diagnostic records either before or during pregnancy 
 were also included. 
x Asthma 
 Records of diagnosed asthma and prescriptions of anti-asthmatic medication 
 were extracted.  Women were defined with asthma if they had an asthma 
 diagnosis ever before the end of the first trimester and had a recording of 
 asthma exacerbation or prescriptions of any anti-asthmatic drugs within one 
 year before and during pregnancy. 
x Epilepsy 
 Records of diagnosed epilepsy were extracted from both Medical and 
 Additional Health Data files and epilepsy medication prescriptions were 
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 extracted from Therapy file.  Women were defined as having epilepsy if they 
 had diagnostic recording of epilepsy ever and had a recording of prescriptions 
 from one year before or during pregnancy. 
4.3.4 Statistical analyses 
Prevalence and overlap of perinatal mental illness 
The prevalence of clinically recognised depression, anxiety and serious mental illness 
with or without treatment in women presenting to UK primary care was calculated as 
the proportions (with 95% confidence intervals [CI]) of all women during the periods 
before, in and after pregnancy using a combination of medical records of mental 
illness and psychotropic drug prescriptions.  I also estimated the prevalence of each 
mental illness by only using recordings of diagnoses/symptoms (but not drug 
prescriptions).  In addition, I restricted prevalence estimates to women whose first 
ever recording of each mental illness fell in each 9-months period to estimate newly-
recognised mental illness before, during and after pregnancy.  The period of 9-
months before pregnancy was used as a reference period as an indication of baseline 
prevalence in women during childbearing, but not the perinatal, period. 
In addition, the overall prevalence of each mental illness measured by combination of 
diagnoses/symptoms and psychotropic drug prescriptions was assessed by maternal 
age, year of childbirth, socioeconomic status, maternal smoking history, maternal BMI 
before pregnancy, pregnancy history and maternal comorbidity (including maternal 
pre-existing diabetes and hypertension and asthma and epilepsy).  To provide 
estimates of concurrent diagnoses (overlapping illness), proportions of women with 
two or more different diagnoses were also calculated. 
Impact of socioeconomic status stratified by age 
Logistic regression was used to calculate odds ratios (ORs) for the association of 
each maternal mental illness during and after pregnancy with socioeconomic 
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deprivation.  Given that the effect of socioeconomic deprivation on mental illness 
could vary substantially by age, I assessed effect modification using the likelihood 
ratio test and presented prevalence estimates to show absolute risks of clinically 
recognised mental illness in each deprivation quintile, stratified by maternal age 
alongside odds ratios adjusted for calendar period and the number of ZRPHQ¶V
previously recorded live births.  I also conducted a sensitivity analysis and assessed 
the impact of socioeconomic status using ZRPHQ¶Vfirst clinically recognised mental 
illnesses. 
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4.4 Results 
4.4.1 Prevalence and overlap of perinatal mental illness 
I identified 116,457 women with at least one pregnancy ending in a live birth.  The 
median age at the end of pregnancy was 31 years (IQR 26-35) and the numbers 
(proportions) of pregnant women aged 15-24, 25-35 and 35-44 years were 21,341 
(18.3%), 64,214 (55.1%) and 30,902 (26.5%) respectively.  Of all women, 23.2% 
(26,984) were from the least socioeconomically deprived group whereas 14.2% 
(16,524) were from the most socioeconomically deprived group (5.3% (6,172) had no 
socioeconomic group recorded). 
Table 4-2 shows the clinical presentation of depression, anxiety and serious mental 
illness in and around pregnancy.  Compared with maternal depression in the period 
before pregnancy (9.3%), prevalence was lower during pregnancy (5.1%) and higher 
postpartum (13.3%).  For anxiety and serious mental illness, prevalence before 
pregnancy was similar to after, although clinical recording for both was lower during 
pregnancy (2.6% and 0.09% respectively).  Compared with all clinical presentations, 
first presentations were less common but had similar prevalence patterns over the 
three periods, such that they were still lowest in the antenatal period.  When 
restricting to mental illness defined by clinical diagnoses/symptoms only during each 
period, the prevalence was as expected decreased for all mental illnesses but the 
similar pattern that the prevalence was lower during pregnancy was observed again. 
Figure 4-1 shows the overlap of different mental illnesses in women in and around 
pregnancy.  Majority women with serious mental illness also had depression or 
anxiety, yet most diagnostic overlap was between common mental illnesses with 
about 20% of women with depression also having anxiety in and around pregnancy 
(Figure 4-1). 
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Table 4-2 Prevalence of maternal depression, anxiety and serious mental 
illnesses presenting to UK general practice in and around pregnancy 
(N=116,457) 
 
Depression Anxiety Serious mental illness 
 
n (%; 95% CI)  n (%; 95% CI) n (%; 95% CI) 
Combination of diagnoses/symptoms and psychotropic drug prescriptions 
Any presentation or treatment 
  
During 9-month before pregnancy 10,802 (9.3; 9.1-9.4) 4,823 (4.1; 4.0-4.3) 143 (0.12; 0.11-0.14) 
During pregnancy   5,926 (5.1; 5.0-5.2) 3,084 (2.6; 2.6-2.7) 110 (0.09; 0.08-0.11) 
During 9-month after pregnancy 15,454 (13.3; 13.1-13.5) 4,325 (3.7; 3.6-3.8) 176 (0.15; 0.13-0.18) 
First presentation or treatment* 
  
During 9-month before pregnancy 3,482 (3.0; 2.9-3.1) 2,253 (1.9; 1.9-2.0) 30 (0.03; 0.02-0.04) 
During pregnancy    975 (0.8; 0.8-0.9) 1,196 (1.0; 1.0-1.1) 14 (0.01; 0.01-0.02) 
During 9-month after pregnancy 5,814 (5.0; 4.9-5.1) 1,621 (1.4; 1.3-1.5) 56 (0.05; 0.04-0.06) 
Clinical diagnoses/symptoms only 
Any presentation 
  
During 9-month before pregnancy   6,481 (5.6; 5.4-5.7) 3,073 (2.6; 2.5-2.7) 61 (0.05; 0.04-0.07) 
During pregnancy   3,333 (2.9; 2.8-3.0) 2,244 (1.9; 1.8-2.1) 45 (0.04; 0.03-0.05) 
During 9-month after pregnancy 12,590 (10.8; 10.6-11.0) 3,024 (2.6; 2.5-2.7) 97 (0.08; 0.07-0.10) 
First presentation*   
During 9-month before pregnancy 2,578 (2.2; 2.1-2.3) 1,741 (1.5; 1.4-1.6) 34 (0.03; 0.02-0.04) 
During pregnancy    979 (0.8; 0.8-0.9) 1,216 (1.0; 1.0-1.1) 21 (0.02; 0.01-0.03) 
During 9-month after pregnancy 5,900 (5.1; 4.9-5.2) 1,576 (1.4; 1.3-1.4) 60 (0.05; 0.04-0.07) 
Serious mental illness includes bipolar disorder (including mania and hypomania), schizophrenia or other related 
psychotic disorders  
3UHYDOHQFHHVWLPDWHVDUHIRUSUHVHQWDWLRQRU WUHDWPHQWRQO\ZKHQ LW ILUVWDSSHDUHG LQDZRPDQ¶V UHFRUGGXULQJ WKH
respective 9-month period, excluding any women with a history of the relevant mental illness 
CI=confidence interval 
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* Serious mental illness includes bipolar disorder, schizophrenia or other related psychotic disorders 
Figure 4-1 Venn diagrams of prevalence of maternal perinatal mental illnesses 
and overlap shown as proportions of all pregnant women (N=116,457) 
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4.4.2 Prevalence estimates by different maternal factors 
The prevalence estimates varied considerably by maternal age, socioeconomic status, 
smoking history, maternal BMI and maternal comorbidities.  The results are shown in 
following tables for depression (Table 4-3), anxiety (Table 4-4), and serious mental 
illness (Table 4-5), separately.  Overall, younger women were more likely to have 
depression in and around pregnancy and older women were more likely to have 
serious mental illness whilst anxiety showed less age variation.  Women from groups 
with greater socioeconomic deprivation were more likely to have all three mental 
illnesses compared with groups with less socioeconomic deprivation during the same 
period.  Women who had a history of smoking, abnormal BMI before pregnancy or 
other chronic conditions were also more likely to have a record of the three mental 
illnesses. 
Figure 4-2 shows the prevalence (log10 scale) of clinically recognised depression, 
anxiety and serious mental illness in women in and around pregnancy in three 
different calendar periods.  The prevalence estimates of each mental illness across 
the different time periods generally remain consistent during the study period.  The 
estimates for depression before and during pregnancy however were slightly higher 
after year 2000. 
Figure 4-3 shows the prevalence (log10 scale) of clinically recognised depression, 
anxiety and serious mental illness in women in and around pregnancy by the number 
of previous known live births.  In general, women with higher parity had higher 
prevalence of depression in and around pregnancy.  For anxiety and serious mental 
illness, the prevalence trend however was more stable. 
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Table 4-3 Prevalence of perinatal depression varied by different maternal 
factors (N=116,457) 
 
During 9-month 
before pregnancy 
During pregnancy During 9-month after 
pregnancy 
n % n % n % 
Maternal age at the end of pregnancy, years 
      
   15=<age<25 (n=21,341) 2,209 10.4 1,300 6.1 3,762 17.6 
   25=<age<35 (n=64,214) 5,910   9.2 3,127 4.9 8,305 12.9 
   35=<age<=45 (n=30,902) 2,683   8.7 1,499 4.9 3,387 11.0 
Townsend deprivation index 
      
   1 (least deprivation) (n=26,984) 1,706   6.3 911 3.4 2,648   9.8 
   2 (n=21,978) 1,671   7.6 869 4.0 2,450 11.2 
   3 (n=23,028) 2,190   9.5 1,188 5.2 3,056 13.3 
   4 (n=21,771) 2,449 11.2 1,347 6.2 3,445 15.8 
   5 (most deprivation) (n=16,524) 2,203 13.3 1,276 7.7 3,026 18.3 
   Missing (n=6,172)    583   9.4 335 5.4    829 13.4 
Maternal smoking history 
      
   No (n=62,867) 4,172   6.6 2,169 3.5 6,490 10.3 
   Yes (n=53,590) 6,630 12.4 3,757 7.0 8,964 16.7 
Maternal BMI before pregnancy (kg/m2) 
      
   Under-weight (<18.5) (n=4,023)   4,51 11.2 241 6.0    574 14.3 
   Normal (18.5-24.9) (n=53,365) 4,636   8.7 2,532 4.7 6,509 12.2 
   Over-weight(25-29.9) (n=22,822) 2,269   9.9 1,193 5.2 3,172 13.9 
   Obese (30-39.9) (n=13,667) 1,701 12.4 970 7.1 2,339 17.1 
   Missing (n=22,580) 1,745   7.7 990 4.4 2,860 12.7 
Maternal comorbidity 
      
   No (n=113,786) 10,441   9.2 5,710 5.0 14,980 13.2 
   Yes (n=2,671)      361 13.5 216 8.1      474 17.7 
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Table 4-4 Prevalence of perinatal anxiety varied by different maternal factors 
(N=116,457) 
 
During 9-month 
before pregnancy 
During pregnancy During 9-month after 
pregnancy 
n % n % n % 
Maternal age at the end of pregnancy, years 
      
   15=<age<25 (n=21,341)    891 4.2 606 2.8 842 3.9 
   25=<age<35 (n=64,214) 2,754 4.3 1,680 2.6 2,462 3.8 
   35=<age<=45 (n=30,902) 1,178 3.8 798 2.6 1,021 3.3 
Townsend deprivation index 
      
   1 (least deprivation) (n=26,984)    892 3.3 532 2.0 800 3.0 
   2 (n=21,978)    779 3.5 498 2.3 707 3.2 
   3 (n=23,028)    921 4.0 619 2.7 851 3.7 
   4 (n=21,771) 1,037 4.8 633 2.9 930 4.3 
   5 (most deprivation) (n=16,524)    939 5.7 637 3.9 820 5.0 
   Missing (n=6,172) 255 4.1 165 2.7 217 3.5 
Maternal smoking history 
      
   No (n=62,867) 1,875 3.0 1,279 2.0 1,800 2.9 
   Yes (n=53,590) 2,948 5.5 1,805 3.4 2,525 4.7 
Maternal BMI before pregnancy (kg/m2) 
      
   Under-weight (<18.5) (n=4,023) 244 6.1 119 3.0 188 4.7 
   Normal (18.5-24.9) (n=53,365) 2,226 4.2 1,375 2.6 2,001 3.7 
   Over-weight(25-29.9) (n=22,822) 968 4.2 634 2.8 851 3.7 
   Obese (30-39.9) (n=13,667) 669 4.9 450 3.3 595 4.4 
   Missing (n=22,580) 716 3.2 506 2.2 690 3.1 
Maternal comorbidity 
      
   No (n=113,786) 4,672 4.1 2,975 2.6 4,180 3.7 
   Yes (n=2,671) 151 5.6 109 4.1 145 5.4 
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Table 4-5 Prevalence of perinatal serious mental illness* varied by different 
maternal factors (N=116,457) 
 
During 9-month 
before pregnancy 
During pregnancy During 9-month after 
pregnancy 
n % n % n % 
Maternal age at the end of pregnancy, years 
      
   15=<age<25 (n=21,341) 23 0.11 13 0.06 25 0.12 
   25=<age<35 (n=64,214) 63 0.10 53 0.08 86 0.13 
   35=<age<=45 (n=30,902) 57 0.18 44 0.14 65 0.21 
Townsend deprivation index 
      
   1 (least deprivation) (n=26,984) 20 0.07 14 0.05 29 0.11 
   2 (n=21,978) 15 0.07 12 0.05 27 0.12 
   3 (n=23,028) 26 0.11 19 0.08 27 0.12 
   4 (n=21,771) 41 0.19 30 0.14 52 0.24 
   5 (most deprivation) (n=16,524) 35 0.21 30 0.18 35 0.21 
   Missing (n=6,172)   6 0.10   5 0.08   6 0.10 
Maternal smoking history 
      
   No (n=62,867) 49 0.08 35 0.06   67 0.11 
   Yes (n=53,590) 94 0.18 75 0.14 109 0.20 
Maternal BMI before pregnancy (kg/m2) 
      
   Under-weight (<18.5) (n=4,023)   3 0.07   6 0.15   5 0.12 
   Normal (18.5-24.9) (n=53,365) 58 0.11 47 0.09 84 0.16 
   Over-weight(25-29.9) (n=22,822) 30 0.13 19 0.08 36 0.16 
   Obese (30-39.9) (n=13,667) 29 0.21 22 0.16 27 0.20 
   Missing (n=22,580) 23 0.10 16 0.07 24 0.11 
Maternal comorbidity 
      
   No (n=113,786) 132 0.12 101 0.09 167 0.15 
   Yes (n=2,671) 11 0.41     9 0.34     9 0.34 
*Severe mental illnesses including bipolar disorder, schizophrenia or other related psychotic disorders 
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Figure 4-2 Prevalence (log10 scale) of depression, anxiety and serious mental illness in and around pregnancy by calendar period 
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Figure 4-3 Prevalence (log10 scale) of depression, anxiety and serious mental illness in and around pregnancy by the number of 
previous known live births 
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4.4.3 Impact of socioeconomic status stratified by age 
The following tables show absolute risks and adjusted ORs of clinically recognised 
depression (Table 4-6), anxiety (Table 4-7) and serious mental illness (Table 4-8) with 
socioeconomic deprivation, stratified by maternal age.  The prevalence of maternal 
depression and anxiety was highest in the youngest women and lowest in the oldest 
women, although this pattern varied considerably by socioeconomic group.  For 
women of all ages, the prevalence of all three mental illnesses during and after 
pregnancy increased with greater socioeconomic deprivation. 
After adjusting for calendar time and number of previously recorded live births, the 
odds of perinatal mental illness increased with each deprivation quintile, compared to 
women in the least socioeconomically deprived quintile.  In the youngest age group, 
several 95% confidence intervals included unity, however, tests for trend with 
increasing socioeconomic deprivation were p<0.001 for depression during and after 
pregnancy (Table 4-6), p=0.06 for anxiety (Table 4-7), and p=0.33 and 0.10 for 
serious mental illness (Table 4-8), which affected very few women. 
In older women, the degree of increase in odds of all three clinical mental illnesses 
with greater socioeconomic deprivation was more marked.  For example, women 
aged 35-45 years from the most socioeconomically deprived quintile had 2.6 times 
the odds of antenatal depression (OR=2.63, 95%CI 2.22-3.13), 2.5 times the odds of 
anxiety (OR=2.48, 95%CI 1.98-3.11) and 7.7 times the odds of serious mental illness 
(OR=7.68, 95%CI 2.92-20.24) as those from the least socioeconomically deprived 
quintile whereas in women aged 15-24, the equivalent ORs were 1.35 (95%CI 1.07-
1.70), 1.49 (95%CI 1.06-2.09) and 1.59 (95%CI 0.19-13.64) respectively. 
Similar patterns of risks were found postnatally.  The p-values from the likelihood ratio 
tests for interaction between socioeconomic deprivation quintile and maternal age 
group were less than 0.001 for antenatal depression, postnatal depression and 
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antenatal anxiety, and 0.09 for postnatal anxiety; however there was weak statistical 
evidence for such interaction in serious mental illness (0.79 antenatal and 0.39 
postnatal) with fairly small numbers of women in each age group. 
$IWHUUHVWULFWLQJWRZRPHQ¶VILUVWFOLQLFDOUHFRUGLQJRIPHQWDOLOOQHVVSUHYDOHQFH
estimates of all three mental illnesses presenting initially during or after pregnancy 
were substantially reduced across all age and socioeconomic groups, which are 
shown in Table 4-9 for depression, Table 4-10 for anxiety, and Table 4-11 for serious 
mental illness.  The impact of socioeconomic deprivation also reduced, yet patterns of 
increasing odds ratios with greater deprivation generally persisted.  The degree of 
increase with deprivation quintile was again greatest in women aged 35-45 for 
antenatal depression (Table 4-9), antenatal and postnatal anxiety (Table 4-10), but 
not for postnatal depression (Table 4-9) which was instead greatest in women aged 
15-24.  Since very few women had a first clinical recording of serious mental illness 
during or after pregnancy, we were not able to stratify by age.  Although adjusted 
odds ratios showed an association with deprivation, 95% confidence intervals were 
extremely wide (Table 4-11). 
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Table 4-6 Absolute risks and adjusted odds ratios for maternal depression associated with socioeconomic status, stratified by 
maternal age (N=110,285*) 
Socioeconomic status 
(deprivation quintile) 
Maternal age 
15-24 years 25-34 years 35-45 years 
 N nÁ % AORa (95% CI) N nÁ % AORa (95% CI) N nÁ % AORa (95% CI) 
Antenatal periodc 20,176 1,223 6.1  60,722 2,952 4.9  29,387 1,416 4.8  
1 (least deprivation) (N=26,984) 1,843 94 5.1 1.00 15,732 492 3.1 1.00 9,409 325 3.5 1.00 
2 (N=21,978) 2,479 109 4.4 0.85 (0.64-1.13) 12,655 482 3.8 1.22 (1.07-1.38) 6,844 278 4.1 1.18 (1.00-1.39) 
3 (N=23,028) 4,052 240 5.9 1.15 (0.90-1.47) 13,069 661 5.1 1.61 (1.43-1.82) 5,907 287 4.9 1.41 (1.20-1.66) 
4 (N=21,771) 5,838 364 6.2 1.21 (0.95-1.52) 11,452 707 6.2 1.93 (1.72-2.17) 4,481 276 6.2 1.77 (1.50-2.09) 
5 (most deprivation) (N=16,524) 5,964 416 7.0 1.35 (1.07-1.70) 7,814 610 7.8 2.39 (2.11-2.70) 2,746 250 9.1 2.63 (2.22-3.13) 
     p value for trend    p<0.001#    p<0.001#    p<0.001# 
Postnatal periodc 20,176 3,550 17.6  60,722 7,840 12.9  29,387 3,235 11.0  
1 (least deprivation) (N=26,984) 1,843 236 12.8 1.00 15,732 1,576 10.0 1.00 9,409 836 8.9 1.00 
2 (N=21,978) 2,479 368 14.8 1.19 (1.00-1.41) 12,655 1,401 11.1 1.12 (1.04-1.21) 6,844 681 10.0 1.14 (1.02-1.27) 
3 (N=23,028) 4,052 708 17.5 1.44 (1.23-1.69) 13,069 1,708 13.1 1.35 (1.25-1.45) 5,907 640 10.8 1.25 (1.12-1.39) 
4 (N=21,771) 5,838 1,100 18.8 1.56 (1.34-1.82) 11,452 1,766 15.4 1.62 (1.50-1.74) 4,481 579 12.9 1.51 (1.35-1.69) 
5 (most deprivation) (N=16,524) 5,964 1,138 19.1 1.58 (1.36-1.84) 7,814 1,389 17.8 1.88 (1.74-2.03) 2,746 499 18.2 2.25 (1.99-2.53) 
     p value for trend     p<0.001#    p<0.001#    p<0.001# 
* 5.3% (6,172) of the original population (116,457) had no socioeconomic status recorded 
c Likelihood ratio test for interaction between deprivation quintile and age group: during pregnancy p<0.001; after pregnancy p<0.001 

 Number of women in each deprivation quintile 
Á
 Number of women with depression 
a
 Odds ratio and 95% confidence interval adjusted for calendar time and number of previous known live births 
#
 p value for trend from least to greatest deprivation excluding women with missing information for socioeconomic status 
CI=confidence interval 
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Table 4-7 Absolute risks and adjusted odds ratios for maternal anxiety associated with socioeconomic status, stratified by maternal 
age (N=110,285*) 
Socioeconomic status 
(deprivation quintile) 
Maternal age 
15-24 years 25-34 years 35-45 years 
 N nÁ % AORa (95% CI) N nÁ % AORa (95% CI) N nÁ % AORa (95% CI) 
Antenatal periodc 20,176 559 2.8  60,722 1,593 2.6  29,387 767 2.6  
1 (least deprivation) (N=26,984) 1,843 41 2.2 1.00 15,732 302 1.9 1.00 9,409 189 2.0 1.00 
2 (N=21,978) 2,479 70 2.8 1.27 (0.86-1.88) 12,655 293 2.3 1.21 (1.03-1.42) 6,844 135 2.0 0.98 (0.78-1.23) 
3 (N=23,028) 4,052 116 2.9 1.29 (0.90-1.85) 13,069 348 2.7 1.39 (1.19-1.62) 5,907 155 2.6 1.31 (1.06-1.62) 
4 (N=21,771) 5,838 135 2.3 1.03 (0.72-1.47) 11,452 345 3.0 1.56 (1.33-1.83) 4,481 153 3.4 1.71 (1.38-2.12) 
5 (most deprivation) (N=16,524) 5,964 197 3.3 1.49 (1.06-2.09) 7,814 305 3.9 2.02 (1.72-2.38) 2,746 135 4.9 2.48 (1.98-3.11) 
     p value for trend    p=0.06#    p<0.001#    p<0.001# 
Postnatal periodc 20,176 804 4.0  60,722 2,330 3.8  29,387 974 3.3  
1 (least deprivation) (N=26,984) 1,843 65 3.5 1.00 15,732 477 3.0 1.00 9,409 258 2.7 1.00 
2 (N=21,978) 2,479 82 3.3 0.93 (0.67-1.30) 12,655 425 3.4 1.11 (0.97-1.27) 6,844 200 2.9 1.07 (0.88-1.29) 
3 (N=23,028) 4,052 165 4.1 1.16 (0.86-1.55) 13,069 502 3.8 1.27 (1.12-1.44) 5,907 184 3.1 1.14 (0.94-1.38) 
4 (N=21,771) 5,838 230 3.9 1.11 (0.84-1.47) 11,452 521 4.6 1.50 (1.32-1.70) 4,481 179 4.0 1.46 (1.20-1.77) 
5 (most deprivation) (N=16,524) 5,964 262 4.4 1.24 (0.94-1.63) 7,814 405 5.2 1.69 (1.47-1.94) 2,746 153 5.6 2.06 (1.68-2.53) 
     p value for trend     p=0.06#    p<0.001#    p<0.001# 
* 5.3% (6,172) of the original population (116,457) had no socioeconomic status recorded 
c Likelihood ratio test for interaction between deprivation quintile and age group: during pregnancy p<0.001; after pregnancy p=0.09 

 Number of women in each deprivation quintile 
Á
 Number of women with anxiety 
a
 Odds ratio and 95% confidence interval adjusted for calendar time and number of previous known live births 
#
 p value for trend from least to greatest deprivation excluding women with missing information for socioeconomic status 
CI=confidence interval 
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Table 4-8 Absolute risks and adjusted odds ratios for serious mental illnessȕ associated with socioeconomic status, stratified by 
maternal age (N=110,285*) 
Socioeconomic status 
(deprivation quintile) 
Maternal age 
15-24 years 25-34 years 35-45 years 
 N nÁ % AORa (95% CI) N nÁ % AORa (95% CI) N nÁ % AORa (95% CI) 
Antenatal periodc 20,176 13 0.06  60,722 48 0.08  29,387 44 0.15  
1 (least deprivation) (N=26,984) 1,843 1 0.05 1.00 15,732 7 0.04 1.00 9,409 6 0.06 1.00 
2 (N=21,978) 2,479 0 --- --- 12,655 7 0.06 1.24 (0.44-3.55) 6,844 5 0.07 1.15 (0.35-3.76) 
3 (N=23,028) 4,052 3 0.07 1.36 (0.14-13.13) 13,069 8 0.06 1.38 (0.50-3.80) 5,907 8 0.14 2.13 (0.74-6.13) 
4 (N=21,771) 5,838 4 0.07 1.26 (0.14-11.31) 11,452 14 0.12 2.75 (1.11-6.81) 4,481 12 0.27 4.21 (1.58-11.22) 
5 (most deprivation) (N=16,524) 5,964 5 0.08 1.55 (0.18-13.24) 7,814 12 0.15 3.46 (1.36-8.78) 2,746 13 0.47 7.45 (2.83-19.63) 
     p value for trend    p=0.33#    p<0.01#    p<0.001# 
Postnatal periodc 20,176 25 0.12  60,722 81 0.13  29,387 64 0.22  
1 (least deprivation) (N=26,984) 1,843 1 0.05 1.00 15,732 15 0.10 1.00 9,409 13 0.14 1.00 
2 (N=21,978) 2,479 1 0.04 0.74 (0.05-11.89) 12,655 17 0.13 1.41 (0.70-2.82) 6,844 9 0.13 0.95 (0.41-2.22) 
3 (N=23,028) 4,052 3 0.07 1.36 (0.14-13.13) 13,069 13 0.10 1.04 (0.50-2.19) 5,907 11 0.19 1.35 (0.60-3.01) 
4 (N=21,771) 5,838 12 0.21 3.79 (0.49-29.20) 11,452 25 0.22 2.29 (1.21-4.35) 4,481 15 0.33 2.43 (1.15-5.11) 
5 (most deprivation) (N=16,524) 5,964 8 0.13 2.47 (0.31-19.79) 7,814 11 0.14 1.48 (0.68-3.22) 2,746 16 0.58 4.24 (2.04-8.82) 
     p value for trend     p=0.10#    p=0.07#    p<0.001# 
* 5.3% (6,172) of the original population (116,457) had no socioeconomic status recorded 
c Likelihood ratio test for interaction between deprivation quintile and age group: during pregnancy p=0.79; after pregnancy p=0.39 
ȕ
 Serious mental illness includes bipolar disorder, schizophrenia or other related psychotic disorders 

 Number of women in each deprivation quintile 
Á
 Number of women with serious mental illness 
a
 Odds ratio and 95% confidence interval adjusted for calendar time and number of previous known live births 
#p value for trend from least to most deprivation excluding women with missing information for socioeconomic status (5.3% missing overall) 
CI=confidence interval 
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Table 4-9 Absolute risks and adjusted odds ratios for first clinically recognised depression associated with socioeconomic status, 
stratified by maternal age (N=110,285*) 
Socioeconomic status 
(deprivation quintile) 
Maternal age 
15-24 years 25-34 years 35-45 years 
 N nÁ % AORa (95% CI) N nÁ % AORa (95% CI) N nÁ % AORa (95% CI) 
Antenatal periodc 20,176 336 1.7  60,722 426 0.7  29,387 164 0.6  
1 (least deprivation) (N=26,984) 1,843 32 1.7 1.00 15,732 80 0.5 1.00 9,409 45 0.5 1.00 
2 (N=21,978) 2,479 34 1.4 0.79 (0.49-1.29) 12,655 75 0.6 1.17 (0.85-1.60) 6,844 31 0.5 0.94 (0.60-1.49) 
3 (N=23,028) 4,052 74 1.8 1.05 (0.69-1.60) 13,069 104 0.8 1.56 (1.16-2.09) 5,907 29 0.5 1.03 (0.64-1.64) 
4 (N=21,771) 5,838 90 1.5 0.89 (0.59-1.33) 11,452 87 0.8 1.48 (1.09-2.01) 4,481 31 0.7 1.42 (0.90-2.26) 
5 (most deprivation) (N=16,524) 5,964 106 1.8 1.02 (0.69-1.53) 7,814 80 1.0 1.98 (1.45-2.71) 2,746 28 1.0 2.09 (1.30-3.37) 
     p value for trend    p=0.64#    p<0.001#    p=0.004# 
Postnatal periodc 20,176 1,823 9.0  60,722 2,931 4.8  29,387 1,083 3.7  
1 (least deprivation) (N=26,984) 1,843 124 6.7 1.00 15,732 692 4.4 1.00 9,409 360 3.8 1.00 
2 (N=21,978) 2,479 199 8.0 1.22 (0.96-1.56) 12,655 590 4.7 1.08 (0.96-1.21) 6,844 223 3.3 0.83 (0.70-0.99) 
3 (N=23,028) 4,052 377 9.3 1.42 (1.15-1.77) 13,069 650 5.0 1.16 (1.04-1.30) 5,907 224 3.8 0.98 (0.83-1.17) 
4 (N=21,771) 5,838 566 9.7 1.52 (1.24-1.88) 11,452 603 5.3 1.25 (1.11-1.40) 4,481 154 3.4 0.88 (0.72-1.07) 
5 (most deprivation) (N=16,524) 5,964 557 9.3 1.45 (1.18-1.79) 7,814 396 5.1 1.18 (1.03-1.34) 2,746 122 4.4 1.12 (0.90-1.39) 
     p value for trend    p<0.001#    p=0.001#    p=0.62# 
* 5.3% (6,172) of the original population (116,457) had no socioeconomic status recorded 
c
 Likelihood ratio test for interaction between deprivation quintile and age group: during pregnancy p=0.21; after pregnancy p<0.001 

 Number of women in each deprivation quintile 
Á
 Number of women with first clinically diagnosed depression 
a
 Odds ratio and 95% confidence interval adjusted for calendar time and number of previous known live births 
#
 p value for trend from least to greatest deprivation excluding women with missing information for socioeconomic status 
CI=confidence interval 
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Table 4-10 Absolute risks and adjusted odds ratios for first clinically recognised anxiety associated with socioeconomic status, 
stratified by maternal age (N=110,285*) 
Socioeconomic status 
(deprivation quintile) 
Maternal age 
15-24 years 25-34 years 35-45 years 
 N nÁ % AORa (95% CI) N nÁ % AORa (95% CI) N nÁ % AORa (95% CI) 
Antenatal periodc 21,341 276 1.3  64,214 648 1.0  30,902 272 0.9  
1 (least deprivation) (N=26,984) 1,843 25 1.4 1.00 15,732 136 0.9 1.00 9,409 69 0.7 1.00 
2 (N=21,978) 2,479 33 1.3 0.98 (0.58-1.66) 12,655 114 0.9 1.04 (0.81-1.34) 6,844 52 0.8 1.04 (0.72-1.49) 
3 (N=23,028) 4,052 55 1.4 1.00 (0.62-1.61) 13,069 147 1.1 1.30 (1.03-1.65) 5,907 61 1.0 1.41 (1.00-2.00) 
4 (N=21,771) 5,838 53 0.9 0.67 (0.41-1.08) 11,452 131 1.1 1.33 (1.04-1.69) 4,481 33 0.7 1.00 (0.66-1.52) 
5 (most deprivation) (N=16,524) 5,964 88 1.5 1.09 (0.70-1.70) 7,814 95 1.2 1.41 (1.08-1.84) 2,746 45 1.6 2.26 (1.55-3.29) 
     p value for trend    p=1.00#    p<0.01#    p<0.01# 
Postnatal periodc 21,341 392 1.8  64,214 874 1.4  30,902 355 1.2  
1 (least deprivation) (N=26,984) 1,843 36 2.0 1.00 15,732 202 1.3 1.00 9,409 95 1.0 1.00 
2 (N=21,978) 2,479 39 1.6 0.80 (0.51-1.27) 12,655 171 1.4 1.05 (0.86-1.29) 6,844 74 1.1 1.07 (0.79-1.45) 
3 (N=23,028) 4,052 76 1.9 0.96 (0.64-1.43) 13,069 175 1.3 1.04 (0.85-1.28) 5,907 72 1.2 1.21 (0.89-1.65) 
4 (N=21,771) 5,838 103 1.8 0.90 (0.61-1.32) 11,452 151 1.3 1.03 (0.83-1.27) 4,481 55 1.2 1.22 (0.87-1.70) 
5 (most deprivation) (N=16,524) 5,964 120 2.0 1.03 (0.71-1.50) 7,814 127 1.6 1.27 (1.02-1.59) 2,746 44 1.6 1.60 (1.11-2.29) 
     p value for trend    p=0.49#    p=0.11#    p=0.01# 
* 5.3% (6,172) of the original population (116,457) had no socioeconomic status recorded 
c
 Likelihood ratio test for interaction between deprivation quintile and age group: during pregnancy p<0.01; after pregnancy p=0.93 

 Number of women in each deprivation quintile 
Á
 Number of women with first clinically diagnosed anxiety 
a
 Odds ratio and 95% confidence interval adjusted for calendar time and number of previous known live births 
#
 p value for trend from least to greatest deprivation excluding women with missing information for socioeconomic status 
CI=confidence interval 
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Table 4-11 Absolute risks of adjusted odds ratios for first clinically diagnosed 
serious mental illnessȕ associated with socioeconomic status (N=110,285*) 
Socioeconomic status 
(deprivation quintile) 
N nÁ % AORa (95% CI) 
Antenatal period 110,285 14 0.01  
1 (least deprivation) 26,984 1 --- 1.00 
2 21,978 1 <0.01 1.22 (0.08-19.55) 
3 23,028 2 0.01 2.36 (0.21-26.14) 
4 21,771 3 0.01 3.97 (0.41-38.63) 
5 (most deprivation) 16,524 7 0.04 13.15 (1.57-110.01) 
     p value for trend    p=0.002# 
Postnatal period 110,285 55 0.05  
1 (least deprivation) (N=26,984) 26,984 14 0.05 1.00 
2 (N=21,978) 21,978 8 0.04 0.71 (0.30-1.69) 
3 (N=23,028) 23,028 5 0.02 0.42 (0.15-1.17) 
4 (N=21,771) 21,771 17 0.08 1.51 (0.73-3.12) 
5 (most deprivation) (N=16,524) 16,524 11 0.07 1.28 (0.56-2.93) 
     p value for trend    p=0.23# 
* 5.3% (6,172) of the original population (116,457) had no socioeconomic status recorded  
ȕ
 Serious mental illness includes bipolar disorder, schizophrenia or other related psychotic disorders 

 Number of women in each deprivation quintile   
Á
 Number of women with serious mental illness 
a
 Odds ratio and 95% confidence interval adjusted for calendar time and number of previous known live births 
#
 p value for trend from least to most deprivation excluding women with missing information for socioeconomic status 
CI=confidence interval 
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4.5 Discussion 
4.5.1 Principal findings 
A substantial burden of depression, anxiety and serious mental illness during the 
perinatal period presents and is managed in UK general practice among women with 
pregnancies ending in live births, although there are considerable variations by 
different maternal characteristics in terms of the absolute risk.  Higher risks of mental 
illness in mothers in more socioeconomically deprived areas compared with those in 
OHVVGHSULYHGDUHDVSHUVLVWZLWKLQFUHDVLQJPDWHUQDODJH:KHQZRPHQ¶VLQLWLDO
clinical presentation of mental illness was during or after pregnancy, the impact of 
socioeconomic deprivation remained yet was reduced, indicating that this was 
partially due to a history of mental illness commonly recurring in the perinatal period. 
4.5.2 Strengths and limitations 
This is the largest study to examine the clinical prevalence and overlap of maternal 
depression, anxiety and serious mental illness presenting to general practice in and 
around pregnancy.  It is also the first to assess the joint effect of maternal age and 
socioeconomic status on the clinical burden of maternal perinatal mental illness in the 
UK.  The considerable sample size means that our findings are unlikely to be due to 
chance.  Equally as data were obtained from a large general practice database with 
prospectively recording, the potential for recall bias of mental illness was excluded. 
The definition of maternal mental illness relies on women presenting to and being 
correctly identified by practitioners.  Such estimates quantify the primary care burden 
in pregnancy, thus excluding undiagnosed illness in women not disclosing feelings to 
their doctor or health visitor.81  A range of diagnostic tools (e.g. EPDS) has been used 
in cohort studies of selected populations, yet there is no universal agreement that 
these are advantageous in a routine clinical setting (or for screening) and as such 
there are no widely applied cut-offs used in practice to diagnose mental illness.145,146  I 
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based case identification on medical diagnostic and prescribing records to reflect 
routine practice, similar to methods used by the Office for National Statistics and 
other published studies of mental illness in general practice databases.76,89±91  Since 
GPs occupy a gate-keeper role to health care in the UK, and are normally the first 
point of contact for non-emergency services, referred via midwives and health visitors, 
I believe that these data are an ideal source for estimating the prevalence of mental 
illness presenting to general practice nationally.  The similarity of my prevalence 
estimates to studies restricting to diagnosed postpartum depression using 
standardized interviewing schedules25,124 and anxiety127 is reassuring. 
The decreased prevalence observed during pregnancy may reflect NICE guidelines to 
reduce psychotropic drug treatment during pregnancy which has been observed 
elsewhere.  However, after estimating the prevalence based on recording of medical 
diagnoses regardless of drug prescriptions, a similar pattern of lower prevalence 
estimates during pregnancy was again observed.  This could also be due to greater 
midwifery antenatal care or diagnostic bias if general practitioners remain more likely 
to diagnose and treat mental illness postpartum. 
4.5.3 Interpretation in context of previous studies 
Although numerous studies have estimated the prevalence of maternal depression, 
fewer have assessed anxiety and serious mental illness and ours is the first to 
compare prospectively all clinically recognised mental illnesses (depression, anxiety 
and serious mental illness) and their overlap before, during and after pregnancy in UK 
general practice.  A systematic review of studies in high-income countries found the 
prevalence of maternal postpartum depression was 13% however individual study 
estimates varied widely.25  A systematic review of maternal anxiety concluded that 
there were too few studies to obtain adequate estimates around pregnancy, however, 
based on three small studies, generalised anxiety disorder ranged from 4.4-8.2% 
postpartum.127  Most previous studies assessed mental illness by, often study-specific, 
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screening with self-administered questionnaires (e.g. Edinburgh postnatal depression 
scale),120 which means they are not directly comparable with this study, which 
represents disease identified through health service use or primary care attendance. 
Previous studies on serious mental illness primarily rely on medical admissions and 
our similar estimates indicate these diagnoses are reasonably captured among 
women registered in general practice.  Nager and colleagues examined Swedish first-
time mothers (n=502,767) and found about 0.07% of mothers had their first hospital 
admission for psychosis postpartum, which is very similar to my estimate of first 
recorded serious mental illness.26  Our estimates also concur with a 1987 Edinburgh 
registry study in which a higher proportion of psychiatric admissions presented in 
women after childbirth than during pregnancy.136  In Denmark, Munk-Olsen and 
colleagues examined over a million first-time parents between 1973 and 2005 and 
found that compared with 6-11 months postpartum, medical contact for any mental 
disorder was more likely during the first month postpartum (relative risk=3.49), and 
less likely during pregnancy (relative risk=0.72), which is consistent with our 
findings.147 
Few studies have estimated the degree of overlap between depression, anxiety and 
serious mental illness in women in and around pregnancy.  Studying 357 women in 
an antenatal clinic in Hong Kong, Lee et al. found 39-47% of women with common 
mental disorders had both anxiety and depressive symptoms when individually 
assessed.138  Two previous cross-sectional studies using self-reported patient 
questionnaires in high-income countries reported an equivalent figure of 28% in the 
general population.141,143 
Socio-demographic factors have an important impact on maternal mental illness yet 
the joint effects of maternal age and socioeconomic deprivation among pregnant 
women and new mothers as predictors of important health burden in the population 
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have not been adequately assessed.  A recent American study of more than 75,000 
non-pregnant women aged 18-44 found that the prevalence of major depression was 
greater in women over 35 years, unmarried, less educated, unable to work or 
unemployed or with low income than in women without such risk factors.20 
Previous studies show that women with greater socioeconomic deprivation were more 
likely to have perinatal mental illness than those with lower socioeconomic deprivation 
after adjusting for other socio-demographic factors.22±25  A Swedish birth cohort study 
found that in first time mothers fewer years of maternal education was not associated 
with the increased risk of postpartum psychosis26 but did appear to have an effect in a 
later study of the same population cohort.27  Patterns of the effect of maternal age on 
perinatal mental illness have been inconsistent in different studies,22,26,28,25 showing 
both decreased28 and increased26,27 risks in older women. 
Rich-Edwards and colleagues investigated whether socio-demographic factors were 
associated with antenatal or postnatal depression.22  They interviewed 1,662 women 
from Boston in the United States of America and found an increased odds of 
postnatal depression in those with financial hardship (OR=3.6, 95%CI 1.9-6.7 after 
adjusting for maternal age, race/ethnicity, immigration status, parity and income).  
Since patients with depression are more likely to have another episode in the later 
stage of their life, this US study also found that a history of depression was the 
strongest risk factor for perinatal depression.  However, similar to my study, the effect 
of financial hardship remained when the authors excluded women with a history of 
depression.  In addition, women under age 23 years had more maternal depression 
during and after pregnancy than women aged 30-34 (OR=2.7, 95%CI 1.4-5.2 mid-
pregnancy and OR=2.4, 95%CI 1.1-5.4 six months postpartum after adjusting for 
race/ethnicity); however effects reduced and were not statistically significant after 
adjusting for household income, suggesting that effect of maternal age was largely 
driven by different financial circumstances. 
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4.5.4 Conclusion and implications 
This study shows that there is considerable primary care burden of maternal perinatal 
mental illness and women in more socioeconomically deprived circumstances are at 
high risk.  This highlights that greater recognition is needed at policy level.  As there is 
currently not enough evidence that perinatal screening tools are advantageous over 
clinical assessment in routine practice,145,146 this should emphasise the need for trials 
of methods to effectively identify women and interventions to prevent and treat 
perinatal mental illness among high-risk women in the primary care setting. 
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5 Live and non-live pregnancy outcomes in women with antenatal 
mental illness with and without psychotropic medication 
Since there is a considerable clinical burden of maternal perinatal mental illness 
presenting to and/or treated in UK general practice, this section describes a 
prospective cross-sectional study conducted to examine the risks of non-live 
pregnancy outcomes in pregnant women with history of mental illness with or without 
psychotropic drug prescriptions compared with those women without mental illness. 
5.1 Introduction 
5.1.1 Non-live pregnancy outcomes in women with antenatal mental illness 
Perinatal death 
Previous research has suggested that women with mental illness (including affective 
disorder, such as depression, and schizophrenia and other related psychotic 
disorders) have increased risks of stillbirth41,43,44,148,149 and neonatal death.43,44,150  For 
instance, Webb et al. conducted a prospective population-based study in Denmark 
including all singleton live births and stillbirths (nearly 1.5 million in total) identified 
using Danish population and birth registers during 1973-1998 and found that after 
adjustment for offspring age and calendar year, women with a history of 
hospitalisation for affective disorder before childbirth (not limited to antenatal mental 
illness only) had a 66% increased risk of stillbirth (OR=1.66, 95% CI 1.29-2.19) and a 
2.5-fold increased risk of neonatal death (OR=2.5, 95% CI 1.93-3.13) compared with 
women with no such history.43  Some other studies however did not find increased 
risks of stillbirth or neonatal death in women with mental health problems.32,34,151  
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Miscarriage 
In contrast, few large population-based studies have been conducted to examine the 
risks of miscarriage in women with mental illness with or without psychotropic 
medication.  Sugiura-Ogasawara and colleagues carried out a study in Japan from 
April 1995 to August 1997 and recruited 45 women with a history of two consecutive 
first-trimester miscarriages, but with no live birth, before the third pregnancy from 
Nagoya City University Hospital.152  After controlling for maternal age and occupation, 
they found that pre-existing depression, but not anxiety, was associated with an 
increased risk of miscarriage in the following pregnancy (p-value=0.04; no measures 
of effects were presented).  A later study from the same cohort also found that scores 
for psychological symptoms of both depression and anxiety (measured by using self-
reported questionnaires administrated both before and within two weeks of pregnancy) 
were higher, especially before pregnancy, in women with subsequent miscarriage 
than in women with normal delivery.153  However, these two studies focused on a 
subset population of women with a history of miscarriage only and no information is 
available for the general population. 
A prospective study in the USA examining 1,186 women in early pregnancy from 
1999 to 2001 found no association of depressive symptoms with the risk of 
miscarriage (OR=0.75, 95% CI 0.47-1.19) after adjusting for maternal and gestational 
age, social support, prior spontaneous abortion, education level and cigarette and 
cocaine use.154  The women were, however, recruited at an emergency department 
with nine weeks of mean gestational age and depressive symptoms were measured 
using self-reported questionnaires at recruitment only. 
Potential explanations 
There are several potential explanations to suggest that there might be increased 
risks of miscarriage and perinatal death in women with mental illness.  Previous 
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research has suggested that poor lifestyle choices (such as smoking) and antenatal 
care could potentially contribute to such raised risks seen across various maternal 
mental illnesses.44  There are also associations between mental illness and maternal 
smoking35 and abnormal endocrine and immune regulation,36 which may directly 
impair the development of the foetus lead to foetal growth retardation and low birth 
weight.37  In addition, women with mental illness are more likely to be from relatively 
socioeconomically deprived groups and receive inadequate antenatal care.155,156  
Pregnant women with mental illness are also more likely to be exposed to 
psychotropic medications.  Although there have been considerable studies examining 
the risks of non-live pregnancy outcomes in women exposed to psychotropic drugs, 
most did not directly compare women with depression or anxiety taking medication 
with those not.  A recent study of only 90 women in the USA showed that among 
women with major depressive disorders, women taking antidepressants during 
pregnancy had shorter gestational age at birth and increased risks of preterm delivery 
than those not exposed to antidepressants.157 
5.1.2 Impact of psychotropic medication during pregnancy 
Many previous studies have been conducted to examine the potential adverse effects 
of exposure to psychotropic medication, particularly antidepressants, in women during 
early pregnancy on the pregnancy outcomes.  Previous research suggests that 
women exposed to antidepressants during early pregnancy have increased risks of 
perinatal death45,46 and miscarriage.45,47,48,158 It has also been suggested that women 
taking antidepressants antenatally are more likely to choose to terminate their 
pregnancy.45,49,159  Table 5-1 (for cohort studies) and Table 5-2 (for case-control 
studies) summarise all such studies published in English language journals since 
1960 until June 2012 through searching PubMed and references of individual papers 
relevant to the study question. 
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Table 5-1 Cohort studies for the impact of depression and/or anxiety on non-live pregnancy outcomes 
Author(s), year Country Study 
period 
Source of study 
population  
Number of 
pregnancies 
Exposure(s) Exposure 
information 
collected 
prior to 
outcome 
occurrence 
Number 
(and/or %) of 
mothers exposed  
Outcome(s) Any co-
variables 
considered  
Findings 
(measure of effects 
with 95% confidence 
interval, if not 
otherwise specified) 
Depression and/or anxiety 
         
Hanlon et al., 
200932 
Ethiopia Jul 2005 
to Feb 
2006 
Health programme 1,046 Common mental 
disorders during the 
third trimester of 
pregnancy 
Y 128+634 Stillbirth and 
neonatal death 
(28 days of 
birth) 
Y No association 
Wisborg et al., 
2008148 
Denmark Sep 1989 
to Aug 98 
Maternity unit in 
hospital 
19,282 Psychological stress 
(measure by GHQ) 
during pregnancy 
Y Not reported Stillbirth Y High psychological 
stress: 
OR=1.9 (1.1-3.2) 
Antidepressants 
         
Einarson et al., 
2009159 
Canada Not 
reported 
Teratology 
information service 
1,874 Antidepressants prior to 
and during the first 
trimester of pregnancy 
Y 937 Miscarriage 
and 
termination 
Y (matched by 
age, smoking 
and alcohol 
consumption) 
Miscarriage: 
relative risk ratio=1.63 
(1.24-2.14); 
Termination: 
relative risk ratio=3.25 
(1.48-7.14) 
Diav-Citrin et al., 
200845 
Israel, Italy 
and 
Germany 
1994-2002 
and 2002-
05 
Teratology 
information service 
2,191 Paroxetine and 
fluoxetine during the first 
trimester of pregnancy 
Y 410 (paroxetine) 
and 314 
(fluoxetine) 
Non-live born 
pregnancies  
Y Fluoxetine: increased 
risk of miscarriage and 
termination; 
Paroxetine: increased 
risk of stillbirth 
Lennestål and 
Källén, 2007160 
Sweden Up to 
2004 
Medical birth registry 
data 
860,215 SSRIs and SNRI/NRI in 
early pregnancy 
Y 6,481+732 Stillbirth and 
infant death 
Y No association 
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Author(s), year Country Study 
period 
Source of study 
population  
Number of 
pregnancies 
Exposure(s) Exposure 
information 
collected 
prior to 
outcome 
occurrence 
Number 
(and/or %) of 
mothers exposed  
Outcome(s) Any co-
variables 
considered  
Findings 
(measure of effects 
with 95% confidence 
interval, if not 
otherwise specified) 
Djulus et al., 
2006161 
Worldwide 
(incl. UK) 
Jun 2002 
to Aug 
2005 
Teratogen 
information 
services/drug safety 
research unit 
312 Mirtazapine during 
pregnancy 
Y 104 Non-live birth 
outcomes 
N Higher prevalence of 
miscarriage but not 
statistically significant 
Wen et al., 200646 Canada 1990-2000 Database 4,850 (matched) SSRIs in the year before 
delivery 
Y 972 Stillbirth and 
infant death 
(less than 1 
year of age) 
Y (matched) Stillbirth:  
OR=2.23 (1.01-4.93); 
Infant death: 
OR=1.96 (0.97-3.94)  
Chun-Fai-Chan et 
al., 2005158 
Canada and 
UK 
Not 
reported 
Teratogenic 
information service 
and drug safety 
research unit 
269 (matched) Bupropion during the 
first trimester of 
pregnancy 
Y 136 Non-live birth 
outcomes 
Y Miscarriage: p=0.009 
Sivojelezova et 
al., 2005162 
Canada Not 
reported 
Teratogen 
information centre 
396 (matched) Citalopram during early 
pregnancy 
Y 132 Non-live birth 
outcomes 
Y No association 
Einarson et al., 
2003163 
Canada Not 
reported 
Teratogenic 
information service 
441 (matched) Trazodone or 
nefazodone during the 
first trimester of 
pregnancy 
Y 147 Non-live birth 
outcomes 
Y No association 
Einarson et al., 
2001164 
Canada Not 
reported 
Teratogenic 
information service 
450 (matched) Venlafaxine during 4th to 
14th week gestation 
Y 150 Miscarriage 
and 
termination 
Y No association 
Ericson et al., 
1999165 
Sweden 1995-97  Birth registry data 281,728 Antidepressants during 
pregnancy 
Y 969 (0.3) Infant death N No association 
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Author(s), year Country Study 
period 
Source of study 
population  
Number of 
pregnancies 
Exposure(s) Exposure 
information 
collected 
prior to 
outcome 
occurrence 
Number 
(and/or %) of 
mothers exposed  
Outcome(s) Any co-
variables 
considered  
Findings 
(measure of effects 
with 95% confidence 
interval, if not 
otherwise specified) 
Kulin et al., 
1998166 
North 
America 
Not 
reported 
Teratogenic 
information service 
534 (matched) SSRIs during the first 
trimester of pregnancy 
Y 267 Non-live birth 
outcomes 
Y No association 
Johnson, 1997167 USA Not 
reported 
Teratogen 
information service 
482 (matched) Fluoxetine during 
pregnancy 
Y 228 Miscarriage N No association 
Chamber et al., 
199649 
USA 1989-95 Teratogenic 
information service 
482 (matched) Fluoxetine during 
pregnancy 
Y 228 Non-live birth 
outcomes 
N Higher rate of 
termination: 
9.6 vs. 2.7% (p=0.002) 
McElhatton et al., 
1996168 
Europe Not 
reported 
Teratology 
information services 
689 exposed 
only 
Tricyclic and nontricyclic 
antidepressants 
Y 689 Non-live birth 
outcomes 
N Higher rate of 
termination in multidrug 
groups than in mono-
therapy groups 
Pastuszak et al., 
199348 
Canada Not 
reported 
Teratogenic 
information service 
256 (matched) Fluoxetine during the 
first trimester of 
pregnancy 
Y 128 Miscarriage 
and 
termination 
Y (matched) Increased risk of 
miscarriage: p=0.03 
Anxiolytics 
          
Ornoy et al., 
199866 
Israel 1988 to 
Jul 1996 
Teratogenic 
information service 
884 (matched) Benzodiazepines during 
pregnancy 
Y 460 Miscarriage 
and 
termination 
N Miscarriage:  
8.7 vs. 5.2% (P=0.01); 
Termination: 
14.1 vs. 4.7% (P<0.01) 
Hartz et al., 
1975169 
USA 1958-1966 Hospital records 50,282 Meprobamate and 
chlordiazeproxide in the 
first 16 weeks of 
pregnancy 
Y 356 meprobamate 
and 257 
chlordiazeproxide 
Stillbirth/death 
to the fourth 
birth day 
Y No association 
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Author(s), year Country Study 
period 
Source of study 
population  
Number of 
pregnancies 
Exposure(s) Exposure 
information 
collected 
prior to 
outcome 
occurrence 
Number 
(and/or %) of 
mothers exposed  
Outcome(s) Any co-
variables 
considered  
Findings 
(measure of effects 
with 95% confidence 
interval, if not 
otherwise specified) 
Milkovich and 
van den Berg, 
1974170 
USA 1959-1966 Health registry data 19,044 Meprobamate and 
chlordiazeproxide in the 
first six weeks of 
pregnancy 
Y 395 meprobamate 
and 172 
chlordiazeproxide 
Perinatal 
death 
N Higher rate of perinatal 
death but not statistically 
significant 
SNRI/NRI included mianserin, mirtazapine, venlafaxine and reboxetine 
GHQ=general health questionnaires 
USA=United States of America; UK=United Kingdom 
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Table 5-2 Case-control studies for the impact of depression and/or anxiety on non-live pregnancy outcomes 
Author(s), year Country Study period Source of study 
population 
Number of 
cases/controls 
Outcome(s) Number 
(and/or %) of 
offspring 
exposed in 
cases 
Exposed Other co-
variables 
considered 
and/or 
adjusted 
Major findings 
Depression and/or anxiety 
        
Gold et al., 2007171 USA Early 1990s National comorbidity 
survey data 
606/1,354* Miscarriage and 
stillbirth 
(41) Any mental health 
disorder diagnosed 
before 1st birth 
Y OR=1.80 (1.35-2.41) mainly in 
affective disorder and substance 
use disorder, but not in anxiety 
disorder 
Nelson et al., 
2003154 
USA Jan 1999 to 
Aug 2001 
Emergency 
department in hospital  
174/798 Miscarriage (47) Depressive 
symptoms measured 
by self-report 
questionnaires 
(CES-D) 
Y No difference 
Antidepressants 
        
Nakhai-Pour et al., 
201047 
Canada 1998-2003 Pregnancy registry 
data 
5,124/51,240* Miscarriage 284 (5.5) Antidepressants 
during pregnancy 
Y OR=1.68 (1.38-2.06); 
SSRIs alone (esp. paroxetine) 
and venlafaxine 
Anxiolytics 
         
Laegreid, 1992172 Sweden 1985-86 Maternal health clinics 
in hospital 
73/73 Stillbirth and early 
neonatal death 
18 Benzodiazepines 
during pregnancy 
N OR=4.0 (2.0-7.9) 
* Retrospective cohort study/nested case control study 
CES-D=Centre for Epidemiologic Studies Depression Scale; USA=United States of America 
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Few studies have examined the effects of exposure to multiple psychotropic drug 
classes.  Previous research found a higher proportion of elective termination in 
mothers with multiple drugs than in those with single drug only (17.6% vs. 10.0%),168 
and a 3-fold increased risk of miscarriage in women with multiple classes of 
antidepressants than those with one class of antidepressants alone (e.g. OR=3.51, 95% 
CI 2.20-5.61 for at least 2 different classes of antidepressants).47  Such studies 
however have not been widely repeated and the results are inconsistent.  For 
example, another study including women identified through teratology information 
service found no increased risks of miscarriage in women exposed to both SSRIs and 
benzodiazepines compared with those exposed to SSRIs alone.45 
Miscarriage and perinatal death 
A Swedish population-based study examining all singleton and twin births from 1995 
to 1997 using national birth registry data found a slightly higher proportion of infant 
deaths (within the first year after delivery) in mothers exposed to antidepressants 
during early pregnancy than mothers unexposed (0.7% vs. 0.6% for any 
antidepressants and 0.8% vs. 0.5% for SSRIs only).165  This Swedish study however 
only identified seven infant deaths in women taking antidepressants and no formal 
statistical analyses were carried out due to the very small numbers of the adverse 
outcome. 
A more recent Swedish study in the same population examined the association 
between exposure to newer antidepressants (i.e. venlafaxine, mirtazapine, miaserin 
and reboxetine) during early pregnancy and the risk of stillbirth.160  After adjusting for 
maternal age, year of birth, parity, maternal smoking and maternal BMI, this study 
found a 70% increased risk, though not statistically significant (OR=1.70, 95% CI 0.6-
3.6), of stillbirth in women exposed to newer antidepressants during the first trimester 
of pregnancy compared with women without exposure to such drugs.  By linking with 
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another similar study from the same cohort, the Swedish study found no increased 
risk of stillbirth in mothers exposed to SSRIs (adjusted risk ratio=0.8, 95% CI 0.5-1.2).  
However, fewer than 1% of women had received SSRIs, much less than other 
European or North American populations,173  which limited statistical power and 
suggested different clinical practice of treating maternal mental illness in Sweden. 
Very few studies have tried to examine the effects of psychotropic medication with 
consideration of past and/or current mental illness.  A case-control study using 
pregnancy registry data in Canada identified nearly 70,000 pregnant women and 
found a 68% (OR=1.68, 95% CI 1.38-2.06) increased risk of miscarriage in women 
with exposure to antidepressants even after adjusting for depression, anxiety, history 
of medication use during one year before pregnancy and the severity of the illness 
(defined as the number of days antidepressants were prescribed and the number of 
visits to a psychiatrist in the year before pregnancy).47  Specifically, this Canadian 
study observed a higher risk of miscarriage in women exposed to SSRIs, but not to 
TCAs (ORs=1.61 and 1.27, 95% CIs 1.28-2.04 and 0.85-1.91, respectively). 
Four very similar prospective cohort studies including mothers consulting the same 
teratology information service (before their pregnancy outcome occurred) in Canada 
found on average 1.5-2 fold increased risks of miscarriage in women taking TCAs, 
SSRIs and newer antidepressants (e.g. venlafaxine) during the first trimester of 
pregnancy compared with women exposed to non-teratogenic drugs (such as 
acetaminophen).48,163,164,166  Nevertheless, all had relatively small sample sizes and 
there was considerable uncertainty in the estimates.  In contrast, a European 
observational study conducted by McElhatton and colleagues in 1996 examined 689 
pregnancies with exposure to antidepressants throughout pregnancy and found a 
similar risk of miscarriage between women exposed to tricyclic and non-tricyclic 
antidepressants in pregnancy (11.5% vs. 11.3%).168 
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By pooling the results from the six cohort studies,48,49,163,164,166,168 Hemels and 
colleagues found a 45% (relative risk ratio [RRR]=1.45, 95% CI 1.19-1.77) increased 
risk of miscarriage in women with antidepressants during early pregnancy compared 
with women unexposed.174  They also examined individual drug classes and found an 
increased risk of miscarriage in all antidepressant classes (RRR=1.23, 1.52, and 1.65, 
95% CIs 0.84-1.78, 1.17-1.98, and 1.02-2.69 for TCAs, SSRIs, and new 
antidepressants, respectively). 
The results are less consistent for specific drugs.  A Canadian study including 5,124 
women entered in the Quebec Pregnancy Registry database between 1998 and 2003 
found increased risks of miscarriage in women with paroxetine and venlafaxine 
(ORs=1.75 and 2.11, 95% CIs 1.28-2.04 and 1.34-3.30, respectively) compared with 
women taking other SSRI drugs.47  In contrast, a multi-centre prospective study 
conducted by Diav-Citrin et al. in high-income countries between 1994 and 2005 
found significantly higher proportions of miscarriage in women with fluoxetine (11.8% 
vs. 6.6% for miscarriage compared with the control group, p<0.05), but not in 
paroxetine, by comparing women with exposures to paroxetine and fluoxetine during 
pregnancy with women exposed to substances known not to be teratogenic, such as 
antibiotics, oral contraceptives and paracetamol.45  After adjusting for maternal age, 
smoking and previous miscarriage history, and prescriptions of other concomitant 
psychotropic medication, the association between exposures to fluoxetine and the 
risk of miscarriage reduced (adjusted OR=1.27, 95% CI 0.76-2.13 for miscarriage).45 
Termination 
Very few studies have been published to examine the risk of termination in women 
exposed to psychotropic drugs during pregnancy.  Unlike miscarriage and perinatal 
death which mostly occurred due to some potential biological mechanism, most 
therapeutic terminations in the UK are voluntary and not for reasons of medical 
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problems for the mother or the child.  Terminations are occasionally done because of 
a known chromosomal or congenital anomaly, yet this is uncommon.175  Discovery of 
pregnancy when taking psychotropic drugs could also contribute to such decisions, 
since women may worry about the potential adverse impact on the health of their 
offspring.159  Women with psychotropic medication may also have more severe 
symptoms of depression and may feel unable to continue the pregnancy.  Findings 
from previous studies have suggested that the increased risk of termination in women 
with psychotropic medication during pregnancy is more evident than the risk of 
miscarriage or perinatal death.49,159 
For example, Chambers et al. conducted a cohort study in 408 American women who 
contacted a teratology information service before pregnancy outcome occurred from 
1989 to 1995 and found a significantly higher proportion of termination (p=0.002), but 
not miscarriage or stillbirth, in pregnant women taking fluoxetine during the first 
trimester.49  Einarson et al. carried out a study in Canada including 937 women taking 
antidepressants during early pregnancy found three-fold increased risk of termination 
in exposed women compared with those unexposed (OR=3.25, 95% CI 1.48-7.14).159  
This study also found an increased, but much less evident, risk of miscarriage 
(OR=1.63, 95% CI 1.24-2.14). 
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5.2 Rationale and objectives 
Although the impact of maternal exposure to psychotropic medication, especially 
antidepressants, during early pregnancy on the risks of non-live pregnancy outcomes 
have been investigated in previous literature, no large population-based studies have 
attempted to differentiate between the effects of psycho-pharmaceutical treatment of 
mental illness and those of maternal mental illness itself, and the contribution of the 
underlying illnesses to these risks remains unclear.  In addition, few studies have 
been conducted to investigate the safety of anti-anxiety drugs (mainly 
benzodiazepines) in pregnant women and to comprehensively examine individual 
classes of psychotropic drugs exclusively.  No studies have been done to assess the 
impact of discontinuing psychotropic medication after women with mental illnesses 
become pregnant, on their pregnancy outcomes. 
The objectives of this study were to examine the impacts of maternal antenatal 
mental illness with and without drug treatments on the risks of non-live pregnancy 
outcomes, and to investigate the risks of each drug class separately.  I also assessed 
whether there was any risk modification after discontinuation of specific drug classes 
when pregnant. 
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5.3 Methods 
5.3.1 Study population 
From Populations 3 and 4 in Figure 2-1, I identified all clinically recognised singleton 
pregnancies among women aged 15-45 years between 1990 and 2009 that ended in 
live birth, stillbirth, termination or miscarriage.  For pregnancies ending in a live birth, I 
searched the records of both mothers and their children, if linked, for recordings of 
infant death within 28 days postpartum, and combined these with stillbirths as a 
measure of perinatal death.  Since the legislation on termination of pregnancy in 
Northern Ireland is more restrictive than that in other parts of the UK, I excluded 
women registered at general practices in this area. Since there were very few women 
with serious mental illness, I excluded all women with evidence of serious mental 
illnesses (bipolar disorder, schizophrenia and other related psychotic disorders), 
comprising less than 0.5% of the original study population. 
5.3.2 Definition of exposures 
As described in Section 4.3.2, depression and anxiety, and exposure to medication 
were defined according to the presence or absence of a relevant medical record in 
the womHQ¶VSULPDU\FDUHHOHFWURQLFKHDOWKUHFRUGVZLWKLQWKHILUVWGD\VIROORZLQJ
the estimated date of conception (the first trimester of pregnancy).  Dates of 
conception were estimated based on a range of recordings relating to pregnancy 
(including expected delivery dates, maturity estimates and timing of routine 
monitoring events), and where no information was available, live births were assumed 
to take place at 40 weeks and miscarriage and termination at 10 weeks.  I extracted 
records of prescriptions of all antidepressants, hypnotics, and anxiolytics that were 
primarily indicated for the treatment of depression or anxiety according to British 
national guidelines.98  To minimise the risk of detecting reverse-causal effects (where 
a non-live outcome may be the trigger for depression or anxiety and its treatment), I 
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excluded prescriptions and diagnoses within the last seven days of pregnancies 
which ended within the first trimester. 
I grouped mothers into eight mutually exclusive categories according to their 
diagnostic and treatment status: 
Group 0:  No history of anxiety or depression (non-exposed group). 
Group 1:  History of anxiety or depression before pregnancy but no diagnostic 
recordings during the first trimester. 
Group 2:  Diagnostic records of anxiety or depression but no prescriptions of interest 
during the first trimester.  
Group 3:  Prescriptions for any tricyclic antidepressants (TCAs) (alone - i.e. no other 
psychotropic medication of interest) during the first trimester 
Group 4:  Prescriptions for any SSRIs (alone) during the first trimester. 
Group 5:  Prescriptions for any benzodiazepines (alone) during the first trimester. 
Group 6:  Prescriptions for any other single class of drug from the following groups 
during the first trimester 
1. Other sedative medications: buspirone, meprobamate, zaleplon, 
zolpidem tartrate, zopliclone, chloral hydrate, triclofos sodium; 
2. Monoamine oxidase inhibitors: phenelzine, isocarboxazid, 
tranylcypromine and moclobemide; 
3. Other antidepressants: duloxetine, mirtazapine, reboxetine, tryptophan 
and venlafaxine; 
Group 7:  Prescriptions for two or more classes of psychotropic drug (mentioned 
above) during the first trimester. 
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5.3.3 Co-variables (maternal socio-demographic and lifestyle factors) 
I identified potential confounders by extracting information on the following 
characteristics of women: maternal age at the end of pregnancy, the most recent 
recording of smoking status before delivery, body mass index (BMI, kg/m2) before 
pregnancy and TXLQWLOHVRI7RZQVHQG¶V,QGH[RI'HSULYDWLRQ176 IRUHDFKZRPDQ¶V
postcode of residence.  Since women aged 15-17 may have different risks of non-live 
pregnancy outcomes from older women,177 we categorised maternal age as follows: 
15-17 years, 18-24 years, 25-34 years, and 35-45 years,QDGGLWLRQVLQFHZRPHQ¶V
prior pregnancy history could affect the risk of subsequent pregnancy loss, or of 
developing mental illness during later pregnancies,178,179 for each pregnancy, I also 
extracted information on the number of previous known live births (a proxy of parity) 
and the number of prior pregnancy losses, which included clinically recognised 
SUHJQDQF\ORVVHVRFFXUULQJGXULQJZRPHQ¶VJHQHUDOSUDFWLFHUHJLVWUDWLRQDQGFOLQLFDO
records of pregnancy history where available (e.g. Read medical code: 1542200 H/O: 
1 miscarriage). 
5.3.4 Statistical analyses 
Multinomial logistic regression models (for study outcomes with more than two values) 
were used to obtain relative risk ratios (RRRs) for perinatal death, miscarriage and 
termination relative to live births in each of the seven exposure groups compared with 
women without any indication of current or prior depression or anxiety.  I included 
PRUHWKDQRQHSUHJQDQF\IRUVRPHZRPHQDQGDFOXVWHUFRUUHFWLRQRQWKHZRPHQ¶V
unique identification codes was applied. 
To identify potential confounders, chi-squared tests were used to determine whether 
maternal age, Townsend deprivation index (in quintiles), maternal smoking history or 
BMI were associated with each exposure, or with any adverse pregnancy outcome 
among women in the referent group.  Co-variables with statistically significant 
associations at the 5% level with both were included in multivariable models to obtain 
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adjusted RRRs.  Missing values for co-variables were fitted as a separate category in 
the analyses to provide an implicit adjustment for any dissimilarity between women 
associated with differential recording. 
In addition, sensitivity analyses were conducted to assess the effects of prior 
pregnancy history.  By using chi-squared tests, the association of prior pregnancy 
history with exposures or with current adverse pregnancy outcomes was examined 
and the variable of previous live births or prior pregnancy losses was added into the 
main multivariable model separately.  The data were open cohort data that included 
all prospectively recorded pregnancy outcomes from the point at which women 
registered with their general practitioners, which could be at any age during the 
potentially fertile period.  Although all women in the UK must be registered with a 
general practitioner to receive obstetric care, people do change general practitioners, 
often because they move home.  I therefore did not have certainty of complete 
pregnancy history for all women, particularly for older women.  I also adjusted for 
previous pregnancy history in a further multivariable model restricted to women who 
were registered by the age of 20 in an attempt to minimise misclassification due to 
unrecorded prior pregnancies.  In addition, to reduce any potential effects of 
pregnancy history, I excluded women with evidence of prior pregnancy losses from 
the main multivariable model, both for the whole population and in women registered 
by age 20 to assess the effects on the main RRR estimates. 
To determine whether the use of psychotropic medication was associated with an 
excess risk of each adverse pregnancy outcome compared with un-medicated 
depression or anxiety, I repeated the main analyses excluding women without current 
depression or anxiety (i.e. excluding the original referent group and group 1), so that 
RRRs were in reference to group 2 (a recording of depression or anxiety, but no 
prescription during the first trimester). 
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Another sensitivity analysis was carried out to investigate whether the risks of 
adverse pregnancy outcomes in women who continued to receive psychotropic 
medications after conception were greater among those who discontinued their use.  
All women exclusively prescribed any TCAs, SSRIs or benzodiazepines (the three 
most common medication classes) within 90 days before pregnancy were identified.  
For each drug class, a multinomial logistic regression model was used to compare the 
outcomes among women who received a repeat prescription for a drug in the same 
class during the first trimester of pregnancy with those who did not.  In recognition of 
the large number of categorisations in each analysis, 99% confidence intervals (CIs) 
were calculated for each measure of association, and exact (3dp) p-values were 
given. 
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5.4 Results 
I identified 512,574 pregnancies among a cohort of 331,414 mothers.  More than half 
of women were aged 25-34 years and 0.4% of their pregnancies ended in perinatal 
death (stillbirth or neonatal death), 12.6% in miscarriage and 14.7% in termination 
(Table 5-3).  Compared with pregnancies ending in live births, pregnancies ending in 
terminations were more likely to be in younger women with a history of smoking and 
from socio-economically deprived groups whilst miscarriage was more common in 
older women.  Pregnancies ending in perinatal death were also more likely to occur in 
women from deprived groups and in those who were overweight or obese compared 
with live-birth pregnancies. 
Pregnancies ending in adverse outcomes were more common in all exposure groups 
compared with the referent group of women with no current or past depression or 
anxiety (Table 5-4).  The prevalence of miscarriage and perinatal death was highest 
among women prescribed psychotropic drugs, especially those receiving 
benzodiazepines, the less common medications (Group 6) and those receiving 
multiple classes of medication.  In women prescribed benzodiazepines only, 0.7% of 
pregnancies ended in perinatal death and 16.2% in miscarriage.  The equivalent 
proportions for women with un-medicated depression or anxiety were 0.6% and 
12.1%, and for those in the referent group were 0.4% and 12.1% respectively (Table 
5-4).  In addition, greater proportions of women terminated their pregnancies if they 
were exposed to psychotropic medication during early pregnancy. 
Table 5-5 presents the relative risk ratios for each adverse outcome for each 
exposure category compared with the referent group.  Compared with women from 
the referent group, women with a history of depression or anxiety and exposure to 
psychotropic medication during the first trimester of pregnancy had consistently 
increased risks of all non-live pregnancy outcomes.  Effect estimates for exposures to 
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different drugs (especially to SSRIs, benzodiazepines and the less common drug 
classes, and to multiple classes) were greater than those for un-medicated current 
illness or for a historical depression or anxiety diagnosis.  The greatest effects were 
found in women prescribed the less common medications (Group 6: unadjusted 
RRRs=4.2, 2.1 and 2.4, 99% CIs 2.1-8.5, 1.7-2.6 and 2.0-2.9 for the risks of perinatal 
death, miscarriage and termination, respectively) (Table 5-5). 
Table 5-6 shows the results after adjusting for maternal age at the end of pregnancy, 
household socioeconomic status, smoking status before delivery and BMI before 
pregnancy.  Compared with the unadjusted results, the adjusted RRRs reduced 
slightly for perinatal death and miscarriage, especially for drug associated risks.  The 
pattern of risks remained the same.  The RRRs for termination were almost 
unchanged. 
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Table 5-3 Maternal characteristic for all pregnancy outcomes 
 
All Live birth Perinatal deatha Miscarriage Termination 
Basic characteristics N=512,574 n=370,443 n=2,096 n=64,511 n=75,524 
 n % n % n % n % n % 
Maternal age at the end of pregnancy, years  
          
  15-17   10,252   2.0    3,708   1.0      22   1.1   1,166   1.8   5,356   7.1 
  18-24 109,793 21.4   69,495  18.8    390 18.6 11,568  17.9 28,340  37.5 
  25-34 282,006 55.0 220,642  59.6 1,140 54.4 31,832 49.3 28,392 37.6 
  35-45 110,523 21.6   76,598 20.7    544 26.0 19,945 30.9 13,436 17.8 
Townsend deprivation index 
          
   1 (least deprived) 117,018 22.8 88,535  23.9 387 18.5 14,920 23.1 13,176  17.5 
   2 96,618 18.9 71,566  19.3 342  16.3 12,346  19.1 12,364  16.4 
   3 100,527 19.6 72,180  19.5 399 19.0 12,743 19.8 15,205  20.1 
   4 97,608 19.0 68,643  18.5 429 20.5 11,961  18.5 16,575 22.0 
   5 (most deprived) 74,482 14.5 51,287  13.8 425  20.3 9,030 14.0 13,740  18.2 
   Missing 26,321   5.1 18,232 4.9 114 5.4 3,511 5.4 4,464 5.9 
Ever smoked before delivery 208,302 40.6 145,953 39.4 915  43.7 26,616 41.3 34,818  46.1 
Maternal BMI before pregnancy (kg/m2) 
          
   Under-weight (<18.5) 17,485 3.4 12,223 3.3 66 3.2 2,195 3.4 3,001  4.0 
   Normal (18.5-24.9) 227,820 44.5 166,999  45.1 787 37.5 28,696 44.5 31,338 41.5 
   Over-weight(25-29.9) 87,909 17.2 65,033  17.6 435  20.8 11,797 18.3 10,644  14.1 
   Obese (30-39.9) 49,594 9.7 36,561  9.9 284  13.6 7,144 11.1 5,605 7.4 
   Missing 129,766 25.3 89,627 24.2 524  25.0 14,679 22.8 24,936 33.0 
a Stillbirth or neonatal death within the first 28 days postpartum 
BMI=body mass index 
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Table 5-4 Breakdown of live and non-live pregnancy outcomes by different antenatal diagnostic and drug exposures 
Mental illness/drug exposuresa 
Live birth Perinatal death Miscarriage Termination 
N=370,443 N=2,096 N=64,510 N=75,524 
Referent categoryb n (%) 287,814 (73.7) 1,474 (0.4) 47,258 (12.1) 54,119 (13.9) 
History of mental illness only n (%) 69,297 (69.0) 480 (0.5) 13,814 (14.0) 16,341 (16.5) 
Un-medicated mental illness n (%) 2,640 (72.4) 20 (0.6) 442 (12.1) 545 (14.9) 
TCAs n (%) 1,983 (65.7) 18 (0.6) 443 (14.7) 575 (19.1) 
SSRIs n (%) 6,205 (60.2) 57 (0.6) 1,539 (14.9) 2,511 (24.4) 
Benzodiazepines n (%) 1,416 (59.4) 16 (0.7) 386 (16.2) 566 (23.7) 
Any other single class n (%) 645 (54.8) 14 (1.2) 223 (18.9) 296 (25.1) 
Multiple classes n (%) 1,443 (59.2) 17 (0.7) 406 (16.7) 571 (23.4) 
a
 Exposures were depression or anxiety with or without exposures to different classes of antidepressants or anti-anxiety drugs.  All categories were mutually exclusive. 
b Reference was no history of or current depression or anxiety 
TCAs=tricyclic antidepressants 
SSRIs=selective serotonin reuptake inhibitors 
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Table 5-5 Unadjusted relative risk ratios of each adverse pregnancy outcome relative to live birth in each antenatal diagnostic and 
drug exposure category compared with no current/past depression or anxiety (512,574 pregnancies in 331,414 women) 
 
Perinatal death Miscarriage Termination 
Mental illness/drug exposuresa n=2,096 n=64,510 n=75,524 
 RRR (99% CI) p RRR (99% CI) p RRR (99% CI) p 
Referent categoryb 1.0  1.0  1.0  
History of mental illness only 1.4 (1.2-1.6) <0.001 1.2 (1.2-1.3) <0.001 1.3 (1.2-1.3) <0.001 
Un-medicated mental illness 1.5 (0.8-2.6) 0.084 1.0 (0.9-1.2) 0.706 1.1 (1.0-1.2) 0.049 
TCAs 1.8 (1.0-3.3) 0.016 1.4 (1.2-1.6) <0.001 1.5 (1.4-1.7) <0.001 
SSRIs 1.8 (1.2-2.6) <0.001 1.5 (1.4-1.6) <0.001 2.2 (2.0-2.3) <0.001 
Benzodiazepines 2.2 (1.1-4.2) 0.002 1.7 (1.4-1.9) <0.001 2.1 (1.9-2.4) <0.001 
Any other single class 4.2 (2.1-8.5) <0.001 2.1 (1.7-2.6) <0.001 2.4 (2.0-2.9) <0.001 
Multiple classes 2.3 (1.2-4.3) 0.001 1.7 (1.5-2.0) <0.001 2.1 (1.9-2.4) <0.001 
a
 Exposures were depression or anxiety with or without exposures to different classes of antidepressants or anti-anxiety drugs.  All categories were mutually exclusive. 
b
 Reference was no history of or current depression or anxiety 
TCAs=tricyclic antidepressants 
SSRIs=selective serotonin reuptake inhibitors 
RRR=relative risk ratio 
CI=confidence interval 
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Table 5-6 Adjusted relative risk ratios of each adverse pregnancy outcome relative to live birth in each antenatal diagnostic and drug 
exposure category compared with no current/past depression or anxiety (512,574 pregnancies in 331,414 women) 
 
Perinatal death Miscarriage Termination 
Mental illness/drug exposuresa n=2,096 n=64,510 n=75,524 
 RRRc (99% CI) p RRRc (99% CI) p RRRc (99% CI) p 
Referent categoryb 1.0  1.0  1.0  
History of mental illness only 1.3 (1.1-1.5) <0.001 1.2 (1.2-1.2) <0.001 1.3 (1.3-1.4) <0.001 
Un-medicated mental illness 1.4 (0.8-2.5) 0.147 1.0 (0.9-1.2) 0.837 1.0 (0.9-1.2) 0.457 
TCAs 1.6 (0.9-2.9) 0.056 1.3 (1.1-1.5) <0.001 1.7 (1.5-1.9) <0.001 
SSRIs 1.6 (1.1-2.4) 0.001 1.5 (1.3-1.6) <0.001 2.2 (2.1-2.4) <0.001 
Benzodiazepines 2.0 (1.0-3.8) 0.007 1.6 (1.4-1.9) <0.001 2.2 (1.9-2.6) <0.001 
Any other single class 3.7 (1.9-7.5) <0.001 2.0 (1.7-2.5) <0.001 2.6 (2.1-3.1) <0.001 
Multiple classes 2.0 (1.0-3.7) 0.006 1.6 (1.4-1.9) <0.001 2.2 (1.9-2.6) <0.001 
a
 Exposures were depression or anxiety with or without exposures to different classes of antidepressants or anti-anxiety drugs.  All categories were mutually exclusive. 
b
 Reference was no history of or current depression or anxiety 
c
 Relative risk ratio after adjusted for maternal age at the end of pregnancy, household socioeconomic status, maternal smoking status before delivery and body mass index before pregnancy 
TCAs=tricyclic antidepressants 
SSRIs=selective serotonin reuptake inhibitors 
CI=confidence interval 
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Results from sensitivity analyses of adjustment for pregnancy history 
Table 5-7 shows relative risk ratios for all adverse pregnancy outcomes in the whole 
population of women (512,574 pregnancies in 331,414 women) after adding the 
variable of previous known live births (a proxy of parity) into the main multivariable 
model.  The results were almost identical to the main estimates in Table 5-6.  Table 
5-8 shows the results from the same analysis but in the 146,887 pregnancies that 
occurred in women registered by age 20 (85,260 women, 26% of the total population).  
Although power was reduced, relative risk ratios were similar to the main results with 
almost all risk estimates remaining within the 99% confidence intervals of the 
estimates in Table 5-6.  Risk estimates for termination did reduce modestly, yet all 
adverse outcomes still showed increased treatment-associated risks. 
I found that current miscarriage or perinatal death was associated with a higher 
number of prior pregnancy losses (p<0.001) whereas termination was associated with 
fewer prior losses (p<0.001).  The number of previous pregnancy losses was also 
associated with a higher likelihood of a recorded history of depression or anxiety 
before the current pregnancy (p<0.001).  Associations of prior pregnancy losses with 
current un-medicated as well as treated depression or anxiety in early pregnancy 
were less marked and women with treated mental illness who had previous losses 
represented only a small proportion of the overall population (Table 5-9). 
Table 5-10 shows the main analyses additionally adjusted for the number of prior 
pregnancy losses in the 146,887 pregnancies that occurred in women registered by 
age 20 (85,260 women, 26% of the total population).  The result patterns were very 
similar to those from the analyses with adjustment for the number of previous known 
live births in women registered by age 20, such that relative risk ratios were similar to 
the main analyses with almost all risk estimates remaining within the 99% confidence 
intervals of the main risk estimates in Table 5-6.  The risk estimates for termination 
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did reduce modestly, yet all adverse outcomes still showed increased treatment-
associated risks.  Table 5-11 and Table 5-12 show the results after excluding women 
with evidence of prior pregnancy losses from the total population (90% of the total 
population) and from women registered by age 20 (26% of the total population), 
respectively.  Results again remained very similar to the main analyses in Table 5-6. 
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Table 5-7 Sensitivity analyses: Adjusted relative risk ratios of each adverse pregnancy outcome relative to live birth in each antenatal 
diagnostic and drug exposure category compared with no current/past depression or anxiety 
 
Perinatal death Miscarriage Termination 
Mental illness/drug exposuresa n=2,096 n=64,510 n=75,524 
 RRRc (99% CI) p RRRc (99% CI) p RRRc (99% CI) p 
Referent categoryb 1.0  1.0  1.0  
History of mental illness only 1.1 (1.0-1.3) 0.025 1.2 (1.2-1.2) <0.001 1.3 (1.3-1.4) <0.001 
Un-medicated mental illness 1.2 (0.7-2.3) 0.361 1.0 (0.9-1.2) 0.854 1.0 (0.9-1.2) 0.434 
TCAs 1.6 (0.9-3.1) 0.051 1.3 (1.1-1.5) <0.001 1.7 (1.5-1.9) <0.001 
SSRIs 1.4 (1.0-2.1) 0.015 1.5 (1.3-1.6) <0.001 2.2 (2.1-2.4) <0.001 
Benzodiazepines 1.9 (1.0-3.8) 0.011 1.6 (1.4-1.9) <0.001 2.2 (1.9-2.6) <0.001 
Any other single class 3.5 (1.6-7.3) <0.001 2.0 (1.7-2.5) <0.001 2.6 (2.1-3.1) <0.001 
Multiple classes 2.0 (1.1-3.8) 0.004 1.6 (1.4-1.9) <0.001 2.2 (1.9-2.6) <0.001 
a
 Exposures were depression or anxiety with or without exposures to different classes of antidepressants or anti-anxiety drugs.  All categories were mutually exclusive. 
b Reference was no history of or current depression or anxiety 
c Relative risk ratio adjusted for maternal age at the end of pregnancy, number of previous known live births, household socioeconomic status, maternal smoking status before delivery and body 
mass index before pregnancy 
TCAs=tricyclic antidepressants 
SSRIs=selective serotonin reuptake inhibitors 
CI=confidence interval 
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Table 5-8 Sensitivity analyses: Adjusted relative risk ratios of each adverse pregnancy outcome relative to live birth in each antenatal 
diagnostic and drug exposure category (women with computerised prospective data from age 20 only; 146,887 pregnancies in 85,260 
women; 26% of total population) 
 
Perinatal death Miscarriage Termination 
Mental illness/drug exposuresa n=526 n=15,027 n=34,008 
 RRRc (99% CI) p RRRc (99% CI) p RRRc (99% CI) p 
Referent categoryb 1.0  1.0  1.0  
History of mental illness only 0.9 (0.7-1.2) 0.343 1.2 (1.1-1.3) <0.001 1.1 (1.1-1.2) <0.001 
Un-medicated mental illness 1.0 (0.3-3.1) 0.994 1.0 (0.8-1.3) 0.996 0.8 (0.7-1.0) 0.014 
TCAs 1.5 (0.4-5.4) 0.428 1.6 (1.2-2.1) <0.001 1.2 (0.9-1.6) 0.073 
SSRIs 1.1 (0.6-2.3) 0.626 1.5 (1.3-1.7) <0.001 1.7 (1.5-1.9) <0.001 
Benzodiazepines 2.5 (0.7-8.7) 0.055 1.6 (1.2-2.2) <0.001 1.7 (1.3-2.2) <0.001 
Any other single class 3.3 (0.8-13.0) 0.027 1.8 (1.2-2.7) <0.001 1.4 (1.0-2.0) 0.024 
Multiple classes 0.7 (0.1-5.1) 0.669 1.6 (1.2-2.2) <0.001 1.6 (1.2-2.0) <0.001 
a
 Exposures were depression or anxiety with or without exposures to different classes of antidepressants or anti-anxiety drugs.  All categories were mutually exclusive. 
b Reference was no history of or current depression or anxiety 
c Relative risk ratio adjusted for maternal age at the end of pregnancy, number of previous known live births, household socioeconomic status, maternal smoking status before delivery and body 
mass index before pregnancy 
TCAs=tricyclic antidepressants 
SSRIs=selective serotonin reuptake inhibitors 
CI=confidence interval 
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Table 5-9 Sensitivity analyses: Diagnoses and medically treated mental illness in early pregnancy stratified by the number of 
previous pregnancy lossesa (512,574 pregnancies in 331,414 women) 
 
Pregnancies by the number of previous pregnancy lossesa 
Mental illness/drug exposuresb 0 1 2  Total 
N=460,122 N=45,030 N=6,061 N=1,361 N=512,574 
n                 % n                 % n                 % n              % n                    % 
No history of or current depression/anxiety 355,221 77.2 30,871 68.6 3,809 62.8 764 56.1 390,665 76.2 
History of depression/anxiety only 84,785 18.4 11,729 26.0 1,916 31.6 502 36.9 98,932 19.3 
Un-medicated antenatal depression/anxiety  3,099 0.7 469 1.0 65 1.1 14 1.0 3,647 0.7 
Depression/anxiety treated with psychotropic drugs in early 
pregnancy 
17,017 3.7 1,961 4.4 271 4.5 81 6.0 19,330 3.8 
a
 Prior clinically recorded miscarriages or perinatal deaths                
b
 Exposures were depression or anxiety with or without exposures to different classes of antidepressants or anti-anxiety drugs. All categories were mutually exclusive.  
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Table 5-10 Sensitivity analyses: Adjusted relative risk ratios of each adverse pregnancy outcome relative to live birth in each 
antenatal diagnostic and drug exposure category (women registered by age 20 with computerised prospective data; 146,887 
pregnancies in 85,260 women, 26% of total population) 
 
 
Perinatal death Miscarriage Termination 
Mental illness/drug exposuresa n=526 n=15,027 n=34,008 
 RRRc (99% CI) p RRRc (99% CI) p RRRc (99% CI) p 
Referent categoryb 1.0  1.0  1.0  
History of mental illness only 0.9 (0.7-1.3) 0.568 1.2 (1.1-1.2) <0.001 1.1 (1.1-1.2) <0.001 
Un-medicated mental illness 1.1 (0.4-3.2) 0.819 1.0 (0.8-1.2) 0.764 0.8 (0.7-1.0) 0.032 
TCAs 1.8 (0.5-5.7) 0.218 1.6 (1.2-2.0) <0.001 1.2 (0.9-1.6) 0.055 
SSRIs 1.3 (0.7-2.6) 0.284 1.5 (1.3-1.7) <0.001 1.7 (1.5-1.9) <0.001 
Benzodiazepines 2.3 (0.7-7.6) 0.070 1.6 (1.1-2.1) <0.001 1.7 (1.3-2.2) <0.001 
Any other single class 3.6 (1.1-12.5) 0.005 1.7 (1.2-2.6) <0.001 1.4 (1.0-2.1) 0.016 
Multiple classes 0.8 (0.1-5.2) 0.768 1.6 (1.2-2.1) <0.001 1.6 (1.2-2.1) <0.001 
a
 Exposures were depression or anxiety with or without exposures to different classes of antidepressants or anti-anxiety drugs.  All categories were mutually exclusive. 
b Reference was no history of or current depression or anxiety 
c Relative risk ratio adjusted for maternal age at the end of pregnancy, number of previous known pregnancy losses, household socioeconomic status, maternal smoking status before delivery and 
body mass index before pregnancy 
TCAs=tricyclic antidepressants 
SSRIs=selective serotonin reuptake inhibitors 
CI=confidence interval 
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Table 5-11 Sensitivity analysis only in women with no previous clinically recorded miscarriages or perinatal deaths: adjusted relative 
risk ratios of each adverse pregnancy outcome relative to live birth in each antenatal diagnostic and drug exposure category 
compared with no current/past depression or anxiety (460,112 pregnancies in 330,549 women, 90% of total pregnancies) 
 
Perinatal death Miscarriage Termination 
Mental illness/drug exposuresa n=1,529  n=54,957  n=71,615  
 RRRc (99% CI) p RRRc (99% CI) p RRRc (99% CI) p 
Referent categoryb 1.0  1.0  1.0  
History of mental illness only 1.1 (1.0-1.4) 0.047 1.2 (1.1-1.2) <0.001 1.3 (1.3-1.4) <0.001 
Un-medicated mental illness 1.7 (0.9-3.2) 0.035 1.0 (0.9-1.2) 0.858 1.1 (0.9-1.2) 0.220 
TCAs 1.9 (1.0-3.7) 0.009 1.2 (1.1-1.4) <0.001 1.7 (1.5-1.9) <0.001 
SSRIs 1.4 (0.9-2.1) 0.076 1.5 (1.4-1.6) <0.001 2.3 (2.1-2.4) <0.001 
Benzodiazepines 2.2 (1.1-4.6) 0.005 1.6 (1.3-1.8) <0.001 2.2 (1.9-2.5) <0.001 
Any other single class 4.1 (1.9-9.1) <0.001 2.1 (1.7-2.6) <0.001 2.6 (2.1-3.2) <0.001 
Multiple classes 2.3 (1.1-4.6) 0.002 1.6 (1.4-1.9) <0.001 2.2 (1.9-2.5) <0.001 
a
 Exposures were depression or anxiety with or without exposures to different classes of antidepressants or anti-anxiety drugs.  All categories were mutually exclusive. 
b Reference was no history of or current depression or anxiety 
c Relative risk ratio adjusted for maternal age at the end of pregnancy, household socioeconomic status, maternal smoking status before delivery and body mass index before pregnancy 
TCAs=tricyclic antidepressants 
SSRIs=selective serotonin reuptake inhibitors 
CI=confidence interval 
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Table 5-12 Sensitivity analysis only in women with no previous clinically recorded miscarriages or perinatal deaths: adjusted relative 
risk ratios of each adverse pregnancy outcome relative to live birth in each antenatal diagnostic and drug exposure category (women 
registered by age 20 with computerised prospective data: 132,611 pregnancies in 85,157 women, 26% of total population) 
 
Perinatal death Miscarriage Termination 
Mental illness/drug exposuresa n=375 n=12,942 n=32,316 
 
RRRc (99% CI) p RRRc (99% CI) p RRRc (99% CI) p 
Referent categoryb 1.0  1.0  1.0  
History of mental illness only 0.9 (0.6-1.2) 0.236 1.2 (1.1-1.2) <0.001 1.1 (1.1-1.2) 0.002 
Un-medicated mental illness 1.5 (0.5-4.8) 0.370 0.9 (0.7-1.2) 0.600 0.8 (0.7-1.0) 0.024 
TCAs 2.6 (0.8-8.5) 0.036 1.6 (1.2-2.1) <0.001 1.2 (0.9-1.6) 0.049 
SSRIs 1.4 (0.6-3.2) 0.326 1.6 (1.4-1.8) <0.001 1.7 (1.5-1.9) <0.001 
Benzodiazepines 2.7 (0.7-10.1) 0.048 1.5 (1.1-2.1) 0.002 1.6 (1.2-2.1) <0.001 
Any other single class 3.7 (0.8-16.9) 0.026 1.5 (0.9-2.4) 0.028 1.4 (1.0-2.1) 0.023 
Multiple classes 1.2 (0.2-10.0) 0.757 1.6 (1.0-2.0) 0.004 1.5 (1.0-2.0) <0.001 
a
 Exposures were depression or anxiety with or without exposures to different classes of antidepressants or anti-anxiety drugs.  All categories were mutually exclusive. 
b Reference was no history of or current depression or anxiety 
c Relative risk ratio adjusted for maternal age at the end of pregnancy, household socioeconomic status, maternal smoking status before delivery and body mass index before pregnancy 
TCAs=tricyclic antidepressants 
SSRIs=selective serotonin reuptake inhibitors 
CI=confidence interval 
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Results from assessing risks of medication use in women with depression or 
anxiety or women continue their medication during pregnancy 
Compared with pregnancies in women with un-medicated depression or anxiety, 
women prescribed psychotropic medication had increased risks of all non-live 
pregnancy outcomes, although most of the results for perinatal death were not 
statistically significant at the 1% level (Table 5-13).  The greatest effects were again 
found among women in Group 6 (adjusted RRRs=2.7, 2.0 and 2.3, 99% CIs 1.1-6.6, 
1.6-2.5 and 1.8-2.8 for the risks of perinatal death, miscarriage and termination, 
respectively). 
Table 5-14 shows the adjusted RRRs of non-live pregnancy outcomes in pregnant 
women continuing with each psychotropic medication during the first trimester of 
pregnancy compared with those who discontinued the medication.  There were no 
increased risks of non-live pregnancy outcomes in women continuing with TCAs 
during pregnancy compared with those discontinuing them.  In contrast, women who 
continued with SSRIs and benzodiazepines had modest increased risks of 
miscarriage (RRRs=1.2 and 1.5, 99% CIs 1.0-1.3 and 1.0-2.1, respectively) as well as 
termination (RRRs=1.5 and 1.9, 99% CIs 1.3-1.6 and 1.4-2.6, respectively) compared 
with those who did not.
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Table 5-13 Adjusted relative risk ratios of each adverse pregnancy outcome relative to live birth in each antenatal drug exposure 
category compared with un-medicated antenatal depression or anxiety 
 
Perinatal death Miscarriage Termination 
Mental illness/drug exposuresa n=111 n=2,784 n=3,991 
 
RRRc (99% CI) p RRRc (99% CI) p RRRc (99% CI) p 
Referent categoryb 1.0  1.0  1.0  
TCAs 1.2 (0.5-2.7) 0.651 1.3 (1.1-1.5) 0.001 1.4 (1.2-1.7) <0.001 
SSRIs 1.2 (0.6-2.3) 0.558 1.4 (1.2-1.7) <0.001 2.0 (1.8-2.3) <0.001 
Benzodiazepines 1.4 (0.6-3.4) 0.305 1.6 (1.3-1.9) <0.001 1.9 (1.6-2.3) <0.001 
Any other single class 2.7 (1.1-6.6) 0.006 2.0 (1.6-2.5) <0.001 2.3 (1.8-2.8) <0.001 
Multiple classes 1.4 (0.6-3.3) 0.308 1.6 (1.3-1.9) <0.001 2.0 (1.6-2.3) <0.001 
a Exposures were depression or anxiety with or without exposures to different classes of antidepressants or anti-anxiety drugs.  All categories were mutually exclusive. 
b Reference was un-medicated depression or anxiety during the first trimester of pregnancy 
c Relative risk ratio adjusted for maternal age at the end of pregnancy, household socioeconomic status, maternal smoking status before delivery and body mass index before pregnancy 
TCAs=tricyclic antidepressants 
SSRIs=selective serotonin reuptake inhibitors 
CI=confidence interval 
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Table 5-14 Adjusted relative risk ratios of each adverse pregnancy outcome relative to live birth in pregnancies where women 
continued psychotropic medication use during the first trimester compared with those where women discontinued use 
Drug exposuresa 
Perinatal death Miscarriage Termination 
n RRRb (99% CI) p n RRRb (99% CI) p n RRRb (99% CI) p 
TCAs only (Nc=4,349) 22   650   708   
Discontinuing (n=2,708) 12 1.0  396 1.0  434 1.0  
Continuing (n=1,641) 10 1.5 (0.4-5.2) 0.406 254 1.0 (0.8-1.3) 0.861 274 1.1 (0.9-1.4) 0.387 
SSRIs only (Nc=14,191) 69   2,069   3,090   
Discontinuing (n=7,203) 30 1.0  1,005 1.0  1,411 1.0  
Continuing (n=6,988) 39 1.4 (0.7-2.6) 0.223 1,064 1.2 (1.0-1.3) 0.002 1,679 1.5 (1.3-1.6) <0.001 
Benzodiazepines only (Nc=3,392) 25   520   654   
Discontinuing (n=2,717) 19 1.0  415 1.0  491 1.0  
Continuing (n=611) 6 1.7 (0.5-6.0) 0.293 105 1.5 (1.0-2.1) 0.004 163 1.9 (1.4-2.6) <0.001 
a
 Women with exposure to TCAs, SSRIs, or benzodiazepines during 90 days before conceptions continued or discontinued with the medication during the first trimester of pregnancy 
b Relative risk ratio adjusted for maternal age at the end of pregnancy, household socioeconomic status, maternal smoking status before delivery and body mass index before pregnancy 
c
 Total exposed pregnancies (ending in live and non-live outcomes) 
TCAs=tricyclic antidepressants 
SSRIs=selective serotonin reuptake inhibitors 
CI=confidence interval 
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5.5 Discussion 
5.5.1 Principal findings 
I found that women with a history of depression or anxiety or exposure to 
psychotropic medication during the first trimester of pregnancy had increased risks of 
perinatal death and miscarriage compared with women in the general population.  
Among women with antenatal depression and anxiety, medicated illness was 
statistically significantly associated with greater risks of miscarriage than un-
medicated illness for every class of psychotropic drugs.  I also found that women 
prescribed SSRIs and benzodiazepines prior to pregnancy had greater risks of 
miscarriage if they continued to receive the medication than if they did not.  The 
magnitude of the medication-associated risks was similar for perinatal death, although 
most results were not statistically significant.  In addition, more women decided to 
terminate their pregnancy if they had medicated depression and/or anxiety during 
pregnancy than if they had not and the relative risks were similar to or higher than for 
miscarriage.  The findings suggest that psychotropic drugs, especially SSRIs and 
benzodiazepines, during the first trimester of pregnancy were associated with an 
excess risk of non-live pregnancy outcomes, although the true effect is likely to be 
marginal. 
5.5.2 Strengths and limitations 
This study is the largest and most comprehensive so far to examine the association 
between maternal depression and anxiety, the use of pharmacological treatment for 
these illnesses during the first trimester of pregnancy and the risks of perinatal death, 
miscarriage and termination.  This study is the first to investigate all of these 
outcomes whilst differentiating between past illness, current illness without medication 
use, and current medication use stratified by medication class and the number of 
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medication types prescribed.  I have also examined the impact of drug discontinuation; 
to my best knowledge this analysis is novel. 
The large sample size and assessments of significance at the 1% level mean that my 
findings are unlikely to be due to chance alone.  Despite this, since perinatal deaths 
are comparatively rare in the UK population, negative results for these outcomes 
should be interpreted cautiously as power is somewhat limited and the possibility that 
I have failed to detect true risks cannot be excluded.  However, given the rarity of 
these events, effects of the observed magnitude would in any case translate to fairly 
small excess risks in absolute terms. 
The data used were obtained from a UK primary care database and prospectively 
recorded by GPs, excluding the possibility of recall bias.  The study may have missed 
some non-live pregnancy outcomes, such as very early miscarriages and private 
terminations, however the observed prevalence of clinically-recognised adverse 
pregnancy outcomes is similar to UK national estimates.180±182  In addition, I may have 
missed some women with depression and anxiety who do not report their symptoms 
to their GPs.  Since all pregnant women must be registered with primary care 
physicians in the UK in order to benefit from antenatal checks and free medication, it 
is unlikely that a high proportion of women with depression and anxiety (and 
especially those with prescriptions for psychotropic medication) were not identified.  
Some women receiving drug prescription may not actually take the medication; this, 
however, would tend to bias the estimates to the null hypothesis (rather than produce 
spurious associations).  Inevitably in these data my population of women with 
depression or anxiety represents those diagnosed and clinically treated and my 
identification of exposure is therefore pragmatic rather than exhaustive. 
I have adjusted for the effects of maternal age, socio-economic deprivation, maternal 
smoking and maternal BMI.  I do not have complete data on these factors, but the 
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absence of any evidence of confounding where data are available suggests that it is 
unlikely that there is substantial residual confounding where data are missing.  I have 
DOVRDGMXVWHGIRUZRPHQ¶VSULRUSUHJQDQF\KLVWRU\E\XVLQJWKHQXPEHURINQRZQOLYH
births and prior pregnancy losses and adding them into the model separately) in the 
overall population and in a sub-set of women registered with a primary health care 
unit by age 20 years.  Although there was some evidence of residual confounding as 
risk estimates did decrease slightly for prior mental illness before pregnancy and 
modestly for termination, drug-associated risks for perinatal death and miscarriage 
remained almost unchanged.  The women in this sub-set population, however, 
represented the youngest group in the study population and were thus less likely both 
to have had a history of mental illness and to have had prior pregnancies.  When I 
restricted to only women with no prior pregnancy losses clinically recorded, I again 
found antenatal treatment for depression or anxiety to be consistently associated with 
all adverse outcomes both in the overall population and in women registered by age 
20.  These analyses demonstrate that the patterns of increased risks did not change 
EDVHGRQDZRPDQ¶VSUHJQDQF\KLVWRU\SDUWLFXODUO\IRUWKHWUHDWPHQW-associated risks 
with miscarriage and perinatal death. 
I acknowledge that other unmeasured factors might partly explain the results.  One 
particularly important effect that I have not quantified is the severity of disease, 
whether in terms of symptoms or other measures.  It is impossible to completely 
separate the effects of psychotropic drugs from the indications for treatment, and the 
receipt of medication might imply more severe illness.  Pregnant women with more 
severe mental illness might be more likely to choose a subsequent termination.  Since 
risk estimates were slightly higher for pregnancies ending in terminations than for 
perinatal death or miscarriage for almost every drug class, it is therefore possible that 
differing severity of underlying illness does partly explain my findings.  However, in 
the analysis of drug continuation in pregnancy, the differing effect of continuing with 
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SSRIs or benzodiazepines from the effect of continuing with TCAs does suggest 
some medication-specific (and therefore pharmacological) contribution to the 
observed increases in risk, although the true effect could be marginal.  In addition, I 
did not examine the effect of other maternal comorbidity (e.g. diabetes) on the 
observed risk estimates; however, such comorbidity is uncommon in the study 
population and is less likely to fully explain my findings.     
5.5.3 Interpretation in context of previous studies 
The findings of increased risks of miscarriage and perinatal death among women with 
a history of medicated depression or anxiety during early pregnancy found in this 
study were generally consistent with previous studies.42,43,43±46,53,142,156±158  To some 
extent, however, the findings also differed from previous work. 
A Swedish study found a 70% increased risk, though not statistically significant 
(adjusted risk ratio=1.7, 95% CI 0.6-3.6), of stillbirth in women exposed to newer 
antidepressants (venlafaxine, mirtazapine, miaserin and reboxetine) during the first 
trimester of pregnancy compared with those without such exposure after adjusting for 
maternal age, year of birth, parity, maternal smoking and maternal BMI, which is 
similar to my study.160  However, there was no increased risk of stillbirth in women 
exposed to SSRIs (adjusted risk ratio=0.8, 95% CI 0.5-1.2).  Women with a history of 
depression or anxiety but no medication during pregnancy were included in the 
referent group for comparison and fewer than 1% of women had received SSRIs (this 
is under half as many as in my UK population, suggesting differing clinical criteria for 
issuance of treatment), limiting statistical power, which may partly explain our 
different findings. 
Four prospective cohort studies investigating women consulting the same teratology 
information service in Canada found on average a 1.5-2 fold increased risk of 
miscarriage in women taking TCAs, SSRIs and newer antidepressants such as 
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venlafaxine during the first trimester of pregnancy.48,163,164,166  All four studies, 
however, had relatively small sample sizes (the largest being 534) and considerable 
uncertainty in the estimates.  Chambers et al. conducted another cohort study in 408 
women who contacted a teratology information service in the USA from 1989 to 1995 
and did not find statistically significantly increased risks of miscarriages or stillbirths in 
pregnant women taking fluoxetine during the first trimester compared with those not 
taking fluoxetine.49  However, by pooling the results from six studies (including the 
studies just mentioned),48,49,163,164,166,168 Hemels and colleagues found a 45% (risk 
ratio=1.45, 95% CI 1.19-1.77) increased risk of miscarriage in mothers taking any 
antidepressants during early pregnancy.174  Specifically, they found increased risks in 
women prescribed SSRIs and newer antidepressants, but not TCAs, compared with 
women who were not prescribed the respective class of drugs (risk ratios=1.23, 1.52 
and 1.65, 95% CIs 0.84-1.78, 1.17-1.98 and 1.02-2.69 for TCAs, SSRIs, and new 
antidepressants, respectively).  It is important to note, however, that study 
populations derived from teratology information services likely represent highly 
selected groups that exclude many exposed women in the general population. 
A more recent case-control study including more than half a million pregnant women 
from Canada found a 68% (95% CI 1.38-2.06) increased risk of miscarriage in women 
prescribed antidepressants even after adjusting for depression, anxiety, history of 
medication use during one year before pregnancy and the severity of the illness 
(defined as the number of days antidepressants prescribed and the number of visits 
to a psychiatrist in the year before pregnancy).47  Specifically, they observed a higher 
risk in women taking SSRIs, but not among those taking TCAs (odds ratios=1.61 and 
1.27, 95% CIs 1.28-2.04 and 0.85-1.91, respectively).  These findings suggest a 
potential pharmaceutical effect with SSRIs but not with TCAs, which is consistent with 
the observations in my study.  The Canadian study also found a three-fold increased 
risk of miscarriage in women with multiple classes of antidepressants compared with 
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those with one class only (odds ratio=3.51, 95% CI 2.20-5.61 for at least 2 different 
classes of antidepressants).  Again, the authors did not directly compare un-
medicated cases with those prescribed medication, nor did they consider the effects 
of anxiolytics, such as benzodiazepines, which were also associated with greater 
risks of non-live pregnancy outcomes in my study. 
My study also found increased risks of miscarriage and perinatal death in women 
prescribed benzodiazepines.  To my best knowledge, only a few studies have 
examined the effect of anti-anxiety drugs on non-live pregnancy outcomes.66,169,170,172  
A large American study in the 1970s found a higher, though not statistically significant, 
risk of perinatal death in women prescribed meprobamate and chlordiazeproxide,170 
and a later case-control study in Sweden showed a 4-fold increased odds of perinatal 
death in women exposed to benzodiazepines during pregnancy (95% CI 2.0-7.9).172  
A prospective study in Israel examining women who contacted the teratogen 
information service during pregnancy found higher rates of miscarriage (8.7% vs. 
5.2%) and termination (14.1% vs. 4.7%) in women exposed to benzodiazepines than 
those exposed to non-teratogenic drugs.66  None of these studies considered 
KRZHYHUDVVHVVHGWKHLPSDFWRIZRPHQ¶VXQGHUO\LQJFRQGLWLRQVRURWKHUPDWHUQal 
characteristics. 
In addition, my finding that women with medicated anxiety or depression during 
pregnancy are more likely to terminate a pregnancy than those who do not receive 
medication is in line with prior research.49,66,159  Unlike miscarriage and perinatal death 
(which typically occur due to trauma or via some biological mechanism) choosing to 
have a termination is usually voluntary, but occasionally due to in utero identification 
of a known chromosomal or congenital anomaly or of a potential risk to the foetus or 
mother if pregnancy continues to term (though such cases are likely uncommon in the 
UK population).  Therefore, the majority of terminations identified in my study are 
more likely to be a matter of personal preference regarding the pregnancy.  
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Compared with the risks of miscarriage and perinatal death, the increases in risks of 
termination found in my study were much greater (e.g. RRRs=1.2, 1.4 and 2.0 for the 
risks of perinatal death, miscarriage and termination respectively in women 
prescribed benzodiazepines during pregnancy shown in Table 5-13), suggesting that 
women receiving medication for depression or anxiety during pregnancy may be 
those who suffer the most severe symptoms and consequently feel unable to cope 
with a child.  The discovery of pregnancy when taking psychotropic medications could 
also contribute to such decisions since women may worry about the adverse impact 
on the health of their offspring subsequently.159  There may also be a marginal degree 
of reverse causation insofar as the small number of mothers who discover that their 
foetus exhibits an abnormality may become depressed and commence treatment 
prior to having a termination.  My findings concur with those of a recent study in 
Canada including 937 women taking antidepressants during early pregnancy, which 
found a 3-fold increased risks of termination in exposed women compared with those 
unexposed (OR=3.25, 95% CI 1.48-7.14), but only a 63% increased risk of 
miscarriage (OR=1.63, 95% CI 1.24-2.14).159 
5.5.4 Conclusion and implications 
This study has shown increased risks of miscarriage, perinatal death and decisions to 
terminate a pregnancy in women with anxiety or depression prior to pregnancy and 
with exposures to psychotropic drugs during the first trimester of pregnancy.  I found 
even greater risks in women with medicated antenatal depression and anxiety 
compared with those who did not receive medication.  Specifically, the risks were 
greatest among pregnant women prescribed SSRIs, benzodiazepines, and newer but 
less common drugs, and in those taking multiple drugs.  While I cannot rule out 
confounding by severity of mental illness, the analysis of women who did and did not 
continue their medication when pregnant implies that longer exposure may be more 
harmful.  Since the risk of developing a new depressive episode during pregnancy in 
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women discontinuing antidepressants remains unclear,184,185 my findings suggest that 
clinicians and obstetricians should continue to take a cautious approach to drug 
treatment in pregnant women with mental illness. 
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6 The risks of congenital anomalies in live-born children exposed 
to psychotropic medication during the first trimester of 
pregnancy 
This chapter describes a study examining the association of any major and system-
specific congenital anomalies with maternal exposure to psychotropic drugs, mainly 
antidepressant or anti-anxiety drugs, during early pregnancy.  A review of the current 
evidence in literature is firstly provided and followed by objectives, methods, results, 
discussion and final conclusions/implications. 
6.1 Introduction 
In recent years, a considerable number of studies have been carried out to 
investigate the potential toxic effects of various psychotropic drugs, mainly newly 
developed antidepressants such as paroxetine, fluoxetine, sertraline, and venlafaxine, 
on the human foetus in terms of the risk of congenital anomalies.  Table 6-1 
summarises all systematic reviews (including meta-analyses) of the association 
between antenatal exposure to psychotropic medication and congenital anomalies as 
published in English language journals from 1990 to June 2012. 
Currently, most reviews have been focused on the safety of selective serotonin 
reuptake inhibitors (SSRIs), especially paroxetine, and suggested a small increased 
risk of congenital anomalies, particularly heart anomalies in children with first 
trimester exposure to paroxetine.186  Less information is available for the safety of 
other antidepressant or anti-anxiety drugs.  In addition, although lithium and mood 
stabilisers are generally considered to be teratogenic, such excess risk is likely to be 
modest (around 2 fold).187±190  There has been very limited evidence available for the 
safety of antipsychotic drugs to draw valid conclusions.38,187
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Table 6-1 Systematic reviews and/or meta-analyses on the association between psychotropic medication and congenital anomalies 
Author(s), 
publication 
year 
Study 
period 
Outcome(s) 
assessed 
Inclusion criteria Studies 
initially 
identified 
Studies 
finally 
included 
Total 
pregnancies 
Number of 
women 
exposed 
Major findings 
Study design Medication and period of 
exposure 
Comparison 
group(s) 
Antidepressants 
         
Wurst et al., 
2010186 
Jan 
1992 to 
Sep 
2008 
Cardiac and 
overall congenital 
anomalies (minor 
included) 
Cohort and case-
control studies 
Paroxetine during the first 
trimester of pregnancy 
Non- paroxetine 37 20 Not reported Not reported Cardiac:  
Prevalence 
OR=1.46 (1.17-1.82);  
Overall:  
Prevalence 
OR=1.24 (1.08-1.43) 
O'Brien et al., 
2008191 
Jan 
1985 
and Nov 
2007 
Cardiovascular 
anomalies 
Cohort and case-
control studies 
Paroxetine during 
pregnancy 
Non- paroxetine 21 9 96,656 Not reported Cohort:  
Risk difference=0.3% (-0.1-
0.7%);  
Case-control: 
OR=1.18 (0.88-1.59) 
Bar-Oz et al., 
2007192 
1985 to 
2006 
Major and 
cardiovascular 
anomalies 
Case-control and 
cohort studies for 
pregnancies ending 
in live births only 
Paroxetine during the first 
trimester (0-14 weeks of 
gestational age) 
Other 
antidepressants 
or other non-
teratogenic 
medication 
Not reported 7 Not reported Not reported Major: 
OR=1.31 (1.03-1.67); 
Cardiac: 
OR=1.72 (1.22-2.42); 
Non-cardiac: 
OR=1.29 (0.86-1.92) 
Bellantuono 
et al., 2007193 
1966 to 
Oct 
2006 
Major congenital 
anomalies 
Prospective cohort 
and retrospective 
designs 
SRIs (SSRIs and SNRIs) 
during the first trimester of 
pregnancy 
Various by studies 16 15 Not reported Not reported Fluoxetine, sertraline, 
citalopram and 
venlafaxine no increased 
risk; 
Paroxetine need caution; 
Other SRIs: the risk remains 
substantially undetermined 
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Author(s), 
publication 
year 
Study 
period 
Outcome(s) 
assessed 
Inclusion criteria Studies 
initially 
identified 
Studies 
finally 
included 
Total 
pregnancies 
Number of 
women 
exposed 
Major findings 
Study design Medication and period of 
exposure 
Comparison 
group(s) 
Rahimi et al., 
2006194 
1990 to 
Aug 
2005 
Major, 
cardiovascular, 
and minor 
anomalies 
Not reported SSRIs (of any therapeutic 
dosage) during pregnancy 
Not reported Not reported 9 1,782 Not reported Major: 
OR=1.39 (0.91-2.15); 
Cardiac: 
OR=1.19 (0.53-2.68); 
Minor:  
OR=0.97 (0.14-6.93) 
Einarson & 
Einarson, 
2005195 
1996 to 
2005 
Major anomalies Prospective cohort 
studies 
SSRIs, reboxetine, 
venlafaxine, nefazodone, 
trazodone, mirtazapine 
and bupropion during the 
first trimester 
Non-exposed 22 7 1,774 Not reported Overall:  
RR=1.01 (0.57-1.80); 
Fluoxetine:  
RR=1.19 (0.47-3.00) 
Altshuler et 
al., 1996196 
1966 to 
1995 
Congenital 
anomalies 
Published studies 
written in English 
TCAs in the first trimester Non-exposed 14 13 over 300,000 414 Safe regarding the risk of 
congenital anomalies 
Anxiolytics 
         
Enato et al., 
2011197 
1966 to 
June 2010  
Major, 
cardiovascular 
anomalies and 
oral cleft 
Cohort and case-
control studies 
Exposure to 
benzodiazepines during 
the first trimester of 
pregnancy 
Not reported Not reported 26 1,051,376 4,342 Major:  
OR=1.07 (0.91-1.25); 
Cardiac:  
OR=1.27 (0.69-2.32) 
Dolovich et 
al., 1998198 
1966 to 
present 
Major anomalies 
and oral cleft 
Cohort and case- 
control studies 
Exposed to 
benzodiazepines at least 
during the first trimester of 
pregnancy 
Non-exposed to 
benzodiazepines 
Over 1,400 
studies  
23 Not reported Not reported Major (cohort):  
OR=0.90 (0.61-1.35); Major 
(case-control): OR=3.01 
(1.32-6.84); Oral cleft 
(cohort): OR=1.19 (0.34-
4.15); Oral cleft (case-
control): OR=1.79 (1.13-
2.82) 
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Author(s), 
publication 
year 
Study 
period 
Outcome(s) 
assessed 
Inclusion criteria Studies 
initially 
identified 
Studies 
finally 
included 
Total 
pregnancies 
Number of 
women 
exposed 
Major findings 
Study design Medication and period of 
exposure 
Comparison 
group(s) 
Altshuler et 
al., 1996196 
1966-1995 Congenital 
anomalies and 
oral cleft 
Published studies 
written in English 
Benzodiazepines in the 
first trimester 
Non-exposed 14 (4 for oral 
cleft) 
14 (3 for 
oral cleft) 
Range from 473 
to over 100,000 
Range from 
4 to 1,354 
Oral cleft: 
OR=2.4 (1.40-4.03) 
Lithium, mood stabilizers/anti-epileptic drugs, and antipsychotic drugs 
      
Galbally et 
al., 2010187 
1950-Jun 
2009 
Congenital 
anomalies 
Original research in 
English-language 
journals 
Lithium, valproate, 
lamotrigine, and 
carbamazepine 
Non-exposed Not reported 28 Not reported Not reported Lithium: limited evidence to 
draw any valid conclusion; 
all mood stabilizers were 
associated with a risk of 
congenital anomalies 
Einarson 
and 
Boskovic, 
200938 
1966-2008 Congenital 
anomalies 
Original research 
published in English  
Antipsychotic drugs Non-exposed Not reported Not 
reported  
Not reported Not clearly 
reported 
(range from 
45 to 1,309) 
No association was found 
but no good quality data and 
limited information  
Nguyen et 
al., 2009188 
1966-2008 Major congenital 
anomalies 
Original research 
published in English-
language journals 
Valproate, lamotrigine, 
carbamazepine, lithium 
and antipsychotic drugs 
Not reported Not reported 19 Not reported Not reported Incidence in: 
valproates: 6.2-20.3%; 
lamotrigine: 1.0-5.6%; 
carbama: 2.2-7.9%; 
lithium: 4.0-12.0; 
Antipsychotics: no good data 
Meador et 
al., 2008189 
1966-May 
2007 
Congenital 
anomalies 
Prospective cohort 
studies 
Pregnant women with 
epilepsy 
Healthy women 1,003 59 Nearly 
1,900,000 
65,533 Incidence in epilepsy: 
7.08% (5.62, 8.54); 
Carbamazepine alone: 
4.62%(3.48-5.76); 
Valproate alone: 
10.73% (8.16-13.29); 
Healthy women: 
2.28% (1.46, 3.10); 
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Author(s), 
publication 
year 
Study 
period 
Outcome(s) 
assessed 
Inclusion criteria Studies 
initially 
identified 
Studies 
finally 
included 
Total 
pregnancies 
Number of 
women 
exposed 
Major findings 
Study design Medication and period of 
exposure 
Comparison 
group(s) 
Altshuler et 
al., 1996196 
1966-1995 Congenital 
anomalies 
Published studies 
written in English 
Lithium, mood stabilizers 
and antipsychotics 
Non-exposed Not reported Not 
reported  
74,337 for 
phenothiazine 
2,591 Phenothiazine: OR=1.21; 
Lithium with a10-20 times 
LQFUHDVHGULVNRI(EVWHLQ¶V
anomaly; 
Mood stabilizer associated 
with increased risks of spina 
bifida 
Cohen et 
al., 1994190 
Not 
reported 
All congenital 
anomalies and 
(EVWHLQ¶VDQRPDO\ 
All published studies Lithium in the first 
trimester 
Non-exposed Not reported Not 
reported 
Not reported Not reported slightly increased risks of 
heart congenital anomalies, 
though not statistically 
significant 
SSRIs=selective serotonin reuptake inhibitors, including citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline 
TCAs=tricyclic antidepressants 
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6.1.1 Maternal use of antidepressant and anti-anxiety drugs accounting for 
impact of underlying illness 
There is concern over the use of some selective serotonin reuptake inhibitors (SSRIs), 
particularly paroxetine, during early pregnancy in terms of the risk of major congenital 
anomalies in the offspring.  The company GlaxoSmithKline,199 the manufacturer of 
PAXIL® (paroxetine hydrochloride tablets), revised their paroxetine label in 2005 and 
added a warning that there may be a small increased risk of congenital anomalies, 
particularly congenital heart anomalies, in children whose mother took paroxetine in 
the first trimester of pregnancy but no other psychotropic drugs have had warnings 
released by their manufactures.  Table 6-2 (for cohort studies) and Table 6-3 (for 
case-control studies) summarise all studies published in English language journals 
(identified through searching the website of PubMed) on the association of congenital 
anomalies with antidepressant or anti-anxiety drugs by cohort and case-control study 
designs separately, showing that most studies have few drug-exposed cases of 
congenital anomalies. 
Previous studies on the teratogenic impact of antidepressant and anti-anxiety drugs in 
early pregnancy have been conducted based on data from different resources and 
have also focused on various combinations of specific drugs and categories of 
congenital anomalies.  Some earlier studies have used detailed information of 
maternal drug use in a small number of patients recruited from teratology information 
centres in various countries.  Others have used retrospective case±control designs, 
with the potential for substantial recall bias and often relatively large nonresponse 
rates.  More recent studies have identified antenatal drug exposure from medical 
registers for a large number of patients, such as studies from Sweden, Denmark, and 
Finland.  Although there are potential problems of misclassification in the exposure as 
a woman who buy a drug might not take it during the organogenetic period, they 
provide a large representative study population.  Variations in different study 
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populations by prevalence of congenital anomalies and antenatal drug use may also 
have some effects on the teratogenic risk estimates.  In addition, whilst the effects of 
SSRIs have been increasingly examined in the literature, very few studies have 
considered the potential effects of other drugs and/or comorbid conditions in women 
during pregnancy. 
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Table 6-2 Cohort studies for antenatal exposure to psychotropic medication with congenital anomalies in offspring 
Author(s), year Country Study 
period 
Source of study 
population 
Number of 
pregnancies 
Exposure(s) Exposure 
information 
collected prior to 
outcome 
occurrence 
Number (%) 
of mothers 
exposed 
Outcome(s) Other co-
variables 
considered 
and/or 
adjusted 
Major findings 
Antidepressants 
         
Colvin et al., 
2011200 
Australia 2002-05 Population-based 
health datasets and 
a national 
pharmaceutical 
claims dataset 
97,262 Dispensed an 
SSRI during the 
first trimester of 
pregnancy 
compared with 
exposed to all 
non-SSRIs 
Y 2,701 (2.8) Major congenital 
anomalies 
Y (maternal 
age only) 
Overall:  
OR=1.05 (0.87-1.27); 
Cardiac:  
OR=1.60 (1.10-2.31) but not 
found in individual drugs; 
Respiratory: sertraline (<3); 
Gastrointestinal: fluoxetine 
Malm et al., 
201153 
Finland 1996-2006 Birth registry data 635,583 SSRIs during the 
first trimester 
Y 6,976 (1.1) Major congenital 
anomalies 
Y SSRIs overall:  
OR=1.08 (0.96-1.22); 
Fluoxetine with isolated 
ventricular septal defects;  
Paroxetine with right 
ventricular outflow tract 
defects;  
Citalopram with neural tube 
defects 
Kornum et al., 
2010201 
Denmark 1991-2007 Prescription 
database and 
National Registry of 
Patients 
216,042 At least one SSRI 
(incl. individual 
drugs) prescription 
in the first 
trimester of 
pregnancy  
Y 2,062 (1.0) Congenital 
anomalies 
Y SSRIs with any anomaly: 
OR=1.3 (1.1-1.6); 
Sertraline: Cardiac: 
OR=3.0 (1.4-6.4) and 
Sepal heart defects: 
OR=3.3 (1.5-7.5) 
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Author(s), year Country Study 
period 
Source of study 
population 
Number of 
pregnancies 
Exposure(s) Exposure 
information 
collected prior to 
outcome 
occurrence 
Number (%) 
of mothers 
exposed 
Outcome(s) Other co-
variables 
considered 
and/or 
adjusted 
Major findings 
Reis and 
Källén, 201058 
Sweden 1 July 1995 
to 2007 
Medical birth registry 
data 
1,077,002 Antidepressants in 
pregnancy (SSRIs 
and TCAs and 
specific SSRI 
drugs) 
Y 14,821 (1.4) Congenital 
anomalies 
Y TCAs: higher risk of severe 
anomalies and cardiac defects 
(VAS and/or ASD) 
Cardiac: paroxetine: OR=1.66  
(1.09-2.53); fluoxetine: 
OR=1.31 (0.85-2.02) 
Einarson et al., 
2009202 
Canada Not reported Teratogenic 
information service 
928+928 Antidepressants 
during the first 
trimester of 
pregnancy 
Y 928 Major congenital 
anomalies 
Y (matched) OR=0.9 (0.5-1.61) 
Merlob et al., 
2009203 
Israel 2000-07 Maternal ward in a 
local tertiary health 
care centre 
1,318 SSRI use during 
the first trimester 
of pregnancy 
Y 235 (17.8) Nonsyndromic 
congenital heart 
anomalies 
N RR=2.17 (1.07-4.39) 
Pedersen et al., 
200956 
Denmark 1996-2003 Several nationwide 
registries 
496,881 Two or more 
redemptions for 
SSRIs from 28 
days before to 112 
days after the 
beginning of 
gestation 
Y 1,370 (0.3) Congenital 
anomalies 
(minor, major 
and 12 specific 
categories) 
Y Only found increased risk for 
septal heart defects: OR=1.99 
(1.13-3.53) (esp in citalopram, 
sertraline and more than one 
type of SSRIs) 
Wichman et al., 
2009204 
USA Jan 1993 to 
15 Jul 2005 
Medical records 
from Mayo Clinic 
25,214 Treated with 
SSRIs during 
pregnancy 
Y 808 (3.2) Congenital heart 
disease 
N No association (0.4% vs. 
o.8%, p=0.23) 
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Author(s), year Country Study 
period 
Source of study 
population 
Number of 
pregnancies 
Exposure(s) Exposure 
information 
collected prior to 
outcome 
occurrence 
Number (%) 
of mothers 
exposed 
Outcome(s) Other co-
variables 
considered 
and/or 
adjusted 
Major findings 
Wisner et al., 
2009205 
USA Jan 2000 - 
Apr 2001 / 
Apr 2003 - 
Jul 2007 
Recruitment of 
pregnant women 
from Cleveland and 
Pittsburgh 
238 Depression and/or 
SSRI during 
pregnancy 
Y 107 (4.5) Congenital 
malformations 
Y No associations 
Diav-Citrin et 
al., 200845 
Israel, Italy 
and 
Germany 
1994-2002 
and 2002-05 
Teratology 
information service 
2,191 Paroxetine and 
fluoxetine during 
the first trimester 
of pregnancy 
Y 410 
(paroxetine) 
and 314 
(fluoxetine) 
Major and 
cardiac 
anomalies 
Y Higher prevalence of major 
anomalies in exposed groups 
(mainly due to cardiac 
anomalies);  
Fluoxetine with increased risk 
of cardiac defects: adjusted 
OR=4.47 (1.31-15.27); 
Paroxetine not: adjusted 
OR=2.66 (0.80-8.90) 
Einarson et al., 
200857 
Canada & 
Worldwide 
Not reported Teratology 
information services 
and published 
studies 
Not reported Paroxetine during 
the first trimester 
of pregnancy 
Y 1,174+2,205 Cardiovascular 
anomalies 
N OR=1.1 (0.36-2.78) 
Oberlander et 
al., 2008*206 
Canada 
(British 
Columbia) 
April 1997 to 
March 2002 
Data from several 
registry datasets 
119,547 SSRI mono-
therapy and 
SSRI+ 
benzodiazepines 
in combination 
during the first 
trimester 
Y 7,883 
(depression 
alone), 2,625 
(SSRIs alone), 
968 (benzos 
only) and 359 
(both drugs)  
Major anomalies 
and congenital 
heart disease 
Y Combination therapy 
associated with increased risk 
of cardiac defects:  
risk difference=1.18 (0.18-
2.18) 
 
          
6.1-176 | P a g e  
 
Author(s), year Country Study 
period 
Source of study 
population 
Number of 
pregnancies 
Exposure(s) Exposure 
information 
collected prior to 
outcome 
occurrence 
Number (%) 
of mothers 
exposed 
Outcome(s) Other co-
variables 
considered 
and/or 
adjusted 
Major findings 
Cole et al., 
2007207 
USA Jan 1995 to 
Sep 2004 
UnitedHealthcare 
(an insurer) 
5,791 Paroxetine and 
compared with all 
other 
antidepressants 
during the first 
trimester 
Y 998 and 797 
mono-therapy 
only 
congenital 
malformations 
(and by organ 
system 
category) 
Y All CAs (mono-therapy): 
OR=1.89 (1.20-2.98); 
All CAs (mono- or poly-
therapy): OR=1.76 (1.18-2.64); 
Not for cardiac anomalies 
Davis et al., 
200759 
USA 1996-2000 5 health centres 50,931 TCAs or SSRIs 
during pregnancy 
Y 1,047 (SSRIs) 
and 221 
(TCAs) 
Congenital 
anomalies 
N SSRIs: no association; 
TCAs: an increased risk of 
limb abnormalities and spina 
bifida 
Källén and 
Otterblad 
Olausson, 
200755 
Sweden 1995-2004 Medical birth register 960,215 SSRIs during early 
pregnancy 
Y 6,481 (0.7) Congenital 
anomalies 
Y No association (overall and for 
each class) 
Lennestål and 
Källén, 2007160 
Sweden Up to 2004 Medical birth register 860,215 SSRIs and newly 
introduced 
antidepressants 
Y 6,481 and 732 Congenital 
anomalies 
N No association 
Djulus et al., 
2006161 
Canada & 
Worldwide 
(incl. UK) 
June 2002 
to August 
2005 
5 teratogen 
information services 
312 Mirtazapine during 
pregnancy 
Y 104 Major anomalies N No association 
Källén and 
Otterblad 
Olausson, 
2006208 
Sweden July 1995-
2003 
Birth registry data Not reported Antidepressants in 
early pregnancy 
Y 6,896 Congenital 
anomalies and 
cardiac 
anomalies 
Y Clomipramine (cardiac):  
OR=2.22 (1.29-3.82); 
Paroxetine (cardiac):  
OR=2.29 (1.28-4.09) 
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Author(s), year Country Study 
period 
Source of study 
population 
Number of 
pregnancies 
Exposure(s) Exposure 
information 
collected prior to 
outcome 
occurrence 
Number (%) 
of mothers 
exposed 
Outcome(s) Other co-
variables 
considered 
and/or 
adjusted 
Major findings 
Wen et al., 
200646 
Canada 1990-2000 Database 972+3,878  SSRIs in the year 
before delivery 
Y 972 Structural 
anomalies 
Y (matched) No association 
Wogelius et al., 
2006209 
Denmark 1991-2003 Several national 
databases 
151,831 SSRIs from 30 
days before 
conception until 
the end of the first 
trimester 
Y 1,051 (0.7) Congenital 
anomalies 
Y Within the second or third 
month after conception :  
OR=1.84 (1.25-2.71) 
Chun-Fai-Chan 
et al., 2005210 
Canada and 
UK 
Not reported Teratogenic 
information service 
136+133  Bupropion during 
the first trimester 
of pregnancy 
Y 136 Major congenital 
anomalies 
Y (matched) No association 
Malm et al., 
2005211 
Finland 1996-2001 Several national 
databases 
1,782+ 1,782  >=1 purchase of 
SSRIs during the 
period 1 month 
before and during 
pregnancy 
Y 1,782 Major congenital 
anomalies 
Y (matched) No association (neither for 
individual drugs) 
Sivojelezova et 
al., 2005162 
Canada 1999-2002 Teratogenic 
information service 
396 (matched) Citalopram during 
the first trimester 
of pregnancy 
Y 132 Major congenital 
anomalies 
Y No association 
Williams and 
Wooltorton, 
2005212 
USA Not reported Insurance 
databases 
3,581 SSRIs during the 
first trimester of 
pregnancy 
Y 527 for 
paroxetine 
exclusively 
Major congenital 
anomalies 
Y Paroxetine: 
OR=2.20 (1.34-3.63)  
Einarson et al., 
2003163 
Canada Not reported Teratogenic 
information service 
147+147+ 147 
(matched) 
Trazodone or 
nefazodone during 
the first trimester 
of pregnancy 
Y 147 Major congenital 
anomalies 
Y RR=1.67 (0.85-3.28) 
6.1-178 | P a g e  
 
Author(s), year Country Study 
period 
Source of study 
population 
Number of 
pregnancies 
Exposure(s) Exposure 
information 
collected prior to 
outcome 
occurrence 
Number (%) 
of mothers 
exposed 
Outcome(s) Other co-
variables 
considered 
and/or 
adjusted 
Major findings 
Hendrick et al., 
2003213 
USA June 1997 
and May 
2002 
Not reported 138 (no 
comparison 
group) 
SSRIs during 
pregnancy 
Y 138 Congenital 
anomalies 
N No association 
Simon et al., 
2002214 
USA 1986-98 Insurance data 788 Antidepressants 
during the 270 
days before 
delivery 
Y 209 
(TCAs)+185 
(SSRIs) 
Congenital 
anomalies 
Y (matched) No association 
Einarson et al., 
2001164 
Canada Not reported Teratogenic 
information service 
450 Venlafaxine during 
4th to 14th week 
gestation 
Y 150 Major congenital 
anomalies 
Y (matched) No association 
Ericson et al., 
1999215 
Sweden 1995-97  Birth registry data 969 (no 
comparison 
group) 
Antidepressants 
during pregnancy 
Y 533 (SSRIs) Congenital 
anomalies 
N No association 
Kulin et al., 
1998166 
North 
America 
Not reported Teratogenic 
information service 
267+267 
(matched) 
SSRIs during the 
first trimester of 
pregnancy 
Y 267 Major congenital 
anomalies 
Y No association 
Goldstein et al., 
1997216 
Worldwide Not reported Drug company data 796 (no 
comparison) 
Fluoxetine during 
the first trimester 
of pregnancy 
Y 796 Congenital 
anomalies 
N No association 
Chamber et al., 
199649 
USA 1989-95 Teratogenic 
information service 
228+254 Fluoxetine during 
pregnancy 
Y 228 Congenital 
anomalies 
N No difference in major 
structural anomalies but in 
three or more minor anomalies 
(p=0.03) 
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Author(s), year Country Study 
period 
Source of study 
population 
Number of 
pregnancies 
Exposure(s) Exposure 
information 
collected prior to 
outcome 
occurrence 
Number (%) 
of mothers 
exposed 
Outcome(s) Other co-
variables 
considered 
and/or 
adjusted 
Major findings 
Pastuszak et 
al., 199348 
Canada Not reported Teratogenic 
information service 
128+128 
(matched) 
Fluoxetine during 
the first trimester 
of pregnancy 
Y 128 Major congenital 
anomalies 
Y No association 
Anxiolytics 
          
Gidai et al., 
2010217 
Hungary 1960-93 Toxicological 
inpatients clinics 
43+29 sib 
controls 
Large dose of 
nitrazepam alone 
or combination 
with other drugs 
Y 43 Structural 
congenital 
anomalies 
Y OR=3.8 (1.0-14.6) 
Leppée et al., 
2010218 
Yugoslavia May 2004 4 hospitals in 
Zagreb 
893 (no 
comparison) 
Benzodiazepines 
in pregnancy 
Y 893 Congenital 
anomalies 
N Not clear 
Gidai et al., 
200863 
Hungary 1960-93 Toxicological 
inpatients clinics 
224  Diazepam in 
pregnancy 
Y 112 Congenital 
anomalies 
Y (matched 
sibs) 
OR=2.0 (0.8-5.0) 
Gidai et al., 
2008219 
Hungary 1960-93 Toxicological 
inpatients clinics 
35+22 (sibs) Chlordiazepoxide Y 35 Congenital 
anomalies 
Y No association 
Wikner et al., 
2007220 
Sweden 1st July 
1995 to 
2004 
Birth register data 875,858 Benzodiazepines 
in early pregnancy 
Y 1,979 (0.2) Congenital 
anomalies 
Not clear Major congenital anomalies: 
OR=1.24 (1.00-1.55) 
Ornoy et al., 
199866 
Israel 1988-Jul 
1996 
Teratogenic 
information service 
460+424 Benzodiazepines 
prior to or in 
pregnancy 
Y 460 Congenital 
anomalies 
N No association (3.1% vs. 
2.6%) 
Bergman, 
1992221 
USA 1980-83 Public health 
insurance system 
(Medicaid) 
104,339 10 or more 
prescriptions of 
benzodiazepines 
in pregnancy 
Y 80 Congenital 
anomalies 
Y 13 vs. 7% (no statistical 
analysis carried out) 
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Author(s), year Country Study 
period 
Source of study 
population 
Number of 
pregnancies 
Exposure(s) Exposure 
information 
collected prior to 
outcome 
occurrence 
Number (%) 
of mothers 
exposed 
Outcome(s) Other co-
variables 
considered 
and/or 
adjusted 
Major findings 
St Clair and 
Schirmer, 
1992222 
USA June 1982-
1990 
From health 
professionals or self-
referred 
411 Alprazolam during 
the first trimester 
of pregnancy 
Y 411 Congenital 
anomalies 
N Not clear 
Hartz et al., 
1975223 
USA 1958-1966 Hospital records 5,282 Meprobamate/ 
chlordiazeproxide 
in the first 16 
weeks of 
pregnancy 
Y 356+257 Congenital 
anomalies 
Y No association 
Milkovich, 
1974170 
USA 1959-1966 Health registry data 19,044 Meprobamate/ 
chlordiazeproxide 
in the first 6 weeks 
of pregnancy 
Y 395+172 Severe 
congenital 
anomalies 
N Higher prevalence in exposed 
groups 
* Examined both antidepressants and anxiolytics.  
CAs=congenital anomalies 
SSRIs=selective serotonin reuptake inhibitors 
TCAs=tricyclic antidepressants 
USA=United States of America 
UK=United Kingdom 
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Table 6-3 Case-control studies for antenatal exposure to psychotropic medication with congenital anomalies 
Author(s), year Country Study period Source of study 
population 
Total number of 
cases/controls 
Outcome(s) Number (%) of 
cases with 
exposures 
Exposure Other co-
variables 
considered 
and/or 
adjusted 
Major findings 
Antidepressants 
        
Bakker et al., 
201054 
Netherlands 1997-2007 Birth registry data  178/4077 Infantile hypertrophic 
pyloric 
stenosis 
3 (1.7) Fluoxetine in the first 
trimester of 
pregnancy 
Y OR=8.7 (2.3-33.2) compared 
with other congenital anomalies 
Bakker et al., 
2010224 
Netherlands 1997-2006 Birth registry data  678/615 Isolated heart 
anomalies 
1.5% Paroxetine during 
the first trimester of 
pregnancy 
Y OR=1.5 (0.5-4.0); for atrial 
septal defects: OR=5.7 (1.4-
23.7) 
Ramos et al., 
2008*225 
Canada Jan 1998 to 
Dec 2002 
Data from 
medication and 
pregnancy registry 
by linking three 
databases 
189/2,140 Major congenital 
anomalies 
Not reported Antidepressant 
during the first 
trimester of 
pregnancy 
N No association 
Bérard et al., 
2007*226 
Canada 1997 to Jun 
2003 
Data from 
Medication and 
Pregnancy registry 
101/1,302 Major and cardiac 
anomalies 
43 (42.6) Paroxetine during 
the first trimester of 
pregnancy 
Y >25 mg/day of paroxetine during 
the first trimester: 
Major anomalies: OR=2.23 
(1.19, 4.17); Major cardiac: 
OR=3.07 (1.00, 9.42) 
Alwan et al., 
2007227 
USA Oct 1997 to 
Dec 2002 
National birth-
defects surveillance 
systems; 
Hospital records or 
state birth-certificate 
records 
9,622/4,092 Major birth defects 
and subcategories 
230 (2.4) SSRIs  from 1 month 
before to 3 months 
after conception 
Y No association for heart defects; 
but anencephaly, 
craniosynostosis, and 
omphalocoele 
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Author(s), year Country Study period Source of study 
population 
Total number of 
cases/controls 
Outcome(s) Number (%) of 
cases with 
exposures 
Exposure Other co-
variables 
considered 
and/or 
adjusted 
Major findings 
Louik et al., 
2007228 
USA 1993-2004 5 study centres 9,849/5,860 7 subgroups of birth 
defects re 
development 
100 (2.7) in 
offspring with 
cardiac 
anomalies 
Any SSRI from 28 
days before through 
112 days after the 
last menstrual 
period 
Y Sertraline associated with 
omphalocoele and septal 
defects; 
Paroxetine and right ventricular 
outflow tract obstruction defects 
Källén and 
Robert-Gnansia, 
2005229 
Sweden and 
France 
1995-2002 Health registers 323/674,491 Craniostenosis Not reported Antidepressant 
during the first 
trimester of 
pregnancy 
Y No association 
Källén and 
Otterblad 
Olausson, 
2003**230 
Sweden Jul 1995 to 
Dec 2001 
Birth registry data 5,015/577,730 Cardiovascular 
anomalies 
1,408 Any drug use in 
early pregnancy 
Y Tricyclic: 
OR=1.77 (1.07-2.91); 
Clomipramine: 
OR=2.03 (1.22-3.40); 
No association with SSRIs or 
benzodiazepines 
Greenberg et al., 
1977**231 
UK 1969-1974 Voluntary reporting 
to health authority 
836/836  Major defects 26 Any drug use during 
the first trimester of 
pregnancy 
Y (matched) No associations for both 
antidepressants and 
benzodiazepines 
Anxiolytics 
         
Czeizel et al., 
2004232 
Hungary 1980-1996 Health registry data 22,865/38,151  Congenital anomalies 201 (0.9) Oral 
chlordiazepoxide 
during early 
pregnancy 
Y (matched) Cardiac anomalies: 
OR=2.5 (1.0-6.0) 
Eros et al., 200264 Hungary 1980-1996 Health registry data 22,865/38,151  Congenital anomalies 57 (0.25) Benzodiazepines in 
pregnancy 
Y (matched) No association 
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Author(s), year Country Study period Source of study 
population 
Total number of 
cases/controls 
Outcome(s) Number (%) of 
cases with 
exposures 
Exposure Other co-
variables 
considered 
and/or 
adjusted 
Major findings 
Bonnot et al., 
200165 
France 1976-1998 Linked health 
registry data 
13,703 (self-
controlled: other 
categories of 
congenital 
anomalies)  
Congenital anomalies 
(specific categories) 
262 (7.3) Benzodiazepines 
during the first 
trimester of 
pregnancy 
Y No association overall; 
Lorazepam with anal atresia: 
OR=6.19 (2.44-15.71); 
Bromazepam with other 
digestive anomalies: 
OR=6.15 (1.88-1.20); 
Oxazepam with genetic 
anomalies: 
OR=0.43 (0.23-0.81); 
Prazepam with neural tube 
defects: 
OR=6.80 (1.80-25.73) 
Laegreid et al., 
199060 
Sweden 1985-1986 Hospital records 18/60 Congenital anomalies 8 (44) Maternal plasma: 
benzodiazepines 
during pregnancy 
N 44% vs. 3.3% 
Czeizel, 198767 Hungary 1980-1984 Health registry data 630/630 Facial clefts 63 (10.0) Benzodiazepines 
during pregnancy 
Y (matched) No association 
 
         
Rosenberg et al., 
198368 
USA Mar 1976 to 
April 1982  
Birth defects 
surveillance data 
611/ 2,498 Facial clefts Not reported Diazepam during the 
first trimester of 
pregnancy 
N No association 
Safra and Oakley, 
197562 
USA 1968-1974 Birth registry data 278/709 Congenital anomalies Not reported Diazepam in the first 
trimester of 
pregnancy 
N Increased risk of facial clefts 
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Author(s), year Country Study period Source of study 
population 
Total number of 
cases/controls 
Outcome(s) Number (%) of 
cases with 
exposures 
Exposure Other co-
variables 
considered 
and/or 
adjusted 
Major findings 
Saxén, 1975233 Finland 1967-1971 Register of 
congenital 
malformations 
599/599  Oral clefts and cleft 
palate 
44.4% Diazepam in the first 
trimester of 
pregnancy 
Y (matched) Yes, p<0.001  
*nested case-control study 
** Examined both antidepressants and anxiolytic drugs 
SSRIs=selective serotonin reuptake inhibitors 
TCAs=tricyclic antidepressants 
UK=United Kingdom 
USA=United States of America 
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Antidepressants  
Selective serotonin reuptake inhibitors 
Recent large, population-based studies are increasingly focused on the safety of 
SSRIs overall and individual SSRI drugs, such as paroxetine, sertraline and fluoxetine.  
For example, a large population-based cohort study carried out by Malm et al. in 
Finland in 2011 using national birth registry data from 1996 to 2006 examined the 
risks of major congenital anomalies in children of women exposed to SSRIs during 
the first trimester of pregnancy compared with those not exposed to SSRIs.53  After 
adjusting for maternal age at the end of pregnancy, parity, year of pregnancy ending, 
marital status, smoking during pregnancy, other reimbursed psychiatric drug 
purchases, and pre-pregnancy diabetes, this study found an association, though not 
statistically significant, between major congenital anomalies and maternal exposure to 
SSRIs (OR=1.08, 95% CI 0.96-1.22).  Malm et al. also examined the teratogenic 
effects of individual SSRI drugs and found associations between maternal use of 
paroxetine and right ventricular outflow tract defects, fluoxetine with isolated 
ventricular septal defects, and citalopram with neural tube defects (OR=2.46, 95% CI 
1.20-5.07), suggesting that psychotropic drugs from the same class may work 
differently in the foetus development, unless the results were chance findings. 
In addition, a population-based Australian study included 97,265 pregnancies from 
national medical and pharmaceutical datasets in 2002-2005 and found increased 
risks of cardiovascular anomalies in children exposed to SSRIs in the first trimester of 
pregnancy compared with children unexposed (OR=1.60, 95% CI 1.10-2.31),200 
similar to the findings from an Israeli study (relative risk=2.17, 95% CI 1.07-4.39 for 
any SSRIs).203  The Australian study also found similar excess risks for specific SSRI 
drugs (i.e. citalopram, sertraline, fluoxetine, and paroxetine), though the results were 
not statistically significant, which could be due to limited study power available for 
6.1-186 | P a g e  
 
individual drugs.  In addition to the excess risks of congenital heart anomalies, the 
Australian study found associations of respiratory system anomalies with first 
trimester exposure to sertraline (OR=3.73, 95% CI 1.18-11.82) and gastrointestinal 
anomalies with fluoxetine (OR=3.08, 95% CI 1.27-7.48). 
Pedersen et al. conducted a population-based cohort study using registry data in 
Denmark from 1996 to 2004 and selected women with two and more SSRI 
redemptions as exposed (1,370, 0.3% of the study population).56  The Danish study 
however only found a higher risk of septal heart defects in children exposed to SSRIs 
(OR=1.99, 95% CI 1.13-3.53), particularly in children with first trimester exposure to 
citalopram, sertraline and more than one type of SSRI. 
In addition, by pooling data from teratology information service centres of several 
high-income countries, a prospective, multicentre, observational study found children 
of women prescribed paroxetine and fluoxetine have higher prevalence of major 
anomalies than of those prescribed drugs deemed to be non-teratogenic (such as 
penicillin, cephalosporin).45  Specifically, this study also demonstrated increased risks 
of cardiac defects in offspring exposed to these drugs (OR=4.81 and 3.47, 95% CIs 
1.56-14.71 and 1.13-10.58 for fluoxetine and paroxetine, respectively) compared to 
those exposed to non-teratogenic agents.  However, after adjustment for concomitant 
psychotropic medications and other maternal factors (such as maternal smoking), the 
odds ratio remained significant only for fluoxetine (OR=4.47, 95% CI 1.31-15.27) but 
not paroxetine (OR=2.66, 95% CI 0.80-8.90).  Despite this, the results for fluoxetine 
are inconsistent and three early studies found no association between fluoxetine 
during early pregnancy and major malformations in offspring,48,49,167 except a slightly 
increased risk in three or more minor anomalies.49  These early studies however had 
very small sample sizes (796 maximum) thus may not be able to detect small 
differences. 
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Although paroxetine has been increasingly investigated in observational studies, very 
few have examined the effect of dosage.  A previous case-control study in Canada226 
used information from medication and pregnancy registry in 1997-2003 and found 
that maternal use of paroxetine at more than 25mg per day during the first trimester of 
pregnancy was associated with increased risks of major congenital anomalies 
(OR=2.2, 95% CI 1.2-4.2) and mainly congenital anomalies in heart (OR=3.1, 95% CI 
1.0-9.4).  This Canadian study however had a relatively small number of children with 
congenital anomalies (101 cases) and nearly half of the cases were exposed.226  In 
addition, some other studies on the effects of paroxetine during early pregnancy 
found no increased risks of congenital heart congenital anomalies in offspring of 
women prescribed paroxetine.57,207 
A large US case-control study (9,622 cases obtained through eight national birth-
defects surveillance systems and 4,092 controls obtained from hospital or state birth-
certificate records) published in 2007 found no association between use of SSRIs and 
the risks of heart defects but found increased risks in neural tube defects, 
craniosynostosis and omphalocoele.227  Another similar US study examined each 
individual SSRI drug and found use of sertraline was associated with omphalocoele 
and septal heart defects and paroxetine associated with right ventricular outflow tract 
obstruction defects.228  These studies however did not fully assess the effects of the 
underlying condition and/or other maternal factors which could potentially affect the 
association of congenital anomalies with maternal exposure to SSRIs. 
Tricyclic and other antidepressants 
Very few studies have examined the effects of different classes of antidepressant 
drugs in a single population.  Overall, there have been fewer studies specifically 
focusing on the safety of old antidepressants such as tricyclic antidepressants (TCAs).  
For example, a population-based study in Sweden that examined maternal drug use 
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in early pregnancy and infant cardiovascular anomalies found that among many other 
drugs women were prescribed, maternal exposure to TCAs during early pregnancy 
was associated with an 80% increased risk of cardiovascular anomalies in offspring 
(OR=1.77, 95% CI 1.07-2.91) after adjusting for year of birth, maternal age, parity, 
smoking habits in early pregnancy and years of involuntary childlessness.230  This 
study did not find any association with SSRIs and benzodiazepines, although it did 
not examine the impact for each specific drug class exclusively or concurrently.  In 
addition, a previous large study carried out in British Columbia, Canada found that it 
was SSRIs combined with benzodiazepines but not SSRIs alone were associated 
with an increased risk of congenital heart defects.206 
Anti-anxiety drugs  
Although anti-anxiety drugs are commonly prescribed to women of childbearing age, 
little information is available for the safety of these drugs in women during early 
pregnancy.  A large prospective population-based study using birth register data in 
Sweden found a borderline increased risk of major malformations in children of 
women prescribed benzodiazepines during early pregnancy (OR=1.24, 95% CI 1.00-
1.55),220 though other studies in different countries did not find an association.63±66 
No studies have examined the effects of anti-anxiety drugs with consideration of 
ZRPHQ¶VXQGHUO\LQJKHDOWKFRQGLWLRQVDQGFRQFXUUHQWH[SRVXUHVRIRWKHUPHGLFDWLRns.  
Two case-control studies from the 1970s found that women prescribed diazepam (the 
most commonly prescribed benzodiazepine) in the first trimester of pregnancy had 
increased risks of facial clefts (oral clefts and clefts palate) in their offspring.62,233  
These two studies had however fairly small sample sizes and did not control for any 
other maternal underlying health conditions and lifestyle factors.  Two more recent 
and larger case-control studies using similar methods did not find any association 
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between use of benzodiazepines during early pregnancy and the risk of facial cleft67,68 
and therefore it is unclear that whether such an association really exists. 
6.1.2 Lithium, mood stabilisers and antipsychotic drugs 
There have been very few studies of the association between serious mental illness 
and the risk of congenital anomalies and such studies generally have had small 
numbers, likely due to the fact that both serious mental illness and congenital 
anomalies are uncommon health conditions in the general population.  Far fewer 
studies were conducted on the safety of antipsychotic drugs and no clear evidence 
about these exists so far.  Although no definitive association has been found between 
maternal exposure to antipsychotic drugs during pregnancy and an increased risk of 
congenital anomalies, there is a lack of large, population-based prospective studies.38  
This is similar for the research on the safety of lithium in pregnant women.187  Recent 
systematic reviews on the safety of mood stabilisers (including valproate, lamotrigine, 
and carbamazepine) in women during pregnancy found a higher incidence of major 
congenital anomalies, especially neural tube defects, in children of women exposed 
to valproate during pregnancy compared with women exposed to other or no mood 
stabilisers.188,189  Since women with these medications are more likely to suffer from 
severe mental illness and other chronic comorbidity, the reported drug associated 
risks cannot have excluded the potential impact of underlying mental health 
conditions. 
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6.2 Rationale and objectives 
Although the potential association of congenital anomalies with psychotropic drugs, 
especially newly developed antidepressants (such as paroxetine), have been 
frequently examined in various populations, the results are very inconsistent and 
there remain no UK-based studies.  In addition, there is little information available on 
the safety of TCAs and benzodiazepines in pregnant women despite their continued 
use in this population and few studies have examined the contribution RIZRPHQ¶V
underlying mental health condition as well as their non-mental health related 
comorbidity. 
The objectives of this UK population-based cohort study therefore were to estimate 
the risk prevalence of major and system-specific major congenital anomalies in live-
born children with or without maternal depression or anxiety during the first trimester 
of pregnancy, and to investigate whether children exposed to SSRIs, TCAs or 
benzodiazepines during early pregnancy had greater risks compared with those 
XQH[SRVHGZLWKFRQVLGHUDWLRQRIZRPHQ¶VGHSUHVVLRQDQGRUDQ[LHW\DQGRWKHU
underlying chronic medical comorbidity. 
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6.3 Methods 
6.3.1 Study population 
The study population comprised all singleton live-born children born to linked women 
aged 15-45 years between 1990 and 2009 from THIN (Population 5 in Figure 2-1).  
Since there were very few children born to women with serious mental illness (6,124 
children of whom 198 had major congenital anomalies; absolute risk=323 per 10,000),  
I excluded children whose mothers had bipolar disorder, schizophrenia, other serious 
psychotic disorders or prescriptions for anti-manic and antipsychotic drugs, 
comprising less than 0.5% of the study population. 
6.3.2 Extracting and defining major congenital anomalies 
All diagnoses of major congenital anomalies were identified in WKHFKLOGUHQ¶VPHGLFDO
records using Read codes that were classified into 16 system-specific groups 
according to the European Surveillance of Congenital Malformations (EUROCAT) 
subgroups,234 which is based on ICD-10 codes (mainly in Q-chapter).  Children with 
recordings of genetic anomalies and known teratogenic anomalies (such as Read 
codes for anomalies due to maternal infections and foetal alcohol syndrome) were 
excluded, comprising less than 0.01% of the original population. 
In addition to the system level, I assessed individual specific anomalies for the three 
most prevalent groups, namely major heart, limb and genital congenital anomalies.  In 
order to directly compare my results with previous research,53 I grouped major heart 
congenital anomalies as follows: septal defects (including atrial sepatal defects, 
ventricular septal defects and atrioventricular septal defects), right ventricular outflow 
tract defects, left ventricular outflow tract defects and others (including transposition 
off great vessels, total anomalous pulmonary venous connection, coarctation of the 
DRUWD(EVWHLQ¶VDQRPDO\WULFXVSLGDWUHVLDDQGVWHQRVLVSDWHQWGXFWXVDUWHURVLV
single ventricle, tetralogy of Fallot, and truncus arteriosus).  I grouped congenital limb 
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anomalies into hip dislocation and/or dysplasia, club foot and others (including limb 
reduction, complete absence of a limb, polydactyly, syndactyly and arthrogryposis 
multiplex congenital).  Congenital anomalies of the genital system were divided into 
hypospadias and others (including indeterminate sex and other unspecific congenital 
anomalies). 
6.3.3 Definition of antenatal exposures 
Maternal exposure to depression and/or anxiety was defined as diagnoses of 
depression or anxiety during the year before conception and the first trimester.  
Antenatal exposure to major psychotropic drugs (SSRIs, TCAs, and benzodiazepines) 
during the first trimester of pregnancy was defined according to the presence or 
absence of relevant drug prescription LQWKHZRPHQ¶VSULPDU\FDUHHOHFWURQLFKHDOWK
records from four weeks before the estimated conception dates up to 12 weeks after.  
The period of four weeks before conception was included to enable inclusion of drug 
prescriptions received immediately before pregnancy and potentially used during 
early pregnancy as used just before conception.53,56,227,228  I therefore grouped 
children into six mutually exclusive categories according to their mRWKHUV¶GLDJQRVWLF
and treatment status as follows: 
Group 0: No maternal depression or anxiety (non-exposed group). 
Group 1: Maternal depression and/or anxiety in the year before conception and the 
first trimester but with no antidepressant or anti-anxiety drugs during the first trimester 
of pregnancy. 
Group 2: Antenatal exposed to SSRIs (alone ± i.e. no TCAs or benzodiazepines) in 
the first trimester.  
Group 3: Antenatal exposed to TCAs (alone) in the first trimester. 
Group 4: Antenatal exposed to benzodiazepines (alone) in the first trimester. 
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Group 5: Antenatal exposed to multiple classes of drugs (i.e. prescriptions of two or 
three classes of SSRIs, TCAs, and benzodiazepines) in the first trimester. 
6.3.4 Maternal socio-demographic characteristics and comorbidity 
I identified potential confounders, by extracting data on the following maternal 
characteristic: maternal age at the end of pregnancy, whether women had ever been 
a smoker before or during pregnancy, maternal body mass index (BMI, kg/m2) before 
pregnancy and socioeconomic deprivation measured using the Townsend Index of 
Deprivation, in quintiles.  Since depression and/or anxiety is often comorbid with other 
chronic medical conditions that could be associated with increased risks of congenital 
anomalies in the offspring, I extracted diagnoses of prior asthma, epilepsy, diabetes 
and hypertension IURPZRPHQ¶VUHFRUGV.  Detailed definitions of these co-variables 
are given in Section 4.3.3. 
6.3.5 Statistical analyses 
To estimate the disease burden of all major and individual system-specific congenital 
anomaly groups, we calculated absolute risks (per 10,000 live births) for the total 
population and children with different antenatal exposures.  Since SSRIs were the 
most commonly prescribed psychotropic drugs in the study population, absolute risks 
were estimated for children born to women exclusively prescribed each individual 
SSRI drug, namely fluoxetine, citalopram, paroxetine, sertraline, and escitalopram, 
during the first trimester of pregnancy, apart from fluvoxamine as this was only 
prescribed exclusively to 27 women.  In addition, I did not include children born to 
women prescribed more than one type of SSRIs as there were only 523 children and 
345 of them were exposed to fluoxetine.  Besides absolute risks, I also calculated the 
number of children exposed to SSRIs when only one would have congenital 
anomalies that would not have otherwise (number needed to harm), using 1 divided 
by the absolute risk differences between antenatal exposures to individual SSRI 
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drugs and not exposed to depression and/or anxiety,235 in groups showing higher 
risks with maternal drug use. 
Logistic regression was used to estimate odds ratios (ORs) with 95% confidence 
intervals (CIs) for any major and each system-specific group of major congenital 
anomalies in offspring and maternal depression or anxiety with or without 
psychotropic medication or with different individual SSRIs during the first trimester of 
pregnancy, with adjustment for all co-variables.  The generalised estimating equation 
approach with exchangeable correlation structure236 was applied to control for 
SRWHQWLDOFOXVWHULQJHIIHFWVIRUFKLOGUHQERUQWRWKHVDPHZRPHQE\XVLQJZRPHQ¶V
unique identification number.  I repeated the main analysis after restricting the overall 
population to children born to women who never smoked before childbirth and had no 
chronic medical comorbidities, with adjustment for the remaining co-variables, namely 
maternal age, year of childbirth, household socioeconomic status and maternal BMI. 
6.3.6 Sample size calculations 
I expected that 2.5% of children with at least one major congenital anomaly.175,237  In 
addition, based on the results in the previous chapter (Section 5.4), approximately 3% 
children had maternal exposure to SSRIs during the first trimester of pregnancy and 1% 
with maternal antenatal exposure to TCAs and benzodiazepines.  For each antenatal 
exposure and system-specific congenital anomaly group pair, I used the absolute 
numbers in the study population to calculate the desirable sample size to detect a 
2.0-fold increased risk of major congenital anomalies in children with different 
antenatal exposures with over 80% power and a 5% significant level by using 
GPower 3.1.238  Based on the series of calculations, I estimated ORs only for exposed 
groups with large enough numbers of children.  For example, I need only 43,663 
children to detect a 2-fold increased risk of congenital heart anomalies in exposure to 
SSRIs with over 80% power and 5% statistical significance, but need at least 318,404 
children for digestive system anomalies, in which case OR was not calculated. 
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6.4 Results 
6.4.1 Study population 
From Population 5 in Figure 2-1, I identified 349,211 live-born singletons, of which 2.7% 
had at least one major congenital anomaly.  Table 6-4 shows the maternal 
characteristics of children with and without major congenital anomalies.  The median 
maternal age at the end of pregnancy was 30 years (IQR 26-34).  Women whose 
children had and had not had major congenital anomalies had similar distributions of 
maternal age, socioeconomic status, maternal smoking before childbirth and maternal 
BMI before conception.  Women whose children had major congenital anomalies 
were more likely to have chronic medical comorbidities, particularly pre-gestational 
diabetes (1.8% vs. 1.0%) and epilepsy (0.8% vs. 0.4%), than those whose children 
had no major congenital anomalies (Table 6-4). 
Table 6-5 shows the maternal characteristics in children with different antenatal 
exposures.  Women with depression, anxiety or antenatal psychotropic medications 
were more likely from socioeconomically deprived groups and to have ever smoked 
and abnormal BMI than women with no depression or anxiety.  These women were 
also more likely to have other chronic illnesses, including prior diabetes, hypertension, 
asthma and epilepsy (Table 6-5).  Other than SSRIs were prescribed much more in 
later calendar time compared with TCAs, there was no considerable difference in the 
ZRPHQ¶VEDVHOLQHFKDUDFWHULVWLFVE\DQWHQDWDOH[SRsure to different classes of 
psychotropic drugs (Table 6-5).
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Table 6-4 Maternal characteristics of all singleton live-born children and 
children with and without major congenital anomalies 
 
All children Children without CAs  Children with CAs 
N=349,211 n=339,812 n=9,399 
  n %   n %   n % 
Maternal age at the end of pregnancy, years 
(Median, IQR) 
  30 26-34   30 26-34   30 26-34 
Year of childbirth       
   1990-1994   51,448 14.7   49,895 14.7 1,553 16.5 
   1995-1999   86,611 24.8   84,133 24.8 2,478 26.4 
   2000-2004 103,256 29.6 100,363 29.5 2,893 30.8 
   2005-2009 107,896 30.9 105,421 31.0 2,475 26.3 
Townsend deprivation index 
      
  1 (Least deprived)   85,164 24.4   82,854 24.4 2,310 24.6 
  2   67,980 19.5   66,205 19.5 1,775 18.9 
  3   68,244 19.5   66,389 19.5 1,855 19.7 
  4   63,293 18.1   61,604 18.1 1,689 18.0 
  5 (Most deprived)   47,216 13.5   45,875 13.5 1,341 14.3 
  Missing   17,314   5.0   16,885   5.0    429   4.6 
Ever smoked before delivery 132,994 38.1 129,473 38.1 3,521 37.5 
BMI before pregnancy (kg/m2) 
      
   Under-weight (<18.5)   11,351   3.3   11,039   3.2    312   3.3 
   Normal (18.5-24.9) 154,148 44.1 150,136 44.2 4,012 42.7 
   Over-weight(25-29.9)   59,016 16.9   57,427 16.9 1,589 16.9 
   Obese (30-39.9)   32,158   9.2   31,181   9.2    977 10.4 
   Missing   92,538 26.5   90,029 26.5 2,509 26.7 
Diabetes 
    3,624   1.0     3,454   1.0    170   1.8 
Hypertension 
  10,958   3.1   10,637   3.1    321   3.4 
Asthma 
  23,054   6.6   22,396   6.6    658   7.0 
Epilepsy 
    1,348   0.4     1,274   0.4      74   0.8 
CAs=congenital anomalies 
IQR=interquartile range 
BMI=body mass index 
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Table 6-5 Numbers and proportions of different maternal characteristics in children with different maternal exposures 
Congenital anomalies No depression or 
anxiety 
Depression or anxietya  SSRIs alone TCAs alone Benzodiazepines alone Multiple classes of drugsb 
n=306,902 n=23,888 n=10,568 n=3,225 n=2,699 n=1,929 
n % n % n % n % n % n % 
Maternal age at the end of pregnancy, 
years (Median, IQR) 
30 26-34 29 25-33 29 24-33 29 25-33 30 26-34 29 24-33 
Year of childbirth 
            
   1990-1994 47,872 15.6 2,210 9.3 401 3.8 534 16.6 303 11.2 128 6.6 
   1995-1999 78,111 25.5 4,785 20.0 1,816 17.2 936 29.0 561 20.8 402 20.8 
   2000-2004 89,145 29.0 7,631 31.9 3,937 37.3 981 30.4 856 31.7 706 36.6 
   2005-2009 91,774 29.9 9,262 38.8 4,414 41.8 774 24.0 979 36.3 693 35.9 
Townsend deprivation index 
            
  1 (Least deprived) 77,551 25.3 4,533 19.0 1,748 16.5 570 17.7 485 18.0 277 14.4 
  2 60,980 19.9 4,118 17.2 1,615 15.3 552 17.1 453 16.8 262 13.6 
  3 59,970 19.5 4,659 19.5 2,153 20.4 557 17.3 533 19.7 372 19.3 
  4 54,043 17.6 5,097 21.3 2,363 22.4 717 22.2 603 22.3 470 24.4 
  5 (Most deprived) 39,150 12.8 4,354 18.2 2,104 19.9 687 21.3 483 17.9 438 22.7 
  Missing 15,208 5.0 1,127 4.7 585 5.5 142 4.4 142 5.3 110 5.7 
Ever smoked before delivery 110,331 35.9 12,556 52.6 5,938 56.2 1,596 49.5 1,398 51.8 1,175 60.9 
BMI before pregnancy (kg/m2) 
            
   Under-weight (<18.5) 9,589 3.1 1,020 4.3 411 3.9 115 3.6 121 4.5 95 4.9 
   Normal (18.5-24.9) 135,967 44.3 10,468 43.8 4,435 42.0 1,405 43.6 1,132 41.9 741 38.4 
   Over-weight(25-29.9) 51,069 16.6 4,528 19.0 1,968 18.6 597 18.5 511 18.9 343 17.8 
   Obese (30-39.9) 26,630 8.7 2,979 12.5 1,521 14.4 420 13.0 317 11.7 291 15.1 
   Missing 83,647 27.3 4,893 20.5 2,233 21.1 688 21.3 618 22.9 459 23.8 
Diabetes 3,032 1.0 305 1.3 173 1.6 49 1.5 36 1.3 29 1.5 
Hypertension 9,332 3.0 851 3.6 462 4.4 123 3.8 118 4.4 72 3.7 
Asthma 18,391 6.0 2,440 10.2 1,217 11.5 405 12.6 320 11.9 281 14.6 
Epilepsy 1,099 0.4 127 0.5 46 0.4 18 0.6 33 1.2 25 1.3 
a
 diagnosed in the year before conception up to the end of the first trimester but with no psychotropic drug prescriptions;  
b prescribed drugs in at least two different classes during the first trimester; BMI=body mass index ; SSRIs=selective serotonin reuptake inhibitors; TCAs=tricyclic antidepressants
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6.4.2 Absolute risks of major and system-specific congenital anomalies 
Table 6-6 shows the numbers and absolute risks of any major and system-specific 
major congenital anomalies in the total population and also in children with different 
maternal antenatal exposures.  Children born to women with depression and/or 
anxiety had higher risks of major congenital anomalies than those born to women with 
no depression or anxiety.  This was more marked in children exposed to psychotropic 
medication (SSRIs and TCAs but not benzodiazepines) during the first trimester of 
pregnancy.  For specific congenital anomalies, heart congenital anomalies were the 
most common group (76 per 10,000 live births).  Compared with children born to 
women with no depression or anxiety, those children born to women with depression 
and/or anxiety had higher risks of major heart congenital anomalies, particularly in 
those with maternal exposure to psychotropic medications during the first trimester. 
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Table 6-6 Absolute risks (per 10,000 live births) of major congenital anomalies according to antenatal first trimester exposure to 
maternal depression, anxiety, antidepressant and anxiolytic medications in UK primary care between 1990 and 2009 
 
All children No depression or 
anxiety 
Depression and/or 
anxietya 
SSRIs alone TCAs alone Benzodiazepines 
alone 
Multiple classes 
of drugsb 
N=349,211 n=306,902 n=23,888 n=10,568 n=3,225 n=2,699 n=1,929 
n  n/10,000 n n/10,000 n  n/10,000 n  n/10,000 n  n/10,000 n  n/10,000 n  n/10,000 
All major CAs combined 9,399 269 8,210 268 665 278 307 290 92 285 68 252 57 295 
Heart 2,648 76 2,276 74 197 82 99 94 29 90 25 93 22 114 
Limb 1,869 54 1,654 54 127 53 50 47 18 56 16 59 4 21 
Genital system 1,392 40 1,223 40 106 44 38 36 12 37 4 15 9 47 
Urinary system 886 25 756 25 72 30 34 32 10 31 7 26 7 36 
Chromosomal 593 17 518 17 49 21 15 14 7 22 3 11 1 5 
Oro-facial cleft 471 13 418 14 33 14 14 13 4 12 1 4 1 5 
Nervous system  513 15 434 14 40 17 21 20 4 12 5 19 9 47 
Musculoskeletal system 468 13 414 13 29 12 15 14 5 16 3 11 2 10 
Digestive system 338 10 294 10 20 8 13 12 4 12 4 15 3 16 
Eye 331 9 298 10 13 5 13 12 2 6 3 11 2 10 
Other malformationsc 328 9 286 9 23 10 11 10 7 22 1 4 0 0 
Respiratory system 222 6 191 6 15 6 10 9 4 12 1 4 1 5 
Ear, face and neck 90 3 77 3 13 5 0 0 0 0 0 0 0 0 
Abdominal wall 74 2 66 2 2 1 5 5 0 0 1 4 0 0 
a
 diagnosed in the mother in the year before conception up to the end of the first trimester but with no psychotropic drug prescriptions  
b
 prescribed drugs in at least two different classes during the first trimester 
c e.g. asplenia, conjoined twins, situs inversus and skin disorders 
SSRIs=selective serotonin reuptake inhibitors 
TCAs=tricyclic antidepressants 
CAs=congenital anomalies 
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6.4.3 Relative risks of major and system-specific congenital anomalies 
The results from statistical analyses are shown in Table 6-7, where missing indicates 
not enough cases available for the analyses, based on my sample size calculation 
(Section 6.3.6).  There was an increased, though not statistically significant, risk of 
major congenital anomalies in children exposed to SSRIs during the first trimester, 
compared with those born to women with no depression or anxiety, after adjusting for 
all maternal characteristics (OR=1.11, 95% CI 0.99-1.25).  Although there were very 
few children with first trimester exposure to multiple drug classes, 86.8% of them 
were exposed to SSRIs and the excess risk was fairly similar to children exposed to 
SSRIs exclusively (adjusted OR=1.10, 95% CI 0.85-1.42).  There were no increased 
risks of major congenital anomalies in children exposed to TCAs (adjusted OR=1.03, 
95% CI 0.83-1.27) or benzodiazepines (adjusted OR=0.93, 95% CI 0.73-1.19).  For 
specific congenital anomalies, most 95% CIs of ORs included unity.  However, there 
was an increased risk of major heart congenital anomalies in children exposed to 
SSRIs during the first trimester (adjusted OR=1.25, 95% CI 1.02-1.53) (Table 6-7).  
After restricting to children born to women who never smoked before childbirth and 
had no pre-gestational diabetes, pre-gestational hypertension, asthma or epilepsy, 
the observed effects decreased for antenatal exposure to psychotropic medication, 
especially to TCAs and benzodiazepines, but slightly increased for un-medicated 
illness (Table 6-8).  
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Table 6-7 Adjusted odds ratios for major congenital anomalies in children with antenatal first trimester exposure to maternal 
depression, anxiety, antidepressant and anxiolytic medications compared with children born to women with no depression or anxiety 
 
Depression and/or anxietya SSRIs alone TCAs alone Benzodiazepines alone Multiple classes of drugsb 
n=23,888 n=10,568 n=3,225 n=2,699 n=1,929 
AORc (95% CI) AORc (95% CI) AORc (95% CI) AORc (95% CI) AORc (95% CI) 
All major CAs combined 1.05 (0.97-1.14) 1.11 (0.99-1.25) 1.03 (0.83-1.27) 0.93 (0.73-1.19) 1.10 (0.85-1.42) 
Heart 1.10 (0.95-1.27) 1.25 (1.02-1.53) 1.16 (0.80-1.70) 1.21 (0.80-1.82) 1.48 (0.98-2.26) 
Limb 1.03 (0.86-1.24) 0.94 (0.71-1.25) 1.01 (0.63-1.60) 1.11 (0.66-1.87) 0.40 (0.15-1.06) 
Genital system 1.11 (0.91-1.35) 0.88 (0.63-1.23) 0.91 (0.52-1.61) 0.36 (0.14-0.97) 1.10 (0.57-2.13) 
Urinary system 1.23 (0.96-1.57) 1.33 (0.94-1.88)     
Chromosomal 1.28 (0.94-1.72) 0.92 (0.55-1.55)     
Oro-facial cleft 0.99 (0.69-1.42) 0.95 (0.56-1.62)     
Nervous system 1.19 (0.85-1.64) 1.39 (0.89-2.16)     
Musculoskeletal system 0.92 (0.63-1.35) 1.11 (0.61-2.02)     
Digestive system 0.86 (0.55-1.36)      
Eye 0.56 (0.32-0.99)      
Other malformationsd 1.14 (0.73-1.78)      
Respiratory system 0.97 (0.57-1.66)      
Ear, face and neck       
Abdominal wall       
a
 diagnosed in the mother in the year before conception up to the end of the first trimester but with no psychotropic drug prescriptions  
b
 prescribed drugs in at least two different classes during the first trimester 
c adjusted for maternal age at the end of pregnancy, year of childbirth, Townsend deprivation index, maternal smoking history, maternal body mass index before pregnancy, maternal pre-existing 
diabetes, pre-existing hypertension, asthma and epilepsy 
d e.g. asplenia, conjoined twins, situs inversus and skin disorders 
AOR=adjusted odds ratio 
SSRIs=selective serotonin reuptake inhibitors 
TCAs=tricyclic antidepressant 
CI=confidence interval 
CAs=congenital anomalies 
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Table 6-8 Subgroup analyses in children born to women never smoked before childbirth and with no pre-gestational diabetes, pre-
gestational hypertension, asthma or epilepsy: Absolute risks (per 10,000 live births) and adjusted odds ratios for major congenital 
anomalies in children with antenatal first trimester exposure to maternal depression, anxiety, antidepressant and anxiolytic 
medications compared with children born to women with no depression or anxiety (N=196,745) 
 
Unexposed Depression and/or anxietya  SSRIs alone TCAs alone Benzodiazepines alone Multiple classes of drugsb 
n=179,795 n=9,878 n=3,945 n=1,390 n=1,118 n=619 
n/10,000  n/10,000 AORc (95% CI) n/10,000 AORc (95% CI) n/10,000 AORc (95% CI) n/10,000 AORc (95% CI) n/10,000 AORc (95% CI) 
All major CAs combined 266  288 1.10 (0.97-1.24) 286 1.11 (0.92-1.34) 273 1.00 (0.71-1.40) 179 0.67 (0.43-1.04) 323 1.21 (0.79-1.87) 
Heart   72    89 1.23 (0.99-1.53)   86 1.20 (0.85-1.68)   58 0.79 (0.39-1.59)   45 0.62 (0.26-1.49)   81 1.12 (0.46-2.69) 
Limb   58    52 0.98 (0.74-1.31)   53 1.05 (0.68-1.63)   58 1.01 (0.51-2.04)   54 1.00 (0.45-2.22)   32 0.62 (0.16-2.49) 
Genital system   38    48 1.25 (0.93-1.68)   28 0.72 (0.39-1.31)   43 1.12 (0.50-2.52)     0    65 1.55 (0.59-4.09) 
Urinary system   25    30 1.22 (0.84-1.76)   35 1.43 (0.84-2.45)   29    27    81  
Chromosomal   19    24 1.29 (0.84-1.97)   15 0.83 (0.37-1.86)   14      0      0  
Oro-facial cleft   13    14 1.10 (0.64-1.89)   13 0.98 (0.40-2.38)   14      9      0  
Nervous system   14    22 1.60 (1.03-2.47)   18 1.23 (0.58-2.63)   29    27    32  
Musculoskeletal system   14      9 0.71 (0.36-1.39)   10 0.81 (0.30-2.19)   22      9    16  
Digestive system     9    10 1.08 (0.57-2.03)   15    14      9      0  
Eye   10      7 0.76 (0.36-1.61)   15      7      0      0  
Other malformationsd   10    13 1.48 (0.83-2.62)   13      0      0      0  
Respiratory system     6      6 0.96 (0.42-2.19)     3      0      9    16  
Ear, face and neck     2      3      0      0      0      0  
Abdominal wall     1      1      5      0      9      0  
a
 diagnosed in the mother in the year before conception up to the end of the first trimester but with no psychotropic drug prescriptions  
b
 prescribed drugs in at least two different classes during the first trimester 
c
 adjusted for maternal age at the end of pregnancy, year of childbirth, Townsend deprivation index, maternal body mass index before pregnancy 
d e.g. asplenia, conjoined twins, situs inversus and skin disorders 
AOR=adjusted odds ratio 
SSRIs=selective serotonin reuptake inhibitors 
TCAs=tricyclic antidepressant 
CI=confidence interval 
CAs=congenital anomalies 
6.4-203 | P a g e  
 
6.4.4 Risks of congenital anomalies for individual SSRI drugs 
The most commonly prescribed SSRI drugs to the women in the study population 
during the first trimester of pregnancy were fluoxetine (1.3%), followed by citalopram 
(0.7%) and paroxetine (0.4%).  Table 6-9 shows that the increased risks of heart 
congenital anomalies were mainly found in children with antenatal exposure to 
paroxetine (OR=1.89, 95% CI 1.24-2.88) but not in those exposed to fluoxetine 
(OR=1.02, 95% CI 0.72-1.45) nor citalopram (OR=1.12, 95% CI 0.74-1.71), after 
adjusted for all maternal characteristics.  Also, children exposed to sertraline and 
escitalopram had increased risks of heart congenital anomalies, although these 
excess risks were no statistically significant (adjusted ORs=1.53 and 1.83, 95% CIs 
0.87-2.69 and 0.82-4.13, respectively). 
Nevertheless, the absolute risks of congenital anomalies in children exposed to 
SSRIs were small.  Table 6-10 shows that if only 455 children had antenatal exposure 
to SSRIs, one would develop major congenital anomalies which otherwise would not 
have.  The number need to harm was much lower for paroxetine and sertraline, 
particularly for congenital heart anomalies (145 for exposure to paroxetine and 233 
for sertraline). 
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Table 6-9 Absolute risks (per 10,000 live births) and adjusted odds ratios for major congenital anomalies in children born to women 
exclusively prescribed specific SSRI drugs during the first trimester of pregnancy compared with children born to women with no 
depression or anxiety 
 
SSRIs during the first trimester of pregnancya 
Fluoxetine Citalopram  Paroxetine Sertraline Escitalopram 
n=4,401 n=2,615 n=1,540 n=1,028 n=434 
n/10,000 AORb (95% CI) n/10,000 AORb (95% CI) n/10,000 AORb (95% CI) n/10,000 AORb (95% CI) n/10,000 AORb (95% CI) 
All major CAs combined 273 1.03 (0.86-1.25) 298 1.17 (0.93-1.48) 325 1.19 (0.90-1.58) 331 1.25 (0.88-1.79) 276 1.11 (0.62-1.96) 
Heart   77 1.02 (0.72-1.45)   84 1.12 (0.74-1.71) 143 1.89 (1.24-2.88) 117 1.53 (0.87-2.69) 138 1.83 (0.82-4.13) 
Limb   48 0.94 (0.61-1.45)   50 1.05 (0.61-1.81)   58 1.08 (0.56-2.08)   39 0.77 (0.29-2.06)   23 0.50 (0.07-3.57) 
Genital system   27 0.66 (0.38-1.18)   34 0.85 (0.44-1.64)   45 1.10 (0.52-2.32)   39 0.95 (0.29-3.13)   46 1.20 (0.30-4.84) 
Urinary system   30    46    26    19    23  
Chromosomal     9      4    26    39      0  
Oro-facial cleft   14    27      0    10      0  
Nervous system   25    19      6    29    23  
Musculoskeletal system     9    19    19    19      0  
Digestive system   18    11      0    19      0  
Eye   16      8      6    10    46  
Other malformationsc   11    15      0    10      0  
Respiratory system   11      4      6    29      0  
Ear, face and neck     0      0      0      0      0  
Abdominal wall     5      4      0      0      0  
a Children born to women treated with each specific SSRI drug exclusively during the first trimester; excluding children born to women treated with fluvoxamine (27 children), multiple SSRI drug 
classes (523 children) or co-prescribed with other antidepressant or anxiolytic drug classes   
b adjusted for maternal age at the end of pregnancy, year of childbirth, Townsend deprivation index, maternal smoking history, maternal body mass index before pregnancy, maternal pre-existing 
diabetes, pre-existing hypertension, asthma and epilepsy 
c e.g. asplenia, conjoined twins, situs inversus and skin disorders 
AOR=adjusted odds ratio 
CAs=congenital anomalies 
CI=confidence interval 
OR=odds ratio 
SSRI=selective serotonin reuptake inhibitors 
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Table 6-10 The number of children exposed to specific SSRI drugs alone during 
early pregnancy when one would develop major congenital anomalies that 
would not have otherwise 
 
SSRIs during the first trimester of pregnancy 
 
Any SSRIa Fluoxetine Citalopram  Paroxetine Sertraline Escitalopram 
 
n=10,568 n=4,401 n=2,615 n=1,540 n=1,028 n=434 
All major CAs combined 455 2,000 333 175 159 1,250 
Heart 500 3,333 1,000 145 233 156 
Limb --- --- --- 2,500 --- --- 
Genital system --- --- --- 2,000 --- 1,667 
Urinary system 1,429 2,000 476 10,000 --- --- 
Chromosomal --- --- --- 1,111 455 --- 
Oro-facial cleft --- --- 769 --- --- --- 
Nervous system 1,667 909 2,000 --- 667 1,111 
Musculoskeletal system 10,000 --- 1,667 1,667 1,667 --- 
Digestive system 5,000 1,250 10,000 --- 1,111 --- 
Eye 5,000 1,667 --- --- --- 278 
Other malformationsb 10,000 5,000 1,667 --- 10,000 --- 
Respiratory system 3,333 2,000 --- --- 435 --- 
Ear, face and neck --- --- --- --- --- --- 
Abdominal wall 3,333 3,333 5,000 --- --- --- 
a Children born to women treated with each specific SSRI drug exclusively during the first trimester; excluding children 
born to women co-prescribed with other antidepressant or anxiolytic drug classes 
b e.g. asplenia, conjoined twins, situs inversus and skin disorders 
CAs=congenital anomalies 
SSRIs=selective serotonin reuptake inhibitors 
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6.4.5 Risks of specific heart, limb and genital anomalies 
Table 6-11 shows the risks of specific congenital anomalies in heart, limb and genital 
system.  Although the 95% CI included unity, there was a 2-fold increased risk of right 
ventricular outflow tract anomalies in children with maternal antenatal exposure to 
SSRIs (OR=2.04, 95% CI 0.96-4.35).  Similar increased risks of right ventricular 
outflow tract anomalies were also found in children exposed to TCAs, 
benzodiazepines and multiple drug classes, although such observed excess risks had 
less power and certainty.  No clear risk pattern was found in specific limb and genital 
congenital anomalies (Table 6-11).  When assessing the risks of specific heart, limb 
and genital congenital anomalies in children born to women exclusively prescribed 
specific SSRI drugs during the first trimester of pregnancy (Table 6-12), there were 
more children with septal defects if they were exposed to paroxetine, sertraline and 
escitalopram compared with fluoxetine and citalopram. 
6.4-207 | P a g e  
 
Table 6-11 Absolute risks (per 10,000 live births) and adjusted odds ratios for specific heart, limb and genital congenital anomalies 
according to antenatal first trimester exposure to maternal depression, anxiety, antidepressant and anxiolytic medications 
Major CAs No 
depression 
or anxiety 
Depression and/or anxietya  SSRIs alone TCAs alone Benzodiazepines alone Multiple classes of drugsb 
n=306,902 n=23,888 n=10,568 n=3,225  n=2,699  n=1,929  
n/10,000  n/10,000 AORc (95% CI) n/10,000 AORc (95% CI) n/10,000 AORc (95% CI) n/10,000 AORc (95% CI) n/10,000 AORc (95% CI) 
Heart 
            
  Septal defectd 47  49 1.03 (0.85-1.25) 48 1.04 (0.78-1.38) 65 1.33 (0.87-2.05) 56 1.15 (0.67-1.97) 57 1.19 (0.66-2.16) 
    ASD 10  11 1.11 (0.74-1.65) 16 1.59 (0.97-2.60) 22 2.03 (0.97-4.25) 15 1.37 (0.41-4.57) 16 1.45 (0.46-4.57) 
    VSD 33  31 0.94 (0.74-1.19) 27 0.84 (0.58-1.22) 37 1.07 (0.60-1.88) 41 1.20 (0.66-2.17) 41 1.23 (0.61-2.48) 
  RVOTD   3    5 1.75 (0.98-3.10)   7 2.04 (0.96-4.35)   6 1.93 (0.48-7.77)   7 2.36 (0.58-9.62) 10 3.25 (0.78-13.46) 
  LVOTD   1    2 1.90 (0.66-5.53)   2 2.15 (0.50-9.26)   3 3.50 (0.47-25.79)   0 ---   0 --- 
  Othere 32  39 1.16 (0.94-1.45) 50 1.50 (1.14-1.99) 31 0.91 (0.46-1.81) 44 1.33 (0.75-2.36) 47 1.38 (0.72-2.64) 
Limb 
            
  Hip dislocation 
and/or dysplasia 
22  16 0.83 (0.60-1.17) 17 0.98 (0.61-1.58) 19 0.85 (0.38-1.89) 15 0.74 (0.28-1.98)   5 0.29 (0.04-2.05) 
  Club foot 14  18 1.29 (0.95-1.76) 16 1.11 (0.68-1.80) 16 1.05 (0.43-2.54) 19 1.27 (0.52-3.05)   5 0.34 (0.05-2.45) 
  Otherf 19  19 1.01 (0.74-1.37) 15 0.81 (0.49-1.33) 22 1.13 (0.53-2.38) 30 1.55 (0.77-3.11) 10 0.54 (0.13-2.15) 
Genital system 
            
  Hypospadias 34  41 1.17 (0.95-1.44) 32 0.90 (0.63-1.28) 31 0.89 (0.48-1.65) 15 0.42 (0.16-1.12) 36 0.98 (0.47-2.07) 
  Otherg   6    4 0.78 (0.41-1.48)   4 0.73 (0.27-1.97)    6 1.02 (0.25-4.17)   0 --- 10 1.87 (0.46-7.55) 
a
 diagnosed in the mother in the year before conception up to the end of the first trimester but with no psychotropic drug prescriptions  
b
 prescribed drugs in at least two different classes during the first trimester 
c
 adjusted for maternal age at the end of pregnancy, year of childbirth, Townsend deprivation index, maternal smoking history, maternal body mass index before pregnancy, maternal pre-existing 
diabetes, pre-existing hypertension, asthma and epilepsy 
d
 atrial, ventricular or combined septal defects 
e WUDQVSRVLWLRQRIIJUHDWYHVVHOVWRWDODQRPDORXVSXOPRQDU\YHQRXVFRQQHFWLRQFRDUFWDWLRQRIWKHDRUWD(EVWHLQ¶VDQRPDO\WUicuspid atresia and stenosis, patent ductus arterosis, single ventricle, 
tetralogy of Fallot, truncus arteriosus 
f limb reduction or complete absence, polydactyly, syndactyly and arthrogryposis multiplex congenital 
g Including indeterminate sex; AOR=adjusted odds ratio; CAs=congenital anomalies; CI=confidence interval 
ASD=atrial septal defects; VSD=ventricular septal defects; RVOTD=right ventricular outflow tract defects; LVOTD=left ventricular outflow tract defects 
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Table 6-12 Absolute risks of specific heart, limb and genital congenital anomalies in children born to women exclusively prescribed 
specific SSRI drugs during the first trimester of pregnancy 
Major CAs No depression or 
anxiety 
SSRIs during the first trimester of pregnancya 
Fluoxetine Citalopram  Paroxetine Sertraline Escitalopram 
n=306,902 n=4,401 n=2,615 n=1,540 n=1,028 n=434 
n n/10,000 n n/10,000 n n/10,000 n  n/10,000 n  n/10,000 n  n/10,000 
Heart 2,276 74 34 77 22 84 22 143 12 117 6 138 
  Septal defects 1,436 47 17 39 10 38 12 78 7 68 3 69 
    ASD 308 10 5 11 5 19 4 26 1 10 0 0 
    VSD 1,027 33 9 20 4 15 7 45 6 58 3 69 
  RVOTD 98   3 2 5 3 11 1 6 1 10 0 0 
  LVOTD 28   1 1 2 1 4 0 0 0 0 0 0 
  Others 997 32 16 36 14 54 12 78 4 39 5 115 
Limb 1,654 54 21 48 13 50 9 58 4 39 1 23 
  Hip dislocation 
and/or dysplasia 678 
 
22 8 18 3 11 2 13 3 29 1 23 
  Club foot 419 14 5 11 8 31 3 19 0 0 0 0 
  Others 573 19 8 18 3 11 4 26 1 10 0 0 
Genital system 1,223 40 12 27 9 34 7 45 4 39 2 46 
  Hypospadias 1,050 34 10 23 7 27 7 45 4 39 2 46 
  Others 177   6 2 5 2 8 0 0 0 0 0 0 
a Children born to women treated with each specific SSRI drug exclusively during the first trimester; excluding children born to women treated with fluvoxamine (27 children), multiple SSRI drug 
classes (523 children) or co-prescribed with other antidepressant or anxiolytic drug classes 
ASD=atrial septal defects; VSD=ventricular septal defects; RVOTD=right ventricular outflow tract defects; LVOTD=left ventricular outflow tract defects; CAs=congenital anomalies 
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6.5 Discussion 
6.5.1 Principal findings 
My study shows that there was an 11% increased risk of major congenital anomalies 
in children born to women prescribed SSRIs during the first trimester of pregnancy 
compared with those born to women with no depression or anxiety, although the 
absolute risk was small.  This excess risk appeared to be mostly related to an 
increased risk of heart congenital anomalies.  Specifically, there was an increased 
risk of septal heart defects in children with first trimester exposure to paroxetine, but 
not to fluoxetine or citalopram, although children exposed to sertraline and 
escitalopram also showed similar increased risks.  For benzodiazepines or TCAs, 
there were no increased risks of overall major congenital anomalies in children 
exposed to these drugs.  However, the risks of right ventricular outflow tract 
anomalies were notably higher for all drug classes. 
6.5.2 Strengths and limitations 
This study is the only UK study that has estimated the risks of major and system-
specific major congenital anomalies in children born to women with depression and/or 
anxiety with and without psychotropic drug treatment during the first trimester of 
pregnancy.  I have also examined the risks of some more specific congenital 
anomalies (e.g. atrial septal defects) and the safety of individual SSRI drugs.  Major 
congenital anomalies are uncommon conditions, especially when divided into system-
specific groups.  Power therefore is an important issue to consider before performing 
any statistical analyses.  I conducted sample calculations and estimated ORs only 
when enough cases were available. 
The data were from UK general practices and prospectively recorded by GPs, thus 
excluding the possibly of recall bias.  Since all pregnant women in the UK are 
required to be registered with a GP in order to benefit from antenatal check and free 
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medication, it is unlikely that a high proportion of women with depression and/or 
anxiety, especially those with prescriptions of psychotropic drugs, were not identified 
through antenatal care.  There was potential misclassification in the exposure as a 
woman receiving a drug prescription may not actually take the medication or take it 
during the organogenetic period, which could bias my estimates to the null hypothesis. 
I have examined the risks of all major and system-specific congenital anomalies in a 
study population representative of the UK population.  In terms of the completeness 
and specificity of congenital anomalies in these data, THIN prevalence figures are 
very comparable to UK data from the European congenital anomaly registers 
(EUROCAT), which are considered the gold standard of population level congential 
anomaly data (Appendix IV).  The prevalence of congenital anomalies diagnosed in 
the first year of life are very similar to EUROCAT, although as I included major 
congenital anomalies diagnosed in children any age, and the median follow-up from 
birth is about 5 years, THIN data overall show a higher prevalence of anomalies than 
in EUROCAT, particularly for certain systems.  Therefore, I believe that this makes 
THIN data very robust for assessing these congenital anomaly risks. 
I have adjusted for the effects of a substantial number of potential confounders, 
including maternal age, year of childbirth, socio-economic deprivation, maternal 
smoking history, maternal BMI, and other maternal comorbidities, including pre-
gestational diabetes, pre-gestational hypertension, asthma, and epilepsy.  Following 
this the adjusted results remained almost identical to the unadjusted ones.  In addition, 
I have repeated the main analyses after restricting to children born to women who 
never smoked before childbirth and had none of the mentioned chronic medical 
conditions I was interested in (please see Table 6-8).  The results from the sub-group 
analyses showed that the increase in the risks of major heart congenital anomalies 
exposed to medications observed in the main analyses decreased, particularly for 
TCAs and benzodiazepines, but the relative risk for un-medicated illness increased 
6.5-211 | P a g e  
 
slightly compared with non-depression or anxiety7KLVPD\VXJJHVWWKDWZRPHQ¶V
underlying mental health problems could also contribute to the observed increased 
risks. 
Although it is impossible to completely separate the effects of psychotropic drugs 
from more severe illness itself, I have tried to assess the effects of underlying 
maternal mental health problems (depression or anxiety) on the risks of major 
congenital anomalies in offspring and I acknowledge that I have not been able to 
directly quantify the disease severity.  It is possible that GPs may prescribe certain 
SSRIs to pregnant women who have more severe symptoms.  However there were 
not considerably marked GLIIHUHQFHVLQZRPHQ¶VEDVHOLQHFKDUDFWHULVWLFVEDVHGRQ
the different SSRI drugs they were prescribed during pregnancy, except that women 
were more likely from socioeconomically deprived groups if they were prescribed 
sertraline and escitalopram compared to women prescribed other SSRI drugs.  This 
may indicate that sertraline and escitalopram could be used to treat women with more 
severe depressed symptoms and previous research has showed these two drugs 
significantly more efficacious than fluoxetine and paroxetine.239 
6.5.3 Interpretation in context of previous studies 
In line with the results observed in this study, recent large population-based studies 
have raised concerns about increased risks of major heart congenital anomalies in 
children with first trimester exposure to SSRIs,200,201,209 particularly to 
paroxetine.58,207,208,226  However, the results on the risks of specific congenital 
anomalies with specific drugs have been inconsistent.45,53,56  In addition, far fewer 
studies have been conducted to examine the safety of TCAs and benzodiazepines 
exclusively regarding the risk of major congenital anomalies and majority of such 
studies have very small sample size.196  The results from my large population-based 
study show no increased risks of major congenital anomalies in children with maternal 
antenatal exposure to TCAs or benzodiazepines, which is consistent to most previous 
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studies.64±66,214,240  There are however some other studies showing increased 
risks.58,206,230 
Colvin et al. conducted a population-based study containing nearly 4,000 births with 
major congenital anomalies in Western Australia from 2002 to 2005.200  They found 
that the risk of congenital heart anomalies was higher in children born to women 
prescribed an SSRI during the first trimester of pregnancy than in those unexposed 
(unadjusted OR=1.60, 95%CI 1.10-2.31), but the risk was not increased for overall 
major congenital anomalies (unadjusted OR=1.05, 95%CI 0.87-1.27).200  This 
Australian study also found excess risks of congenital heart anomalies, though not 
statistically significant, in children with first trimester exposure to specific individual 
drugs namely sertraline (OR=1.74, 95% CI 0.96-3.17), citalopram (OR=1.48, 95% CI 
0.74-2.99), paroxetine (OR=1.76, 95% CI 0.83-3.72) and fluoxetine (OR=1.98, 95% 
CI 0.74-5.33), compared to those not exposed to SSRI drugs.  However, this 
Australian adjusted their results for maternal age only and did not FRQVLGHUZRPHQ¶V
underlying mental and physical health problems. 
In contrast, a Finish study containing approximately 7,000 children exposed to SSRIs 
during the first trimester of pregnancy found an increased risk of cardiovascular 
congenital anomalies in children exposed to fluoxetine (adjusted OR=1.40, 95%CI 
1.01-1.95), but not to paroxetine (adjusted OR=1.09, 95%CI 0.66-1.79), after 
adjustment for maternal age, parity, year of pregnancy ending, marital status, 
smoking, other psychiatric drug purchases, and prescription reimbursement for pre-
pregnancy diabetes.53 
Very few studies have been conducted to examine the risks of different classes of 
psychotropic drugs in a single population.  A previous study in Sweden58 including 
15,000 children with maternal antenatal exposure to SSRIs from 1995 to 2007 found 
an increased risk of cardiovascular congenital anomalies in children exposed to 
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paroxetine (OR=1.66, 95%CI 1.09-2.53), but not to fluoxetine (OR=1.31, 95%CI 0.85-
2.02), after adjustment for maternal age, year of childbirth, parity, maternal smoking 
history and BMI.  To some extent, my study is fairly similar to this Swedish study in 
terms of sample size and results.  However, unlike my study finding no excess risks in 
TCAs, this Swedish study58 found an increased risk of major congenital anomalies in 
children with maternal antenatal exposure to TCAs (OR=1.36, 95%CI 1.07-1.72), 
particularly clomipramine, which was consistently reported in earlier studies of the 
same dataset.208,230 
In addition, a previous case-control study in US included 9,622 children with 
congenital anomalies and 4,092 without congenital anomalies and found children with 
first trimester exposure to SSRIs overall had no increased risks of congenital heart 
anomalies or most other specific congenital anomalies.227  This study however found 
an increased risks, though not statistically significant, of congenital heart anomalies in 
children with first trimester exposure to paroxetine (OR=1.7, 95% CI 0.9-3.1), after 
adjusting for maternal ethnicity, obesity, smoking status and family income.  This 
study also reported increased risks of anecephaly, craniosynostosis and omphalocele 
in children exposed to SSRIs, specifically to paroxetine (OR=4.2, 95% CI 2.1-8.5) and 
citalopram (OR=4.0, 1.3-11.9).  In contrast, another slightly bigger case-control 
studies in US228 (9,849 cases and 5,860 controls) did not find increased risks of 
craniosynostosis and omphalocele in children exposed to SSRIs overall, but did find 
statistically significant associations between first trimester exposure to sertraline and 
excess risks of omphalocele (OR=5.7, 95% CI 14.6-20.7) and septal defects (OR=2.0, 
95% CI 1.2-4.0) and between first trimester exposure to paroxetine and right 
ventricular outflow tract defects (OR=3.3. 95% CI 1.3-8.8). 
Pedersen et al. conducted a study using data from Danish national registries and 
identified 1,370 children exposed to SSRIs during the first trimester of pregnancy.56  
After adjustment for maternal age, calendar year, income, marital status, and smoking, 
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the Danish study reported a significant increased risk of septal heart defects 
(OR=1.99, 95%CI 1.13-3.53), but not all major cardiovascular anomalies (OR=1.44, 
95% CI 0.86-2.40), in children with SSRI exposure compared to unexposed.  In 
addition, the Danish study found excess risks of septal heart defects in children 
exposed to citalopram (OR=2.5, 95% CI 1.0-6.1), sertraline (OR=3.3, 95% CI 1.2-8.8), 
and more than one type of SSRIs (OR=4.7, 95% CI 1.7-12.7), but not to fluoxetine 
and paroxetine.  Another recent Danish study published in 2010 also found increased 
risks of septal heart defects in children exposed to sertraline (OR=3.3, 95% CI 1.5-7.5) 
and escitalopram (OR=4.2, 95% CI 1.0-17.1), but not to citalopram.201  These studies 
however contained very small numbers of exposed cases (e.g. in children with septal 
heart defects, 5 exposed to citalopram and 4 to sertraline and more than one type of 
SSRIs56), and GLGQRWFRQVLGHUZRPHQ¶VXQGHUO\LQJSK\VLFDODQGPHQWDOKHDOWK
problems. 
6.5.4 Conclusion and implications 
The findings of this study indicate an increased risk of major congenital heart 
anomalies in children born to women prescribed SSRIs, especially paroxetine, during 
the first trimester of pregnancy.  Children with first trimester exposure to sertraline 
and escitalopram also have similar increased risks of congenital heart anomalies, 
though the excess risks are not statistically significant.  Maternal use of TCAs and 
benzodiazepines could also be associated with increased risks of specific congenital 
heart anomalies.  Despite this, the overall absolute risk of congenital heart anomalies 
in the general population and the possible excess risks associated with these 
psychotropic drugs are still relatively small.  GPs, obstetricians and other health 
professionals are advised to discuss the potential risks and benefits of treated and 
untreated mental health problems with pregnant women.  The findings in this first UK 
study provide vital information for this purpose and can be used to help communicate 
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magnitude of risk of major congenital anomalies to women with use of different 
psychotropic drugs in context of the baseline risk in the general population. 
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7 Conclusion and implications of the work 
7.1 Summary of main findings 
7.1.1 Clinical burden of maternal mental illness 
The work in this thesis has shown that a substantial burden of maternal mental illness, 
particularly depression and anxiety, presents to and is managed in UK general 
practice.  Furthermore, GP prescribing of psychotropic drugs, especially 
antidepressants, has increased considerably in the last two decades in women of 
childbearing age.  Although the number of women with a diagnosis of depression and 
anxiety has also increased, the increases have been more modest compared with 
drug prescribing. 
Compared with the antenatal period, more women have their first episode or repeated 
episodes of depression, anxiety or other serious mental illnesses identified and/or 
treated in general practice in the 9 months after pregnancy.  There is also 
considerable variation in the absolute risks of experiencing maternal mental illness 
according to different maternal characteristics, such as higher risks in mothers from 
more socioeconomically deprived areas compared with those from less deprived 
areas, which persist with increasing maternal age.  Women with mental illnesses are 
also more likely to have ever smoked and to have other comorbidity prior to 
pregnancy.  :KHQZRPHQ¶VLQLWLDOFOLQLFDOSUHVHQWDWLRQRIPHQWDOLOOQHVVis during or 
after pregnancy, the impact of socioeconomic deprivation is modestly attenuated, 
indicating that this is only partially due to a history of mental illness commonly 
recurring in the perinatal period. 
7.1.2 Impact of treated and untreated perinatal mental illness 
Besides the considerable burden of maternal depression and anxiety in UK primary 
care, these women are also more likely to have adverse pregnancy outcomes.  
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Although it is impossible to completely separate the effects of psychotropic drugs 
from more severe illness itself and other residual confounding, it is likely that women 
treated with antidepressant or anxiolytic drugs, particularly SSRIs, during pregnancy 
have small increased risks of unfavourable pregnancy outcomes, such as miscarriage, 
perinatal death and major congenital anomalies.  I found that women with medicated 
depression and anxiety during pregnancy had 1.5-2 fold increased risks of 
miscarriage compared to women with no depression or anxiety.  In addition, women 
prescribed SSRIs and benzodiazepines prior to pregnancy had greater risks of 
miscarriage if they continued to receive these medications than if they did not.  The 
magnitude of the medication-associated risks was similar for perinatal death.  I also 
found that a woman was more likely to have a medical termination of her pregnancy if 
she had medicated depression or anxiety than if not.  The risks associated with 
termination are often higher than those associated with miscarriage or perinatal death, 
which indicates the effects were partially but not fully explained by severity of mental 
illness. 
I have carried out the first UK study to assess the absolute and relative risks of major 
congenital anomalies in children with first trimester exposure to SSRIs, TCAs and 
benzodiazepines in a single population.  The findings show that whilst there was no 
important increase in the risk of congenital anomalies overall for any drug classes, 
children with in utero exposure to SSRIs during the first trimester of pregnancy have a 
small increased risk of congenital heart anomalies.  In line with some previous 
observational studies from other countries, such increased risks are found in children 
with first trimester exposure to paroxetine (and, with less power, to sertraline and 
escitalopram), but not to fluoxetine or citalopram, which may suggest a biological 
mechanism in the association.  Despite this, the absolute risk of congenital heart 
anomalies is relatively small in the general population (7.6 per 1000 children) and the 
excess risk in children exposed to paroxetine is 6.7 per 1000 children.  Further 
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analyses of specific heart anomalies suggest that the excess risks found in children 
exposed to paroxetine, sertraline and escitalopram appear to be mostly related to 
increased risks of septal heart defects, which can be self-limited and mostly 
spontaneously close in the first year of a child¶V life.241±244  For TCAs and 
benzodiazepines, although no increased risks of overall congenital anomalies were 
found, my findings support remaining concerns for a potential association with right 
ventricular outflow tract anomalies. 
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7.2 Clinical and policy implications from this thesis 
This thesis provides evidence that there is a high prevalence of antepartum and 
postpartum mental illness, mainly depression, presenting to and being treated in UK 
primary care.  Women in more socioeconomically deprived circumstances are at 
particularly high risk of these illnesses.  This reinforces the need for greater 
recognition at policy level to target detection and effective interventions to high risk 
women in order to promote general population health. 
With regard to the potential teratogenic effects of psychotropic drugs, especially 
paroxetine, sertraline and escitalopram, clinicians and obstetricians should continue 
to take a cautious approach to drug treatment in women of childbearing age.  When 
prescribing psychotropic drugs to these women prior to pregnancy, clinicians should 
be aware of DZRPDQ¶V fertility plan during the treatment period.  The findings in this 
thesis reinforce current guidelines of managing maternal mental illness.  Adequate 
health care should be provided to women with mental illness based on whether they 
are prior to, in early, in late or after pregnancy, and also in consideration of their 
mental health history. 
GPs and other clinicians should conduct an appropriate psychiatric assessment to 
evaluate whether a woman need psychotropic drug treatment to control her 
symptoms, via the initial case identification proposed by NICE guidelines (Appendix 
V).  Considering that current evidence raises uncertainty over the effectiveness of 
psychotropic medication over non-pharmacological treatment, such as cognitive 
behaviour therapy particularly in less severe depression, health care professionals 
should communicate that pharmacological treatment may pose small excess risks of 
non-live pregnancy outcomes and major congenital anomalies.  Although I did not 
completely exclude the potential effect of disease severity, discontinuing medication 
when pregnant showed no more harm in the risks of adverse pregnancy outcomes.  
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The information provided in the thesis could be used to help communicate the 
magnitude of these risks for women using different psychotropic drugs in context of 
the baseline risk for all pregnancies in the general population.  Finally, the adverse 
pregnancy effects of mental illness itself when untreated had continued and increased 
recognition by clinicians and policy makers as a priority for maternal and child health 
in the UK. 
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7.3 Suggestions for further research 
The work in this thesis, alongside other research using general practice data, has 
hopefully demonstrated the potential and usefulness of large routinely collected 
primary care databases for future epidemiological research in maternal mental health.  
The suggestions in this section are therefore mainly related to database research. 
Risks of recurrent mental illness episodes following pregnancy losses 
Although there have been several studies on the association between therapeutic 
abortion and the increased risks of subsequent mental illness, these studies have 
inadequately controlled for previous mental health problems.  Although I have found 
an increased risk of termination in women with depression or anxiety even after 
considering their prior pregnancy losses, it would be useful to examine the 
association between therapeutic termination and subsequent occurrence of mental 
health problems, and how this in turn impacts upon the outcome of any subsequent 
pregnancy.  One possible way to do this would be to examine two or more 
consecutive pregnancies in the same woman and assess the changes in risk of 
termination in women with or without mental illness after the first pregnancy.  The fact 
that the excess risks observed for termination were similar to or higher than those 
risks for miscarriage and perinatal death also needs to be examined in further 
research using data with an internal comparison.  The potential explanations for 
observed increased risks of termination and other pregnancy losses related to 
maternal mental health need further exploration. 
Non-pharmacological treatment  
In this thesis, due to the limitations of the data, I was unable to evaluate the 
effectiveness of non-pharmacological treatment compared with drug treatment for 
women during the perinatal period.  One possible way to study this would be to 
conduct interviews with women with mental illness, preferably linked to primary care 
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data.  Although the potential financial cost of carrying out such research in a great 
number of women could be substantial, there are few current studies in this area. 
Cost-effectiveness of antenatal interventions 
Some researchers have suggested foetal echocardiography screening for women 
taking SSRIs or specifically paroxetine during pregnancy.245  The cost-effectiveness 
of such performance needs to be fully assessed in future research. 
Serious mental illness and assessment of disease severity 
Statistical power is a very important concern for uncommon mental health conditions 
(e.g. schizophrenia).  Even larger studies are needed to assess the potential effects 
of serious mental illness on the risk of adverse pregnancy outcomes, especially for 
rare outcomes, such as perinatal death and congenital heart anomalies.  Since 
women with more severe symptoms of mental illness are also more likely to be 
treated in psychiatric hospitals and outpatient units, especially when they get 
pregnant, further research links with prospective data collected from hospitals, such 
as hospital episode statistics, and outpatient units could provide more comprehensive 
information on the severity of perinatal mental illness. 
The effect of psychotropic medication in late pregnancy 
Previous research has suggested that maternal use of antidepressants during the 
third trimester of pregnancy has an adverse impact on early neonatal health, such as 
respiratory distress syndrome.59  Less information however is available in UK 
population.  The linked mother-child dataset used in this thesis provides a great 
opportunity to examine this association in a large representative UK population. 
Long-term mental and physical health outcomes in children 
Less information is available for the long-term mental and physical health of children 
born to women with mental illness.  The UK primary care data used in this thesis 
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contain a large cohort of children who are prospectively followed over time.  The 
median time of child follow-up in the linked mother-and-child dataset in THIN is 4.5 
years (IQR 1.8-9.0), so this is an ideal dataset to assess the longer-term health 
outcomes in children exposed to different maternal risk factors during pregnancy.  
One example is to investigate the impact of pre-existing, antenatal or episodic mental 
illness LQPRWKHUVGXULQJWKHLUFKLOGUHQ¶VHDUO\OLIHRQWKHULVNRIGHYHORSLQJFKURQLF
conditions, such as autism, or acute health outcomes, such as childhood injuries, in 
offspring over time. 
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9 Appendices 
9.1 Appendix I Read codes for mental illnesses 
A. Read codes for depression 
 
1B17.00 Depressed 
1B17.11 C/O - feeling depressed 
1B1U.00 Symptoms of depression 
1B1U.11 Depressive symptoms 
1BT..00 Depressed mood 
1BT..11 Low mood 
2257.00 O/E - depressed 
62T1.00 Puerperal depression 
6G00.00 Postnatal depression counselling 
E11..12 Depressive psychoses 
E112.00 Single major depressive episode 
E112.11 Agitated depression 
E112.12 Endogenous depression first episode 
E112.13 Endogenous depression first episode 
E112.14 Endogenous depression 
E112000 Single major depressive episode, unspecified 
E112100 Single major depressive episode, mild 
E112200 Single major depressive episode, moderate 
E112300 Single major depressive episode, severe, without psychosis 
E112400 Single major depressive episode, severe, with psychosis 
E112z00 Single major depressive episode NOS 
E113.00 Recurrent major depressive episode 
E113.11 Endogenous depression - recurrent 
E113000 Recurrent major depressive episodes, unspecified 
E113100 Recurrent major depressive episodes, mild 
E113200 Recurrent major depressive episodes, moderate 
E113300 Recurrent major depressive episodes, severe, no psychosis 
E113400 Recurrent major depressive episodes, severe, with psychosis 
E113700 Recurrent depression 
E113z00 Recurrent major depressive episode NOS 
E118.00 Seasonal affective disorder 
E11y200 Atypical depressive disorder 
E11z200 Masked depression 
E130.00 Reactive depressive psychosis 
E130.11 Psychotic reactive depression 
E135.00 Agitated depression 
E200300 Anxiety with depression 
E204.00 Neurotic depression reactive type 
E204.11 Postnatal depression 
E290.00 Brief depressive reaction 
E290z00 Brief depressive reaction NOS 
E291.00 Prolonged depressive reaction 
E2B..00 Depressive disorder NEC 
E2B0.00 Postviral depression 
E2B1.00 Chronic depression 
Eu32.00 [X]Depressive episode 
Eu32.11 [X]Single episode of depressive reaction 
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Eu32.12 [X]Single episode of psychogenic depression 
Eu32.13 [X]Single episode of reactive depression 
Eu32000 [X]Mild depressive episode 
Eu32100 [X]Moderate depressive episode 
Eu32200 [X]Severe depressive episode without psychotic symptoms 
Eu32211 [X]Single episode agitated depressn w'out psychotic symptoms 
Eu32212 [X]Single episode major depression w'out psychotic symptoms 
Eu32300 [X]Severe depressive episode with psychotic symptoms 
Eu32311 
[X]Single episode of major depression and psychotic 
symptoms 
Eu32312 [X]Single episode of psychogenic depressive psychosis 
Eu32313 [X]Single episode of psychotic depression 
Eu32314 [X]Single episode of reactive depressive psychosis 
Eu32400 [X]Mild depression 
Eu32y00 [X]Other depressive episodes 
Eu32y11 [X]Atypical depression 
Eu32z00 [X]Depressive episode, unspecified 
Eu32z11 [X]Depression NOS 
Eu32z12 [X]Depressive disorder NOS 
Eu32z13 [X]Prolonged single episode of reactive depression 
Eu32z14 [X] Reactive depression NOS 
Eu33.00 [X]Recurrent depressive disorder 
Eu33.11 [X]Recurrent episodes of depressive reaction 
Eu33.12 [X]Recurrent episodes of psychogenic depression 
Eu33.13 [X]Recurrent episodes of reactive depression 
Eu33.14 [X]Seasonal depressive disorder 
Eu33.15 [X]SAD - Seasonal affective disorder 
Eu33000 [X]Recurrent depressive disorder, current episode mild 
Eu33100 [X]Recurrent depressive disorder, current episode moderate 
Eu33200 [X]Recurr depress disorder cur epi severe without psyc sympt 
Eu33211 [X]Endogenous depression without psychotic symptoms 
Eu33212 [X]Major depression, recurrent without psychotic symptoms 
Eu33300 [X]Recurrent depress disorder cur epi severe with psyc symp 
Eu33311 [X]Endogenous depression with psychotic symptoms 
Eu33313 
[X]Recurr severe episodes/major depression+psychotic 
symptom 
Eu33314 [X]Recurr severe episodes/psychogenic depressive psychosis 
Eu33315 [X]Recurrent severe episodes of psychotic depression 
Eu33316 [X]Recurrent severe episodes/reactive depressive psychosis 
Eu33y00 [X]Other recurrent depressive disorders 
Eu33z00 [X]Recurrent depressive disorder, unspecified 
Eu33z11 [X]Monopolar depression NOS 
Eu34100 [X]Dysthymia 
Eu34111 [X]Depressive neurosis 
Eu34113 [X]Neurotic depression 
Eu34114 [X]Persistant anxiety depression 
Eu3y111 [X]Recurrent brief depressive episodes 
Eu41200 [X]Mixed anxiety and depressive disorder 
Eu41211 [X]Mild anxiety depression 
Eu53011 [X]Postnatal depression NOS 
Eu53012 [X]Postpartum depression NOS 
R007z13 [D]Postoperative depression 
 
 
NOS=not otherwise specified; C/O=complain of; O/E=on examination of  
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B. Read codes for anxiety 
 
1B13.00 Anxiousness 
1B13.11 Anxiousness - symptom 
1B1L.00 Stress related problem 
1B1T.00 Feeling stressed 
1B1V.00 C/O - panic attack 
1Ba0.00 Obsessional thoughts 
2258.00 O/E - anxious 
E200.00 Anxiety states 
E200000 Anxiety state unspecified 
E200100 Panic disorder 
E200111 Panic attack 
E200200 Generalised anxiety disorder 
E200300 Anxiety with depression 
E200400 Chronic anxiety 
E200500 Recurrent anxiety 
E200z00 Anxiety state NOS 
E203.00 Obsessive-compulsive disorders 
E203000 Compulsive neurosis 
E203100 Obsessional neurosis 
E203z00 Obsessive-compulsive disorder NOS 
E292y00 Adjustment reaction with mixed disturbance of emotion 
E292z00 Adjustment reaction with disturbance of other emotion NOS 
E293.00 Adjustment reaction with predominant disturbance of conduct 
E293000 Adjustment reaction with aggression 
E293100 Adjustment reaction with antisocial behaviour 
E293200 Adjustment reaction with destructiveness 
E293z00 
Adjustment reaction with predominant disturbance conduct 
NOS 
E294.00 Adjustment reaction with disturbance emotion and conduct 
E29y.00 Other adjustment reactions 
E29y100 Other post-traumatic stress disorder 
E29y200 Adjustment reaction with physical symptoms 
E29y300 Elective mutism due to an adjustment reaction 
E29y400 Adjustment reaction due to hospitalisation 
E29y500 Other adjustment reaction with withdrawal 
E29yz00 Other adjustment reactions NOS 
E29z.00 Adjustment reaction NOS 
Eu34114 [X]Persistant anxiety depression 
Eu40012 [X]Panic disorder with agoraphobia 
Eu41.00 [X]Other anxiety disorders 
Eu41000 [X]Panic disorder [episodic paroxysmal anxiety] 
Eu41011 [X]Panic attack 
Eu41012 [X]Panic state 
Eu41100 [X]Generalized anxiety disorder 
Eu41111 [X]Anxiety neurosis 
Eu41112 [X]Anxiety reaction 
Eu41113 [X]Anxiety state 
Eu41200 [X]Mixed anxiety and depressive disorder 
Eu41211 [X]Mild anxiety depression 
Eu41300 [X]Other mixed anxiety disorders 
Eu41z00 [X]Anxiety disorder, unspecified 
Eu41z11 [X]Anxiety NOS 
Eu42.00 [X]Obsessive - compulsive disorder 
Eu42.12 [X]Obsessive-compulsive neurosis 
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Eu42000 [X]Predominantly obsessional thoughts or ruminations 
Eu42100 [X]Predominantly compulsive acts [obsessional rituals] 
Eu42200 [X]Mixed obsessional thoughts and acts 
Eu42z00 [X]Obsessive-compulsive disorder, unspecified 
Eu43.00 [X]Reaction to severe stress, and adjustment disorders 
Eu43000 [X]Acute stress reaction 
Eu43011 [X]Acute crisis reaction 
Eu43012 [X]Acute reaction to stress 
Eu43014 [X]Crisis state 
Eu43100 [X]Post - traumatic stress disorder 
Eu43111 [X]Traumatic neurosis 
Eu43200 [X]Adjustment disorders 
Eu43y00 [X]Other reactions to severe stress 
Eu43z00 [X]Reaction to severe stress, unspecified 
Eu51511 [X]Dream anxiety disorder 
Z4L1.00 Anxiety counselling 
 
C/O=complain of; O/E=on examination of 
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C. Read codes for bipolar disorder 
 
1BY..00 Elevated mood 
225C.00 O/E - elated 
E11..11 Bipolar psychoses 
E11..13 Manic psychoses 
E110.00 Manic disorder, single episode 
E110.11 Hypomanic psychoses 
E110000 Single manic episode, unspecified 
E110100 Single manic episode, mild 
E110200 Single manic episode, moderate 
E110300 Single manic episode, severe without mention of psychosis 
E110400 Single manic episode, severe, with psychosis 
E110z00 Manic disorder, single episode NOS 
E111.00 Recurrent manic episodes 
E111000 Recurrent manic episodes, unspecified 
E111100 Recurrent manic episodes, mild 
E111200 Recurrent manic episodes, moderate 
E111300 Recurrent manic episodes, severe without mention psychosis 
E111400 Recurrent manic episodes, severe, with psychosis 
E111z00 Recurrent manic episode NOS 
E114.00 Bipolar affective disorder, currently manic 
E114.11 Manic-depressive - now manic 
E114000 Bipolar affective disorder, currently manic, unspecified 
E114100 Bipolar affective disorder, currently manic, mild 
E114200 Bipolar affective disorder, currently manic, moderate 
E114300 Bipolar affect disord, currently manic, severe, no psychosis 
E114400 Bipolar affect disord, currently manic,severe with psychosis 
E115.00 Bipolar affective disorder, currently depressed 
E115.11 Manic-depressive - now depressed 
E115000 Bipolar affective disorder, currently depressed, unspecified 
E115100 Bipolar affective disorder, currently depressed, mild 
E115200 Bipolar affective disorder, currently depressed, moderate 
E115300 Bipolar affect disord, now depressed, severe, no psychosis 
E115400 Bipolar affect disord, now depressed, severe with psychosis 
E116.00 Mixed bipolar affective disorder 
E116000 Mixed bipolar affective disorder, unspecified 
E116200 Mixed bipolar affective disorder, moderate 
E116300 Mixed bipolar affective disorder, severe, without psychosis 
E116400 Mixed bipolar affective disorder, severe, with psychosis 
E116z00 Mixed bipolar affective disorder, NOS 
E117.00 Unspecified bipolar affective disorder 
E117000 Unspecified bipolar affective disorder, unspecified 
E117100 Unspecified bipolar affective disorder, mild 
E117200 Unspecified bipolar affective disorder, moderate 
E117300 Unspecified bipolar affective disorder, severe, no psychosis 
E117400 Unspecified bipolar affective disorder,severe with psychosis 
E117z00 Unspecified bipolar affective disorder, NOS 
E11y.00 Other and unspecified manic-depressive psychoses 
E11y000 Unspecified manic-depressive psychoses 
E11y100 Atypical manic disorder 
E11y300 Other mixed manic-depressive psychoses 
E11yz00 Other and unspecified manic-depressive psychoses NOS 
Eu30.00 [X]Manic episode 
Eu30.11 [X]Bipolar disorder, single manic episode 
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Eu30000 [X]Hypomania 
Eu30100 [X]Mania without psychotic symptoms 
Eu30200 [X]Mania with psychotic symptoms 
Eu30212 [X]Mania with mood-incongruent psychotic symptoms 
Eu30y00 [X]Other manic episodes 
Eu30z11 [X]Mania NOS 
Eu31.00 [X]Bipolar affective disorder 
Eu31.11 [X]Manic-depressive illness 
Eu31.12 [X]Manic-depressive psychosis 
Eu31.13 [X]Manic-depressive reaction 
Eu31000 [X]Bipolar affective disorder, current episode hypomanic 
Eu31100 [X]Bipolar affect disorder cur epi manic wout psychotic symp 
Eu31200 [X]Bipolar affect disorder cur epi manic with psychotic symp 
Eu31300 [X]Bipolar affect disorder cur epi mild or moderate depressn 
Eu31400 [X]Bipol aff disord, curr epis sev depress, no psychot symp 
Eu31500 [X]Bipolar affect dis cur epi severe depres with psyc symp 
Eu31600 [X]Bipolar affective disorder, current episode mixed 
Eu31y00 [X]Other bipolar affective disorders 
Eu31z00 [X]Bipolar affective disorder, unspecified 
Eu33213 [X]Manic-depress psychosis,depressd,no psychotic symptoms 
Eu33312 
[X]Manic-depress psychosis,depressed type+psychotic 
symptoms 
Eu34000 [X]Cyclothymia 
Eu3y011 [X]Mixed affective episode 
 
O/E=on examination of 
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D. Read codes for schizophrenia and other related psychoses 
 
1B1E.00 Hallucinations 
1BH..00 Delusions 
1BH..11 Delusion 
E1...00 Non-organic psychoses 
E10..00 Schizophrenic disorders 
E100.00 Simple schizophrenia 
E100000 Unspecified schizophrenia 
E100100 Subchronic schizophrenia 
E100200 Chronic schizophrenic 
E100300 Acute exacerbation of subchronic schizophrenia 
E100400 Acute exacerbation of chronic schizophrenia 
E100z00 Simple schizophrenia NOS 
E101.00 Hebephrenic schizophrenia 
E101000 Unspecified hebephrenic schizophrenia 
E101100 Subchronic hebephrenic schizophrenia 
E101200 Chronic hebephrenic schizophrenia 
E101300 Acute exacerbation of subchronic hebephrenic schizophrenia 
E101400 Acute exacerbation of chronic hebephrenic schizophrenia 
E101z00 Hebephrenic schizophrenia NOS 
E102.00 Catatonic schizophrenia 
E102000 Unspecified catatonic schizophrenia 
E102100 Subchronic catatonic schizophrenia 
E102200 Chronic catatonic schizophrenia 
E102300 Acute exacerbation of subchronic catatonic schizophrenia 
E102400 Acute exacerbation of chronic catatonic schizophrenia 
E102z00 Catatonic schizophrenia NOS 
E103.00 Paranoid schizophrenia 
E103000 Unspecified paranoid schizophrenia 
E103100 Subchronic paranoid schizophrenia 
E103200 Chronic paranoid schizophrenia 
E103300 Acute exacerbation of subchronic paranoid schizophrenia 
E103400 Acute exacerbation of chronic paranoid schizophrenia 
E103z00 Paranoid schizophrenia NOS 
E104.00 Acute schizophrenic episode 
E104.11 Oneirophrenia 
E105.00 Latent schizophrenia 
E105000 Unspecified latent schizophrenia 
E105100 Subchronic latent schizophrenia 
E105200 Chronic latent schizophrenia 
E105300 Acute exacerbation of subchronic latent schizophrenia 
E105400 Acute exacerbation of chronic latent schizophrenia 
E105z00 Latent schizophrenia NOS 
E106.00 Residual schizophrenia 
E106.11 Restzustand - schizophrenia 
E107.00 Schizo-affective schizophrenia 
E107.11 Cyclic schizophrenia 
E107000 Unspecified schizo-affective schizophrenia 
E107100 Subchronic schizo-affective schizophrenia 
E107200 Chronic schizo-affective schizophrenia 
E107300 Acute exacerbation subchronic schizo-affective schizophrenia 
E107400 Acute exacerbation of chronic schizo-affective schizophrenia 
E107z00 Schizo-affective schizophrenia NOS 
E10y.00 Other schizophrenia 
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E10y.11 Cenesthopathic schizophrenia 
E10y000 Atypical schizophrenia 
E10y100 Coenesthopathic schizophrenia 
E10yz00 Other schizophrenia NOS 
E10z.00 Schizophrenia NOS 
E11..00 Affective psychoses 
E11..11 Bipolar psychoses 
E11..12 Depressive psychoses 
E11..13 Manic psychoses 
E110.11 Hypomanic psychoses 
E110400 Single manic episode, severe, with psychosis 
E111400 Recurrent manic episodes, severe, with psychosis 
E112400 Single major depressive episode, severe, with psychosis 
E113400 Recurrent major depressive episodes, severe, with psychosis 
E114400 Bipolar affect disord, currently manic,severe with psychosis 
E115400 Bipolar affect disord, now depressed, severe with psychosis 
E116400 Mixed bipolar affective disorder, severe, with psychosis 
E117400 Unspecified bipolar affective disorder,severe with psychosis 
E11y.00 Other and unspecified manic-depressive psychoses 
E11y000 Unspecified manic-depressive psychoses 
E11y300 Other mixed manic-depressive psychoses 
E11yz00 Other and unspecified manic-depressive psychoses NOS 
E11z.00 Other and unspecified affective psychoses 
E11z000 Unspecified affective psychoses NOS 
E11zz00 Other affective psychosis NOS 
E12..00 Paranoid states 
E120.00 Simple paranoid state 
E121.00 Chronic paranoid psychosis 
E122.00 Paraphrenia 
E123.11 Folie a deux 
E12y.00 Other paranoid states 
E12yz00 Other paranoid states NOS 
E12z.00 Paranoid psychosis NOS 
E13..00 Other nonorganic psychoses 
E13..11 Reactive psychoses 
E130.00 Reactive depressive psychosis 
E130.11 Psychotic reactive depression 
E131.00 Acute hysterical psychosis 
E132.00 Reactive confusion 
E133.00 Acute paranoid reaction 
E134.00 Psychogenic paranoid psychosis 
E13y.00 Other reactive psychoses 
E13y000 Psychogenic stupor 
E13y100 Brief reactive psychosis 
E13yz00 Other reactive psychoses NOS 
E13z.00 Nonorganic psychosis NOS 
E13z.11 Psychotic episode NOS 
E1y..00 Other specified non-organic psychoses 
E1z..00 Non-organic psychosis NOS 
E212200 Schizotypal personality 
Eu2..00 [X]Schizophrenia, schizotypal and delusional disorders 
Eu20.00 [X]Schizophrenia 
Eu20000 [X]Paranoid schizophrenia 
Eu20011 [X]Paraphrenic schizophrenia 
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Eu20100 [X]Hebephrenic schizophrenia 
Eu20111 [X]Disorganised schizophrenia 
Eu20200 [X]Catatonic schizophrenia 
Eu20211 [X]Catatonic stupor 
Eu20212 [X]Schizophrenic catalepsy 
Eu20213 [X]Schizophrenic catatonia 
Eu20214 [X]Schizophrenic flexibilatis cerea 
Eu20300 [X]Undifferentiated schizophrenia 
Eu20311 [X]Atypical schizophrenia 
Eu20400 [X]Post-schizophrenic depression 
Eu20500 [X]Residual schizophrenia 
Eu20511 [X]Chronic undifferentiated schizophrenia 
Eu20512 [X]Restzustand schizophrenic 
Eu20600 [X]Simple schizophrenia 
Eu20y00 [X]Other schizophrenia 
Eu20y11 [X]Cenesthopathic schizophrenia 
Eu20y12 [X]Schizophreniform disord NOS 
Eu20y13 [X]Schizophrenifrm psychos NOS 
Eu20z00 [X]Schizophrenia, unspecified 
Eu21.00 [X]Schizotypal disorder 
Eu21.11 [X]Latent schizophrenic reaction 
Eu21.12 [X]Borderline schizophrenia 
Eu21.13 [X]Latent schizophrenia 
Eu21.14 [X]Prepsychotic schizophrenia 
Eu21.15 [X]Prodromal schizophrenia 
Eu21.16 [X]Pseudoneurotic schizophrenia 
Eu21.17 [X]Pseudopsychopathic schizophrenia 
Eu21.18 [X]Schizotypal personality disorder 
Eu22.00 [X]Persistent delusional disorders 
Eu22000 [X]Delusional disorder 
Eu22011 [X]Paranoid psychosis 
Eu22012 [X]Paranoid state 
Eu22013 [X]Paraphrenia - late 
Eu22014 [X]Sensitiver Beziehungswahn 
Eu22015 [X]Paranoia 
Eu22100 [X]Delusional misidentification syndrome 
Eu22111 [X]Capgras syndrome 
Eu22200 [X]Cotard syndrome 
Eu22y00 [X]Other persistent delusional disorders 
Eu22y11 [X]Delusional dysmorphophobia 
Eu22y12 [X]Involutional paranoid state 
Eu22y13 [X]Paranoia querulans 
Eu22z00 [X]Persistent delusional disorder, unspecified 
Eu23.00 [X]Acute and transient psychotic disorders 
Eu23000 
[X]Acute polymorphic psychot disord without symp of 
schizoph 
Eu23011 [X]Bouffee delirante 
Eu23012 [X]Cycloid psychosis 
Eu23100 
[X]Acute polymorphic psychot disord with symp of 
schizophren 
Eu23111 [X]Bouffee delirante with symptoms of schizophrenia 
Eu23112 [X]Cycloid psychosis with symptoms of schizophrenia 
Eu23200 [X]Acute schizophrenia-like psychotic disorder 
Eu23211 [X]Brief schizophreniform disorder 
Eu23212 [X]Brief schizophrenifrm psych 
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Eu23213 [X]Oneirophrenia 
Eu23214 [X]Schizophrenic reaction 
Eu23300 [X]Other acute predominantly delusional psychotic disorders 
Eu23312 [X]Psychogenic paranoid psychosis 
Eu23y00 [X]Other acute and transient psychotic disorders 
Eu23z00 [X]Acute and transient psychotic disorder, unspecified 
Eu23z11 [X]Brief reactive psychosis NOS 
Eu23z12 [X]Reactive psychosis 
Eu24.00 [X]Induced delusional disorder 
Eu24.11 [X]Folie a deux 
Eu24.12 [X]Induced paranoid disorder 
Eu24.13 [X]Induced psychotic disorder 
Eu25.00 [X]Schizoaffective disorders 
Eu25000 [X]Schizoaffective disorder, manic type 
Eu25011 [X]Schizoaffective psychosis, manic type 
Eu25012 [X]Schizophreniform psychosis, manic type 
Eu25100 [X]Schizoaffective disorder, depressive type 
Eu25111 [X]Schizoaffective psychosis, depressive type 
Eu25112 [X]Schizophreniform psychosis, depressive type 
Eu25200 [X]Schizoaffective disorder, mixed type 
Eu25211 [X]Cyclic schizophrenia 
Eu25212 [X]Mixed schizophrenic and affective psychosis 
Eu25y00 [X]Other schizoaffective disorders 
Eu25z00 [X]Schizoaffective disorder, unspecified 
Eu25z11 [X]Schizoaffective psychosis NOS 
Eu2y.00 [X]Other nonorganic psychotic disorders 
Eu2y.11 [X]Chronic hallucinatory psychosis 
Eu2z.00 [X]Unspecified nonorganic psychosis 
Eu2z.11 [X]Psychosis NOS 
Eu32300 [X]Severe depressive episode with psychotic symptoms 
Eu32311 [X]Single episode of major depression and psychotic symptoms 
Eu32312 [X]Single episode of psychogenic depressive psychosis 
Eu32313 [X]Single episode of psychotic depression 
Eu32314 [X]Single episode of reactive depressive psychosis 
Eu33300 [X]Recurrent depress disorder cur epi severe with psyc symp 
Eu33311 [X]Endogenous depression with psychotic symptoms 
Eu33312 
[X]Manic-depress psychosis,depressed type+psychotic 
symptoms 
Eu33313 
[X]Recurr severe episodes/major depression+psychotic 
symptom 
Eu33314 [X]Recurr severe episodes/psychogenic depressive psychosis 
Eu33315 [X]Recurrent severe episodes of psychotic depression 
Eu33316 [X]Recurrent severe episodes/reactive depressive psychosis 
Eu53111 [X]Puerperal psychosis NOS 
R001.00 [D]Hallucinations 
R001000 [D]Hallucinations, auditory 
R001100 [D]Hallucinations, gustatory 
R001200 [D]Hallucinations, olfactory 
R001300 [D]Hallucinations, tactile 
R001400 [D]Visual hallucinations 
R001z00 [D]Hallucinations NOS 
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9.2 Appendix II BNF codes for psychotropic drugs 
A. BNF codes for list of antidepressants 
BNF code 04.03.01.00 
 
04.03.02.00 04.03.03.00 04.03.04.00 
List of drugs Amitriptyline Hydrochloride Iproniazid Citalopram Duloxetine 
 
Amoxapine 
 
Isocarboxazid Escitalopram Flupentixol 
 
Butriptyline 
 
Moclobemide Fluoxetine L-tryptophan 
 
Clomipramine 
 
Phenelzine Fluvoxamine Mirtazapine 
 
Desipramine 
 
Tranylcypromine Paroxetine Nefazodone 
 
Dibenzepin Hydrochloride Trifluoperazine Sertraline Reboxetine 
 
Dosulepin 
     
Tryptophan 
 
Dothiepin Hydrochloride 
    
Venlafaxine 
 
Doxepin 
       
 
Imipramine 
      
 
Iprindole 
       
 
Lofepramine 
      
 
Maprotiline 
      
 
Mianserin 
      
 
Nomifensine Hydrogen Maleate 
    
 
Nortriptyline 
      
 
Opipramol Hydrochloride 
     
 
Protriptyline 
      
 
Trazodone 
      
 
Trimipramine Maleate 
     
 
Viloxazine 
      
 
Zimeldine Hydrochloride 
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B. BNF codes for list of hypnotics and anxiolytics 
BNF code 04.01.01.00 04.01.02.00 
List of drugs Chloral Hydrate Alprazolam 
 
Clomethiazole Bromazepam 
 
Dipenhydramine Buspirone Hydrochloride 
 
Flunitrazepam Chlordiazepoxide Hydrochloride 
 
Flurazepam Chlormezanone 
 
Loprazolam Diazepam 
 
Lormetazepam Ketazolam 
 
Melatonin Lorazepam 
 
Methyprylone Medazepam 
 
Nitrazepam Meprobamate 
 
Nitrados 
 
Oxazepam 
 
Promethazine Prazepam 
 
Temazepam Sardiazepam 
 
Triazolam 
 
 
Zaleplon 
  
 
Zolpidem 
Tartrate 
 
 
Zopiclone 
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C. BNF codes for list of lithium and mood stabilisers 
BNF code 04.02.03.00 04.08.01.00 
List of drug(s) Lithium 
 
Carbamazepine 
   
Sodium Valproate 
   
Valproic acid 
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D. BNF codes for list of antipsychotics 
BNF code 04.02.01.00 04.02.02.00 
List of drugs Amisulpride Flupentixol Decanoate 
 
Aripiprazole Fluphenazine Decanoate 
 
Benperidol Fluspirilene 
 
Chlorpromazine Haloperidol 
 
Clozapine Pipotiazine Palmitate 
 
Cyamemazine Zuclopenthixol Decanoate 
 
Droperidol 
  
 
Flupentixol 
  
 
Fluphenazine 
  
 
Haloperidol 
  
 
Levomepromazine 
  
 
Loxapine 
   
 
Olanzapine 
  
 
Oxypertine 
  
 
Paliperidone 
  
 
Pericyazine 
  
 
Perphenazine 
  
 
Pimozide 
   
 
Promazine 
  
 
Quetiapine 
  
 
Remoxipride 
  
 
Risperidone 
  
 
Sertindole 
  
 
Sulpiride 
   
 
Thiopropazate Hydrochloride 
 
 
Trifluoperazine 
  
 
Zotepine 
   
 
Zuclopenthixol Dihydrochloride 
 
Ziprasidone 
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9.3 Appendix III Edinburgh Postnatal Depression Scale (EPDS) 
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9.4 Appendix IV Risk estimates of major and system-specfic congenital 
anomalies identified in THIN and in EUROCAT 
 
THIN population EUROCAT populationa 
N=349,211 N=3,254,489 
Diagnosed at any age Diagnosed before age 1   
n  n/10,000 n n/10,000 n n/10,000 
All major CAs combined 9,399 269 6,880 197 54,499 168 
Heart 2,648 76 2,096 60 14,996 46 
Limb 1,869 54 1,461 42 9,195 28 
Genital system 1,392 40 994 28 4,862 15 
Urinary system 886 25 653 19 7,297 22 
Chromosomal 593 17 461 13 5,896 18 
Oro-facial cleft 471 13 405 12 4,582 14 
Nervous system  513 15 318 9 2,943 9 
Musculoskeletal system 468 13 289 8 1,861 6 
Digestive system 338 10 290 8 4,755 15 
Eye 331 9 201 6 1,188 4 
Other malformationsb 328 9 151 4 1,420 4 
Respiratory system 222 6 189 5 1,592 5 
Ear, face and neck 90 3 51 1 429 1 
Abdominal wall 74 2 72 2 1,605 5 
a Data were extracted from EUROCAT website (http://www.eurocat-network.eu/) by Rachel Sokal; b e.g. asplenia, 
conjoined twins, situs inversus and skin disorders 
 
9.5-257 | P a g e  
 
9.5 Appendix V NICE clinical guideline on identification and recognition of 
depression in UK general practice 
Case identification and recognition1 
 
1 National institute for Health and Clinical Excellence. Depression: The treatment and management of depression in 
adults. 2009. Available at: http://www.nice.org.uk/guidance/index.jsp?action=byID&o=12329. 
